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Nybomycin was discovered in 1955, but was never developed for clinical use. The 
compound was noticed again in recent years when it displayed bactericidal activity 
against certain fluoroquinolone-resistant bacterial species. The work presented 
here aims chiefly at describing the effect of nybomycin on Mycobacterium 
tuberculosis. The study is made up of three parts. 
  
In the first part, in vitro nybomycin susceptibility testing was conducted with 
various fluoroquinolone-susceptible and fluoroquinolone-resistant bacterial 
species. All M. tuberculosis isolates displayed low nybomycin inhibitory 
concentrations regardless of fluoroquinolone resistance. Similar susceptibility 
results were obtained for N. gonorrhoeae isolates, but results obtained with other 
bacterial species were less promising. 
 
In the second part, in silico investigations were conducted to elucidate the 
mechanism of action of nybomycin in M. tuberculosis. Results show that 
nybomycin binds to M. tuberculosis gyrase enzyme with an affinity at least similar 
to that of fluoroquinolones. No clear differences in binding affinity were observed 
when gyrA mutations, commonly associated with fluoroquinolone resistance, were 
considered. The results suggest that the mechanism of action of nybomycin 
against M. tuberculosis involves inhibition of gyrase enzyme. 
 
In the third part, M. tuberculosis mutants with increased nybomycin minimum 
inhibitory concentrations were selected and compared with the wild type organism 
 ii 
through whole genome sequencing. None of the isolates harbored any mutations 
commonly linked to known drug resistance mechanisms. This indicates that         
M. tuberculosis likely employs a novel mechanism of resistance against 
nybomycin. This may further signify that nybomycin has an additional mechanism 
of action against M. tuberculosis, besides the action on gyrase enzyme, as 
suggested by the in silico results from this study. Twenty-two genes were identified 
through whole genome sequencing that may potentially be linked to the 
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CHAPTER 1 - INTRODUCTION 
 
1.1   Background and research rationale 
 
Mycobacterium tuberculosis has been destroying the lives of individuals and 
communities for millennia, its devastation unparalleled by any other microbe in 
known history. It has been advancing largely unabated despite humankind’s best 
efforts to prevent, control and treat it. Notwithstanding some victories in richer 
countries over the previous millennium, disease due to M. tuberculosis escalated 
in poorer countries against a backdrop of emerging drug resistance and large 
portions of human populations co-infected with HIV. The development of new and 
effective antimicrobial remedies for treatment is of obvious importance, but novel 
antibiotics have not been very forthcoming since the “golden age” of antibiotic 
discovery more than 60 years ago. Drug discovery and development is a 
complicated and expensive enterprise, especially for antimicrobials. Researchers 
are increasingly beginning to pursue alternative avenues to add to our anti-
tuberculosis armamentarium, including the re-evaluation of previously discovered 
but “forgotten” compounds. Nybomycin is such a compound that recently sparked 
the imagination of researchers when it was baptized the first “reverse antibiotic” 
because of its inhibitory in vitro effect on fluoroquinolone-resistant   
Staphylococcus aureus and Enterococcus faecalis, despite very poor activity 
against fluoroquinolone-susceptible isolates.  It further exhibited some in vitro 
activity against drug-susceptible M. tuberculosis, thereby begging further 
investigation to determine its potential activity and mechanism of action against 
drug-resistant bacteria such as fluoroquinolone-resistant M. tuberculosis.  
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To investigate the in vitro inhibitory effect of nybomycin on common 
fluoroquinolone-resistant human bacterial pathogens, including M. tuberculosis, 








To examine the mechanism of resistance M. tuberculosis against nybomycin. 
 




Determine and compare the in vitro minimum inhibitory concentrations of 
nybomycin in fluoroquinolone-resistant and fluoroquinolone-susceptible human 






Predict the mechanism of action of nybomycin on M. tuberculosis gyrase enzyme 





Isolate M. tuberculosis mutants with increased nybomycin minimum inhibitory 
concentrations (µg/ml) and identify potential mechanism/s of resistance of                  
















CHAPTER 2 - LITERATURE REVIEW 
 
2.1    A brief history of antibiotic discovery 
 
In 1929 the bacteriologist Alexander Fleming reported his fortuitous discovery of 
penicillin1. As there was no drug discovery platform available to systematically 
investigate drug leads, Fleming resorted to sending samples of his Penicillium to 
his collaborators and anyone who requested for it2,3. Unfortunately, they all failed 
to isolate penicillin from the fungal cultures and interest in penicillin slowly 
waned2,3. Ten years later in 1939, the pathologist Howard Walter Florey and 
biochemists Ernst Boris Chain and Norman Heatley secured funding to isolate 
penicillin and examine its biological characteristics2,3. Within one year they 
managed to isolate pure penicillin from an extract of the Penicillium mold and used 
it to successfully conduct animal experiments2–4. In 1941, Albert Alexander 
became the first person to be treated with penicillin and by 1945, penicillin was 
made available to the public2,3,5. 
 
The drug discovery and development process surrounding penicillin took more 
than 10 years partly due to the absence of a methodical approach2,3. Soil 
microbiologists Albert Schatz and Selman Waksman introduced the first reliable 
drug discovery platform with their discovery of streptomycin in 19446–8. 
Pharmaceutical companies eagerly adopted this platform whereby they could 
systematically screen soil samples and fungal extracts for antimicrobials, thereby 
heralding the “Golden Age” of antibiotic discovery8–12. Nearly all the antibiotic 
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classes in use today were discovered with the Waksman platform from the 1940s 
to the 1960s11,13–15. 
 
The Waksman platform is a simple and effective low-throughput screening system: 
soil samples are first cultured and screened for potential antimicrobial producing 
organisms such as Actinomycetes. Potential antibiotic-producing isolates are then 
inoculated into shake flasks and cultured using various combinations of culture 
media, temperatures and agitation speeds, to induce the production of 
antimicrobial substances. Next, possible antimicrobial substances are extracted 
from the cultured broths and deposited on filter paper disks that are thereafter 
placed onto agar plates with a suitable broth as the nutrient base, freshly seeded 
with a susceptible indicator organism. After overnight incubation, if the cultured 
broth contains any substance capable of killing the susceptible indicator 
microorganism, then there will be a growth-free area i.e. a zone around the paper 
disk where the indicator microorganism failed to grow. Purified products produced 
by Actinomycetes and other microbial species can then be further investigated for 
antimicrobial action first using in vitro and then with in vivo methods7,8,16–18. 
 
The first three decades of antimicrobial discovery mostly followed a paradigm of: 
(1.) phenotypic screening, (2.) isolation and structural characterization of the 
compound, (3.) establishing the mode of action, (4.) animal and human clinical 
trials, and finally (5.) introduction into the market8. The methodologies pioneered 
by Waksman et al to isolate organisms from the environment, to grow them in 
liquid culture and to extract and purify antimicrobials from these cultures have not 
changed significantly for many years. However, major improvements made with 
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nuclear magnetic resonance spectroscopy and mass-spectrometry translated into 
faster and easier compound structure determination and analysis. These 
technologies proved to be very useful at identifying already known substances and 
thereby avoiding expensive and time consuming re-investigation of previously 
discovered compounds7,8,16–18. 
 
The “Golden Age” of antibiotic discovery that took off at the end of the second 
world war lasted only little more than two decades6,9,10. By the 1970s all the “low-
hanging fruit” of easily discoverable natural products have been picked and 
antimicrobials were increasingly being re-discovered using the Waksman platform, 
making it an unattractive and costly endeavor for many pharmaceutical 
companies6,9,11,19.  
 
From the 1970s onwards, significant technological progress enabled investigators 
to (1.) determine the mechanism of action (MOA) of newly isolated compounds 
much faster, (2.) develop synthetic compounds and (3.) produce semi-synthetic 
analogues of existing compounds8. The preferred approach of pharmaceutical 
companies therefore soon shifted from the Waksman platform to medicinal 
chemistry methodologies whereby existing antibiotics and antibiotic scaffolds were 
being modified and improved through various means in an effort to create 
analogue compounds and derivatives with increased antimicrobial activity and 
fewer clinical side-effects8,14,15. This approach yielded many new but similar 
compounds with often only marginal improvements compared to the original 
antimicrobials6,11,14,15. The ensuing steady stream of analogues and derivatives of 
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previously discovered antimicrobial classes, that started in the 1970s, became a 
trickle by the late 1980s6,11,14,15. 
 
In the aftermath of the “Golden Age” of antimicrobial discovery, scientists also 
gradually began to employ a “reversed” approach to drug discovery by first 
identifying drug targets and then using various methods to devise a successful 
synthetic compound against the identified target12. An ideal drug target is normally 
an enzyme that forms part of a critical or essential function in the microbe12. These 
microbial enzymes should be absent or significantly different from those found in 
human cells, in order to avoid unwanted side-effects12. Thus target-based 
screening was born8. 
 
With the older drug-based approaches, such as the Waksman platform, the MOA 
is only determined once a compound has been identified to exert an inhibitory 
effect on the target organism8. Target-based screening on the other hand, is 
based on either a previously or a newly described or assumed drug target8. 
Potential drug targets i.e. essential and conserved microbial proteins are identified 
through techniques offered by cumulative technological advances in the fields of 
genetics, genomics, proteomics and biochemistry8,11,12. A number of reviews have 
been published delineating different target-based drug screening approaches20–22. 
 
Rational drug design, a multi-disciplinary approach whereby several disciplines 
work together to design drug targets, slowly started to develop and mature over 
the ensuing decades23. In order to find hit molecules, investigators can follow 
either one or both of the following two routes: (1.) design small molecules that will 
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bind to and inhibit the target molecule, or (2.) screen collections of chemicals, or 
partially purified extracts of natural products, with the help of biochemical assays 
that identify target inhibition8,12. Once a positive interaction has been identified 
between the target and a test compound, then the test compound is further studied 
using in vitro and thereafter in vivo investigations8,11,12. 
 
The 1990s saw the advent of sophisticated genomics and a maturing field of 
biochemistry8. The development of combinatorial chemistry provided investigators 
with thousands of unique molecules derived from hundreds of chemical scaffolds8. 
Robotics together with various chemical assays enabled pharmaceutical 
companies to embark on high-throughput screening (HTS) programs pairing 
enormous libraries of synthetic chemicals against a growing number of potential 
drug targets delivered by genomic investigations8,11,12. The much slower low-
throughput screening for identifying useful natural compounds was therefore 
abandoned by almost all pharmaceutical companies in the period between the 
mid-1990s and mid-2000s8. This time period of roughly 10 years saw more 
compounds being screened than in the preceding 60 years put together8. The 
high-throughput biochemical assay-based platform proved very successful in 
identifying novel targets and in producing structurally optimized inhibitor 
molecules8,11. Unfortunately, out of a number of hits only a few useful leads 
followed, but no broad-spectrum antibiotics reached the market using this 
approach11,12. Bedaquiline, a narrow-spectrum antimicrobial discovered in 1997 
and only effective against Mycobacterium tuberculosis, was as of 2017 the only 
antimicrobial with a truly novel mechanism of action, discovered through the HTS 
approach that has reached the market11,12. The general failure of the HTS platform 
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is commonly ascribed to the fact that compounds identified this way were usually 
unsuccessful in adequately penetrating bacterial cell walls or cell membranes and 
therefore did not reach high enough concentrations at their intended target 
site11,12. In recent years drug discovery efforts have thus started to move back to 
whole-cell screening, but now it is coupled with a strong emphasis on high target 
specificity12. Delamanid is a good example of where HTS coupled with rational 
drug design lead to a drug that successfully reached the market24. This narrow-
spectrum drug is only active against M. tuberculosis24. However, delamanid is a 
dihydro-nitroimidazooxazole derivative, related to metronidazole and is therefore 
not considered to have a completely novel mechanism of action25,26. Bedaquiline 
(2012) and delamanid (2014) are the only new drugs that have been specifically 
developed against M. tuberculosis in almost 70 years that have reached the 
market27. 
 
Since the 1980s there was a steady decline in the approval of new antibiotics by 
the United States Food and Drug Administration13. Excluding drugs against          
M. tuberculosis, the last 20 years saw only two novel classes of systemic 
antibiotics reach the market, the oxazolidinones (linezolid in 2000) and cyclic 
lipopeptides (daptomycin in 2003)13,28.  Both drugs are only useful against Gram-
positive bacteria30. For Gram-negative bacteria, there have been no novel 
antibiotic classes discovered since nalidixic acid and the fluoroquinolones in the 
1960s28. 
 
Advances in genomics and the dire global need for novel antibiotics led to the re-
evaluation of the “old-fashioned” whole-cell or drug-based approach to the 
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screening of natural compounds. Investigation of the Streptomyces genome in the 
early 2000s revealed surprisingly large numbers of gene clusters coding for 
secondary metabolites not previously found to be expressed during laboratory 
culture methods8. It was subsequently estimated that less than 10% of these 
genes are expressed in sufficient amounts using the current culture conditions 
applied in drug screening programs8. Investigators are now pursuing various new 
culture and genetic manipulations to entice the organisms to reveal their “hidden” 
metabolites8. Natural product screening and drug-based antimicrobial design 
recently gained attention through a new innovation, called the iChip14,31. 
Historically 99% of all microbial species on our planet could not be cultured using 
current methodologies11,32. This greatly limits the number of bacteria that can be 
investigated for antibiotic production14,31,32. Some of these previously  “non-
culturable” bacteria have recently been grown inside diffusion chambers that were 
incubated in the natural environment of soil bacteria11,14,31,32. This approach has 
been improved and resulted in the development of the iChip, a device that allows 
for high-throughput cultivation of several bacterial species at the same time14,31,32. 
Teixobactin was the first novel natural-product antibiotic in nearly thirty years. It 
was discovered in 2015 using the iChip method and has subsequently shown 
great promise against S. aureus and M. tuberculosis32–34. 
 
Although not very successful, drug modifications and the screening of synthetic 
compound libraries remained the principal platforms for discovering new antibiotics 
for many years6,11,14. Fortunately, scientific and technological advances during the 
last 20 years provided researchers with a greatly enhanced toolbox with which to 
approach antimicrobial discovery14,35,36. Alongside the return of compound-based 
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screening methodologies and HTS, there also evolved a myriad of new and non-
traditional methodologies and screening systems. These methodologies have 
been employed with varying degrees of success9,14,15. This includes (1.) discovery 
of novel cellular functions, (2.) targeting of critical survival functions in vivo,        
(3.) targeting of different physiological states of bacteria, (4.) regulation of host cell 
functions, and (5.) investigations to identify effective drug combinations36. 
 
The role of computational methods in antimicrobial design and discovery has been 
increasing over the last three decades, and various in silico methodologies have 
been developed that now form an integral part of the drug discovery and 
development landscape36–38. Computer-aided drug design (CADD) specifically 
assists with the identification of potentially effective compounds, predict their 
pharmacological actions and side effects, and enhances their bioavailability. It so 
promises to reduce both the cost of drug discovery and the time for new drugs to 
reach the clinic39. CADD potentially plays three leading parts in the antimicrobial 
discovery process: (1.) virtual screening to reduce the number of compounds 
earmarked for in vitro and in vivo testing, (2.) evaluation and optimization of the 
absorption, distribution, metabolism and excretion and toxic characteristics 
(ADMET) of lead compounds and (3.) designing of effective derivatives and novel 
compounds39,40. 
 
Target identification can be either ligand-based or structure-based. Ligand-based 
CADD is an indirect approach that utilizes current knowledge of known active and 
inactive compounds. Pharmacophore modeling and quantitative structure-activity 
relationship (QSAR) modeling are two of the most popular ligand-based 
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approaches used by CADD specialists today39,40. Pharmacophore modeling allows 
description of the crucial features of a ligand that are responsible for a particular 
biological interaction when interacting with another molecule39. The 
pharmacophore model can also be used for lead optimization, virtual screening 
approaches and de novo drug design39. QSAR modeling provides a mathematical 
association between the structural characteristics and the target response of a 
collection of molecules39. 
 
Structure-based CADD involves the construction and investigation of three-
dimensional (3D) structures of molecules and exploits this knowledge about the 
target protein structure to compute the interaction energies between the protein 
target and test compounds39. The premise of this approach is that the ability of a 
molecule to interact with a protein and exhibit the intended biological effect, is 
dependent on its potential to appropriately interact with a specific binding site on 
the target protein in the first place39. Information about target protein structures is 
typically obtained from X-ray crystallography or magnetic resonance 
investigations39. In the absence of these techniques, in silico methods such as 
homology modelling can sometimes be employed to predict the target’s 3D 
structure39. Molecular docking simulations that have been in use since the 1980s, 
as well as de novo ligand design are two widely used structure-based CADD 
approaches39,40. 
 
Molecular docking is used to predict the energy interactions within ligand-receptor 
complexes39,40. Molecular docking experiments usually involve first sampling and 
then the assessment of the binding affinity using a predetermined scoring 
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system39,40. During the sampling stage, the ligand conformation, pose, position 
and orientation are predicted39,40. This process generates a large variety of target-
ligand complex conformations and orientations that may include many 
inappropriate poses and inactive molecules39,40. To make sense of the data, a 
predetermined scoring system is used to estimate and rank the target-ligand 
complex conformations and this can be done according to empirical scoring 
functions, knowledge-based scoring functions, consensus scoring functions and 
molecular mechanics based functions, also called force-field based functions39,40. 
Molecular docking can be done blindly i.e. without knowledge of the potential 
binding sites, but knowing beforehand where the potential binding site might be 
markedly improves docking efficiency40. For blind docking, potential binding sites 
may be identified with the help of cavity detection software or online servers such 
as PASS, Metapocket and POOL41–43. 
 
Molecular dynamics simulations are used to gain insight into the potential 
conformational changes and fluctuations during ligand-target protein interactions; 
as well as to investigate the adaptability and variability potentials of the target 
protein39,40. Commonly used software packages for molecular dynamics simulation 
investigations include AMBER, NAMD and GROMACS39,43. Molecular dynamics 
simulations performed on high-speed supercomputers are usually completed 
within a few nanoseconds to microseconds39. 
 
Computational techniques are also increasingly being used to predict a 
pharmacokinetic i.e. ADMET profile of potential compounds and therefore provide 
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a useful early screening tool39. The in silico obtained ADMET profiles can also be 
used to optimize test compounds before further investigations are executed39. 
 
Several drug discovery approaches have been attempted through the years, with 
varying degrees of success6,10,27,35,44–52. Some recent non-traditional approaches 
include: 
 
Human microbiome. The human microbiome is investigated for commensal 
antibiotic-producing organisms that help one commensal to compete with other 
commensals14,53. An example of where this bared fruit was when Zipperer et al 
discovered that Staphylococcus lugdunensis produces a potent antibiotic 
compound called lugdunin, that is active against Staphylococcus aureus14,53. Both 
these organisms are commensals of the anterior nares of humans14,53. 
 
Bacteriocins. Bacteriocins are peptides produced by bacteria that are active 
against other bacteria but not against its producer14. Theoretically, bacteriocins 
could help wild type bacteria replace its drug-resistant counterparts without 
negatively affecting other commensals14. To date, very little in vivo data have been 
published that successfully demonstrate this effect14.  
 
Phages and phage components. Bacteriophages and phage lysins are interesting 
avenues that have been explored in recent years, but published evidence is still 
sparse and unconvincing14,54,55. Tailocins are tail structures from defective phages 
that display antimicrobial properties14,56. Gebhart et al isolated tailocins from 
Clostridium difficile isolates by inducing the bacterium’s SOS response57,58.     
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These tailocins were modified by Kirk et al and produced promising results against 
Clostridium difficile in mice14,59. 
 
Bacteriovores. A fascinating concept that has lately received attention is that of 
bacteriovores14. Bacteriovores such as Bdellovibrio bacterivorus and Micavibrio 
aeruginasavorus consume other bacteria and have shown some encouraging 
results both with in vitro investigations and with in vivo investigations using animal 
models60–64.  
 
Despite major scientific advances and a plethora of new technologies at our 
disposal, the majority of antibiotics in use today have been derived from natural 
products and target the bacterial cell wall, DNA or ribosomes8,15. The role of 
natural products as a source of novel antimicrobials cannot be overstated. 
 
2.2    A brief history of antimicrobial resistance 
 
With the start of the “Golden Age” of antibiotic discovery, humanity finally had at its 
disposal real weapons with which to address the scourge of microbial 
infections11,29. It is believed that antibiotics have increased average human life 
expectancy by 10 to 20 years29. Unfortunately, our microbial adversaries very 
soon started to respond to our new wonder weapons with a myriad of clever 
resistance mechanisms11,29. The discovery and development of new antibiotics 




As microbes replicate they naturally produce numerous small subpopulations with 
various combinations of genomic mutations. If the microbial population is exposed 
to any external threat such as an antibiotic, there may very well be a 
subpopulation of microbes that is already resistant to this new threat. The 
antibiotic may therefore kill off the susceptible microbes, but not the drug-resistant 
subpopulation. This drug-resistant subpopulation consequently gets “selected” by 
the antibiotic and can continue to proliferate and spread. The resistance-conferring 
genes are then vertically passed on to the next generation of microbial offspring. 
More frighteningly is the fact that such resistance mechanisms can spread 
horizontally between members of the same species, and even to other species. 
This is accomplished through various mobile genetic elements that transfer 
resistance genes between microbes by mechanisms known as transformation, 
conjugation and transduction65–67. Apart from the mechanism whereby use of 
antimicrobials select drug-resistant subpopulations, there is also emerging 
evidence suggesting a more direct correlation between antimicrobial use and 
resistance68,69. One possible mechanism is the induction of mutations by sub-
inhibitory concentrations of antimicrobials68,69. 
 
The resistance-acquiring capabilities and activities of microbes are part of their 
natural survival living processes and have been at work long before the 
introduction of antimicrobials in modern medicine6,69–71. It is therefore not 
surprising that resistance was reported to sulfonamides within two years after 
humans started administering these compounds to patients. These sulfonamides 
were the first effective antimicrobials that reached the market in 193769,72. This 
pattern of the introduction of a new antimicrobial followed by microbial resistance 
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to the antimicrobial soon thereafter has been repeated ever since, without any 
exceptions15,69,70,73. In fact, many antibiotics that have reached the market, did so 
with the scientific community’s knowledge that bacteria already displayed natural 
resistance to it11. 
 
Infections due to antimicrobial resistant pathogens have a significant clinical and 
economic impact that is of growing global concern13,74. High mortality rates have 
been reported from hospitals across the globe for infections caused by antibiotic 
resistant bacteria, especially in intensive care units (ICU)74. 
 
In the United States alone, the Centers for Disease Control and Prevention 
estimated in 2013 that two million individuals contract infections due to drug-
resistant bacteria every year, 23 000 of which are fatal13,69. The estimated annual 
direct and indirect cost to the country was estimated at $55 billion13,69. In the 
European Union, antimicrobial resistance is held responsible for the death of 
approximately 25 000 humans and an annual monetary loss of approximately   
€1.5 billion74–76. This is excluding the indirect costs related to antimicrobial 
resistance. For developing countries, good quality data on the clinical and 
economic impact of antimicrobial resistance are lacking but the situation is likely at 
least similar if not worse than for developed countries28,69,74,77. 
 
Current estimates for annual global deaths attributable to antimicrobial resistance 
sits at approximately 700 000 individuals and is predicted to increase to 10 million 
individuals annually by 2050, surpassing the number of deaths due to cancer.    
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The collective cost that antimicrobial resistance will pose to the world economy is 
estimated to be $100 trillion per year13,19,29,77. 
 
Enterococcus spp, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter 
baumanii, Pseudomonas aeruginosa and Enterobacter spp are collectively 
represented by the widely used acronym ESKAPE and are globally recognized as 
the most common antimicrobial-resistant bacterial species associated with 
infections that carry a higher risk of mortality13,74. Multidrug-resistant (MDR) 
ESKAPE organisms are associated with an increased length of hospital stay and 
higher health care costs compared to infections with their drug-susceptible 
counterparts13,74. In 2017 the World Health Organization (WHO) went further and 
published a list of the priority antimicrobial resistant pathogens requiring intensive 
drug discovery research efforts to combat infections due to these organisms28,78. 
Addressing M. tuberculosis separately, other organisms were grouped into 
different prioritized categories28,78.  The “critical priority” category consisted of      
A. baumannii (carbapenem-resistant), P. aeruginosa (carbapenem-resistant) and 
Enterobacteriaceae (carbapenem-resistant and/or third generation cephalosporin-
resistant)28,78. Almost one third of hospital acquired infections in acute care 
settings, and over 40% in ICUs are caused by these “critical priority” pathogens79. 
A previous report by the WHO stated that infections due to antimicrobial resistant 
K. pneumoniae (third generation cephalosporin-resistant and carbapenem-
resistant) and Escherichia coli (third generation cephalosporin-resistant, including 
extended spectrum beta-lactamase positive and fluoroquinolone-resistant) lead to 
a significant increase in the 30-day as well as all-cause mortality of hospitalized 
patients80. The WHO’s “high priority category” was made up by E. faecium 
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(vancomycin-resistant), S. aureus (vancomycin-resistant and/or methicillin-
resistant), Helicobacter pylori (clarithromycin-resistant), Campylobacter spp 
(fluoroquinolone-resistant), Salmonella spp (fluoroquinolone-resistant) and 
Neisseria gonorrhoeae (third generation cephalosporin-resistant and/or 
fluoroquinolone-resistant)28,78. Drug-resistant S. aureus and E. faecium are the two 
most important Gram-positive bacteria on the WHO list; and although there are 
significantly more drugs available to treat infections caused by them, as well as 
compounds in the drug-development pipeline compared to the Gram-negative 
bacteria, they are still considered highly problematic28,78. Infections due to 
methicillin-resistant S. aureus compared to methicillin-susceptible S. aureus are 
responsible for substantial increases in all-cause mortality, S. aureus attributable 
mortality, ICU mortality, septic shock and length of hospital stay69,81. Enterococci 
resistant to vancomycin ranks as the second most common cause of nosocomial 
infections in the United States, but data from developing countries and particularly 
Africa is limited82–85. Drug-resistant M. tuberculosis is also a global threat which 
will be discussed in section 2.3. 
 
Several generic principles have been proposed over the years to curb the problem 
of antimicrobial resistance and maximize the lifespan usefulness of the currently 
available antimicrobials, for example optimal diagnosis, prescription an 
administration practices, avoidance of use of antimicrobials in agriculture, 
development of new and novel antimicrobials, quality assurance of antimicrobials 
and enhanced surveillance systems67. Programs and interventions employing 
these principles are generally referred to as antimicrobial stewardship practices 
and are encountered in diverse contexts such as human health, animal health and 
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the environment86. Faced with divergent definitions of antimicrobial stewardship,         
Dyar et al recently proposed the following simple definition: “A coherent set of 
actions which promote using antimicrobials responsibly”86. In the context of human 
healthcare, the generic principles mentioned above have been expounded upon in 
detailed guidelines and academic publications by prominent advisory bodies such 
as the Infectious Diseases Society of America (IDSA), the Society of Healthcare 
Epidemiology of America (SHEA) and the European Society of Clinical 
Microbiology and Infectious Diseases (ESCMID)67,86–90. In their updated 
antimicrobial stewardship guidelines of 2016, IDSA identified “preauthorization of 
antimicrobial prescriptions and/or prospective audit and feedback” as the 
backbone of any healthcare antimicrobial stewardship program89. The only other 
interventions that received strong recommendations in this guideline were:         
(1.) interventions that promote the appropriate use of oral antibiotics for initial 
therapy as well as switching from intra-venous to oral therapy, (2.) use of 
antimicrobials for the shortest effective time possible, (3.) pharmacokinetics 
monitoring and adjustment of aminoglycoside therapy and (4.) avoidance of 
antimicrobials with a high risk for Clostridium difficile infections89. 
 
Antimicrobial resistance has been rightfully identified as a serious threat to public 
health as early as the 1990s91,92. During the G8 Summit of 2013, antimicrobial 
resistance was further described as the “major health security challenge of the 21st 
century” that demands intensive global collaboration34. Despite these and many 
other warnings, our predicament just keep getting worse due to the “selective 
pressures” effected by our misuse and overuse of antimicrobials34,69. The world 
may soon have to face a “post-antibiotic” era due to our inability to change the 
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trajectory of our actions15,34,93. The WHO Director, Margaret Chan ominously 
stated in 2012 that the post-antibiotic era may very well mean an end to modern 
medicine as we know it34,94. In this tug-of-war between humans and microbes it 
currently seems like the microbes will have the final say and that the prophesized 
dawn of the “post-antibiotic” era is upon us11,29,95. 
 
The discovery of new antibiotics is therefore of obvious importance to the 
continued availability of drugs effective against the rising wave of drug-resistant 
bacteria14. Unfortunately, discovering and developing new antibiotics is not seen 
as an economically lucrative use of scarce resources by pharmaceutical 
companies, especially when natural product screening is involved14. The discovery 
and development of new antibiotics is a complex, expensive and time-consuming 
process12. Newly introduced antibiotics are usually subjected to restrictive 
regulatory constraints resulting in limited use and therefore low sale profits14. 
Discouragingly the development of a new drug, from concept to market, currently 
takes up to 15 years and is estimated to cost more than $1 billion or even         
$2.5 billion9,12,29. Adding to this economic hurdle the numerous regulatory and 
scientific hindrances, and it becomes clear why 10 of the 15 largest 
pharmaceutical companies have since the turn of the century abandoned or 
drastically reduced their antibiotic research efforts28,34,96. However, the recent 
discovery that Actinomycetes may be able to produce a much larger number of 
active compounds than previously believed, has now opened up again the avenue 




Another serious consideration is the re-investigation of natural compounds that 
were previously discovered, but that were not considered high-quality leads at the 
time and consequently never reached the market. Three good examples of this are 
fidaxomicin, linezolid and streptogrammin B, discovered in 1948, 1955 and 1963; 
that respectively only reached the market much later in 1998, 2000 and 201111. 
 
2.3    Background to the problem of Mycobacterium tuberculosis 
 
M. tuberculosis is a causative agent of tuberculosis (TB), a leading cause of 
mortality worldwide, especially when associated with HIV98. During 2017 
approximately 10 million individuals were infected with M. tuberculosis and 1.6 
million succumbed to this infection98. M. tuberculosis and HIV act synergistically 
and is particularly lethal when combined with antimicrobial resistance99,100.       
MDR TB is defined as TB with in vitro resistance to first-line drugs isoniazid and 
rifampicin101–103. MDR TB accounted for roughly 510 000 cases and 230 000 
deaths during 201798. Extensively drug-resistant (XDR) TB is MDR TB with         
M. tuberculosis with additional in vitro resistance to fluoroquinolones and at least 
one of the second-line injectable agents101–103. Roughly 8.5% of individuals with 
resistance to isoniazid and rifampicin have XDR TB98. With a worldwide mortality 
of at least 30% and a South African mortality rate of 47% in 2012, XDR TB 
presents a serious threat to public health, especially in populations with a high 
prevalence of HIV98,102. New treatment options are urgently needed to address the 
growing problem of drug-resistant tuberculosis. 
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2.4    A brief history of antimycobacterial discovery 
 
The first antibiotic found to be effective against M. tuberculosis was streptomycin, 
discovered by Albert Schatz, Elizabeth Bugie and Selman Waksman in 1943 from 
the screening of soil samples containing Actinomyces bacteria7,104. This was soon 
followed by para-aminosalicylic acid (1946)105, isoniazid (1951)104, pyrazinamide 
(1952)106, cycloserine (1952)107–109, ethionamide (1956)110,111, kanamycin 
(1957)104,112, the rifamycins (1957)104,113–115, capreomycin (1960)104,116 and 
ethambutol (1961)104,117 by various different investigators. These drugs are still in 
use today and many of them continue to form the backbone of tuberculosis 
treatment programs worldwide98,101. After the initial flurry of drug discoveries and 
the subsequent treatment successes, new drug discoveries effectively came to a 
standstill6,104. Unfortunately, during the 1980’s and 1990’s, drug-resistant             
M. tuberculosis started to raise its ugly head and authorities realized that our 
treatment arsenal needs to be expanded104,118. To this end several known drugs 
were reinvestigated, with varying degrees of success, for potential use as 
antimycobacterial agents, including the rifamycins, fluoroquinolones, linezolid and 
clofazimine104. To date, the only new drugs developed specifically against drug-
resistant M. tuberculosis that reached the market since the 1960’s were 
bedaquiline and delamanid50,78,104. Disappointingly, limited access and drug 
resistance have already undermined the expected success of both drugs24,27,50,119. 
Towards the end of 2017 the WHO reported on the current drug development 
pipeline, including drugs against M. tuberculosis28,78. Only one drug is currently in 
phase three clinical trials (pretomanid), two in phase two trials (delpazolid,        
SQ-109) and four in phase one trials (GSK-3036656, Q-203, PBTZ-169 and    
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OPC-167832)28,78. Two of these drugs, pretomanid and delpazolid are closely 
related to currently available drugs, and cross-resistance may therefore markedly 
reduce their anticipated usefulness28,78. Despite the progress made since the early 
2000s, when no new drugs were in clinical development, the global plea for novel, 
safe and effective antimycobacterials remains as urgent as ever27,28,46,78,120. 
 
Strategies for the screening and discovery of new antimycobacterial drugs are 
generally classified as either “target-to-drug” (or “target-based”) or “drug-to-target” 
(or cell-based or phenotypic) approaches, but oftentimes investigators make use 
of a combination of these two strategies48,52. 
 
Drug-to-target approach. The starting point of this approach is typically the in vitro 
exposure of live cultures of M. tuberculosis to various concentrations of potentially 
active compounds usually obtained from specific compound collections or 
libraries11,35,48. HTS approaches are used to screen large numbers of compounds 
without necessarily having knowledge about its molecular structure or what the 
molecular target might be11,35,48. In vitro bactericidal activity usually implies that the 
compound can cross the bacterial cell wall and reach a sufficient concentration to 
exert a killing effect11,35,48. Once this effect has been evaluated, then the MOA 
should be determined11,48. A whole plethora of methodologies are available 
making use of genomics, transcriptomics, proteomics, metabolomics, live-cell 
imaging and electron microscopy11,48,121,122. It is important to identify the MOA and 
the drug target to enable researchers to improve the primary compound, for 
example improving its bactericidal capability or water solubility11,35,48,123. 
Deciphering the MOA can however be a very challenging endeavour35,48.       
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Whole genome sequencing (WGS) plays a central role in elucidating the drug 
target: drug-resistant mutants are selected by exposing wild type M. tuberculosis 
to various concentrations of the testing compound124–129. By comparing the 
genome of the wild type and the mutant with each other, the mechanism of 
resistance (MOR) may be elucidated126,130–132. This knowledge is then used to 
extrapolate the MOA through recombineering and complementation 
techniques48,124,126,133. A common approach to elucidate the MOA is to “knock-out” 
the implicated gene in a wild type organism and then compare its in vitro 
susceptibility to the testing compound, with that of the wild type 
organism125,132,134,135. Unfortunately there may be a mismatch between the MOR 
and the MOA and additional investigations are usually required48. Furthermore, 
many antimycobacterial drugs function as produgs and comparative genomics 
may rather identify mutations in genes coding for non-essential enzymes 
responsible for activating the prodrug instead of the genes coding for the essential 
target48. 
 
Advantageously, the drug-to-target approach lends itself to the early discovery of 
additional target and pathways, as well as the possibility of finding valuable pro-
drugs52. Initial screening sometimes includes experiments where M. tuberculosis is 
cultured and exposed to the investigating compound inside macrophages or lung 
fibroblast cells48,134,136. This provides further evidence that the compound might 
have in vivo effectivity48,134,136. Together with positive in vitro screening outcomes 
and identification of the drug target, it is usually necessary to determine the 
cytotoxic and apoptotic potential of the testing compound48,134,137. 
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Target-to-drug approach. Investigators exploit our growing body of scientific 
knowledge, especially in the fields of chemistry and molecular biology, to identify 
potential drug targets11,35,48. These hypotheses are then used to engineer large 
libraries of compounds that may act on these potential drug targets11,35,48. Several 
HTS methods can then be utilized to screen such compound libraries to identify 
possible hits for further investigation11,35,48. Target-based HTS has become 
widespread for M. tuberculosis since the early 2000s, but has had limited success 
when used alone48,52. Probable reasons for its disappointing performance include: 
(1.) deficient information on target susceptibility, (2.) poor drug penetration into 
microbe or surrounding tissue, (3.) drug metabolism problems and (4.) efflux of 
drugs out of microbes48. Target-based hits must therefore always be followed up 
with selected whole-cell phenotypic investigations before in vivo testing can be 
pursued10,11,48,105. 
 
The drug-to-target approach is considered by some as more successful than the 
target-to-drug approach with both bedaquiline and delamanid having been 
discovered this way48,138. However, this approach has several limitations: (1.) it is 
often very difficult to unravel the molecular target of the compound, (2.) selection 
and genomic investigation of phenotypic drug-resistant mutants in order to 
describe the MOR often does not help to identify the MOA, (3.) relatively high rate 
of discovering pro-dugs and (4.) many compounds end up being highly 
promiscuous in their target binding48,139–141. 
 
In the overlap between the drug-to-target and target-to-drug approaches, several 
disciplines have made integral contributions in recent years and include amongst 
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others: (1.) comparative genomics to identify genes that correspond with 
phenotypic resistance, (2.) structural genomics to generate 3D structures of gene 
products that inform our understanding of protein folding, binding and functioning, 
(3.) protein crystallization and X-ray data provides 3D structures of important 
proteins that can be used for in silico screening, molecular docking investigations 
and to expand our knowledge of binding-site interactions and specifically ligand-
receptor binding51,123,142. 
 
2.5    Nybomycin 
 
Nybomycin is a naturally occurring compound that was discovered in the 1950s 
during the “Golden Age” of antibiotic discovery, but was never developed for 
clinical use143–147. Asheshov et al first reported on the broad anti-phage spectrum 
of activity of culture liquids from a streptomycete, designated A 717, found in 
Missouri soil144. A colorless crystalline compound was subsequently isolated from 
this culture liquid and mycelia and it was named nybomycin145,147. On further 
investigation nybomycin displayed antibacterial activity as well145. Strelitz et al 
described the antibacterial activity of nybomycin in a small collection of bacterial 
isolates using disk diffusion and broth dilution methods in parallel145. The two 
methods were in agreement and included seven E. coli isolates, four S. aureus 
isolates and one isolate each of K. pneumoniae, P. aeruginosa,        
Mycobacterium smegmatis, Staphylococcus muscae, Bacillus subtilis, B. cereus 
and B. mycoides145. Nybomycin had an observable inhibitory effect on most 
isolates, but noticeably had no effect on the majority of E. coli isolates, two out of 
the four S. aureus isolates and the one P. aeruginosa isolate145. Susceptibility of 
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Gram-negative bacteria to nybomycin could not be reproduced during more recent 
studies143,148. The same investigators also performed preliminary toxicity studies in 
mice and reported that the mice tolerated intra-peritoneal nybomycin doses of 250 
mg/kg145. In 1961, Rinehardt et al described the chemical structure of nybomycin 
as well as one of its degradation products, deoxynybomycin149. A separate group 
of investigators isolated deoxynybomycin from Streptomyces hyalinum in 1970 
and reported a higher bactericidal activity than with nybomycin itself150. In the 
same year Rinehardt et al published their revised structure of nybomycin151. The 
synthesis of nybomycin was further described and refined during the 1970s152–155. 
During this time nybomycin was classified as a pyridoquinoline compound152,156. 
Interestingly, Rinehardt et al also synthesized anthraquinone during their early 
work with nybomycin149,157. This compound was subsequently renamed to 
deoxynyboquinone and is described as a potent antineoplastic agent with a 
currently unknown mechanism of action157,158. The quinoline ring that is found in 
nybomycin’s structure is also found in fluoroquinolone antibiotics, certain anti-
malarial drugs and some anticancer drugs152,156,159. This may indicate similar 
mechanisms of actions shared between these drugs and a self-evident starting 
point for further investigations to unravel nybomycin’s mechanism of 
action152,156,160. The quinoline ring itself has been described as a promising 
scaffold for future anti-tuberculosis drug development161,162. 
 
More recently in 2011, nybomycin was noticed again after Chinese investigators 
isolated deoxynybomycin from Pseudonocardia SCSIO 01299, a marine 
actinomycete found in a deep-sea sediment collected from the South China 
Sea163,164. Two groups from Japan also isolated nybomycin in recent years143,165. 
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The first group while screening soil samples for antibacterial activity against               
S. aureus and the second group from Streptomyces spp MS44 found in marine 
sediment collected in 2000 at Maizuru, Japan143,165. 
 
In 2012, Hiramatsu et al examined the in vitro effect of nybomycin on S. aureus 
(including methicillin-resistant S. aureus) and Enterococcus faecalis (including 
vancomycin-resistant Enterococci spp); and found fluoroquinolone-resistant 
bacteria to be susceptible to nybomycin and fluoroquinolone-susceptible bacteria 
to be resistant to nybomycin143. This unexpected inverse relationship was further 
investigated through the selection of nybomycin-resistant mutants143. Nine 
independent fluoroquinolone-resistant S. aureus isolates were methodically 
exposed to nybomycin so that nybomycin resistant-mutants could be selected 
out143,166. These nybomycin-resistant S. aureus mutants were found to be 
fluoroquinolone-susceptible and DNA sequencing confirmed that their gyrA genes 
mutated back to the original wild type143,166. 
 
Nybomycin therefore possibly has a novel mechanism of action whereby it 
specifically inhibits mutated DNA gyrase in S. aureus, but not the wild type 
enzyme143,166. Hiramatsu et al coined the term “reverse antibiotic” to refer to 
compounds that exhibit this phenomenon and categorized nybomycin as the first 
antibiotic in this new class143. Flavones such as apigenin are natural antibiotics 
produced by plants and is the second group of compounds to have been 
designated reverse antibiotics in relation to fluoroquinolones166–168. It is further 
postulated that the alternation of an antibiotic with its specific reverse antibiotic 
when treating an infection, may possibly keep the offending organism susceptible 
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to either one of the two antimicrobials, thereby overcoming the problem of 
accumulating resistance and multidrug-resistant bacteria altogether143,166. 
 
Quinolone compounds, some of which are antibacterial, are naturally produced by 
some animals, plants and bacteria169,170. It is known that certain environmental 
bacteria are resistant to fluoroquinolones, often due to mutations in the quinolone 
resistance-determining region (QRDR) of the gyrA gene143,171. For example, 
fluoroquinolone antibiotics cannot stably bind to the quinolone binding pocket of 
staphylococcal GyrA when a S84L mutation is present, and such isolates are 
therefore resistant to fluoroquinolones166. Docking simulation studies by Hiramatsu 
et al showed that the loss of the serine residue in position 84 of GyrA of S. aureus 
does not negatively affect stable binding of nybomycin to the mutated binding 
pocket166.  It is suggested that because quinolone antibiotics have been present in 
nature before the introduction of synthetic fluoroquinolones, that certain bacteria 
started to produce nybomycin in order to compete with fluoroquinolone-resistant 
bacteria143,171. 
 
Fluoroquinolone resistance in most clinically significant bacteria is the result of a 
large variety of potential mutations in genes coding for both subunits of the gyrase 
enzyme, in addition to other resistance mechanisms such as efflux 
pumps160,172,173. This is in contrast to M. tuberculosis where fluoroquinolone 
resistance is very seldom due to mutations in gyrB and almost exclusively 
confined to a small number of mutations in codons 90, 91 and 94 of gyrA160,173–175. 
Globally the most commonly identified gyrA QRDR amino acid substitutions are 
that of alanine to valine in codon 90 and aspartic acid to glycine in                   
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codon 94160,173,174. Mutations in codons 90 and 94 correlate well with increased 
minimum inhibitory concentrations (MIC) to ciprofloxacin, ofloxacin and 
moxifloxacin173,174,176. In the KwaZulu-Natal province of South Africa, the A90V 
amino acid substitution was identified as the dominant gyrA mutation in XDR TB 
isolates120,160,174. 
 
DNA is naturally in a supercoiled state that hinders DNA transcription and 
replication172. DNA gyrase briefly reverses this ATP-dependent supercoiling by 
catalyzing double-stranded DNA (dsDNA) breaks172. Fluoroquinolones disrupt 
bacterial growth by forming covalent, but reversible gyrase-DNA adducts, that 
block the resealing of these dsDNA breaks177. In most bacterial species, 
fluoroquinolones bind via a hydrated magnesium ion bridge to the serine residue 
located in the second position of the helix α4 of the GyrA subunit of gyrase177. 
However, for wild type M. tuberculosis this amino acid is alanine and corresponds 
to codon 90 of the QRDR of GyrA175. This difference translates into a markedly 
naturally lower binding affinity between fluoroquinolones and M. tuberculosis GyrA 
as compared to other bacterial species177. Recent investigations by Aldred and 
Blower et al emphasized this point by showing how fluoroquinolone-gyrase binding 
was improved when the naturally occurring alanine was replaced with a 
serine175,177. They further described how fluoroquinolones form weaker non-
anchoring bonds with Ala90 and stronger anchoring bonds with downstream 
Asp94, but that the alanine at codon 90 is essential for facilitating Asp94 to anchor 
the drug-GyrA bridge175,177. 
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Morimoto et al (2013) investigated the effect of nybomycin on E. coli148. All          
14 isolates tested resistant to nybomycin, irrespective of the fluoroquinolone 
susceptibility status148. However, all isolates had markedly improved nybomycin 
activity (MIC ≤ 1 μg/ml) when tested in the presence of an efflux pump inhibitor 
Phe-Arg beta-naphtylamide (PAβN)148. This suggests that efflux pumps may be an 
important nybomycin resistance mechanism in E. coli and possibly other Gram-
negative bacteria148. 
 
Arai et al investigated the antimicrobial effect of nybomycin on M. smegmatis and 
M. bovis BCG165. Both organisms displayed a minimum inhibitory concentration of 
1.0 μg/ml during active (aerobic) growth as well as in hypoxia-induced dormant 
growth states165. They further observed morphological changes similar to those 
found with mutations in pknA, pknB, ftsZ and whmD genes165. The investigators 
proceeded to perform WGS on spontaneously nybomycin-resistant M. smegmatis, 
but did not identify any mutations in the pknA, pknB, ftsZ, whmD, gyrA and gyrB 
genes165. They did however identify two amino acid level mutations: L59P in tetR 
family transcriptional repressor and A23V in glycine/D-amino acid oxidase165. 
Nybomycin was further found to have moderately low MICs against 
fluoroquinolone-susceptible M. tuberculosis, but drug-resistant isolates were not 
investigated165. Their results suggest that nybomycin directly binds to various 
areas of mycobacterial DNA rather than any one specific gene or protein165. This 
binding of nybomycin hypothetically leads to the inhibition of DNA replication and 
transcription165. Their proposed mechanism of action is in keeping with the 
proposed mechanisms of action of pyridoquinoline-related compounds used 
against malaria such as quinine, chloroquine, mefloquine and primaquine178. 
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Deoxynybomycin has also been investigated in recent years143,166,179. Due to the 
insolubility of deoxynybomycin in aqueous solutions, Parkinson and Hergenrother 
et al synthesized and evaluated a collection of deoxynybomycin derivatives179. The 
most promising of their derivatives, designated DNM-2, produced very favorable in 
vivo results when treating sepsis in mice due to fluoroquinolone-resistant                     
S. aureus179. Seventy-two minutes after administration of an oral dose of 50 
mg/kg, a peak serum concentration (Cmax) of 12.8 µg/ml was recorded179. DNM-2 
further exhibited low minimum inhibitory concentrations (MIC) against 
fluoroquinolone-resistant S. aureus and was able to effectively clear an infection 
with this organism from mice179. There is currently no published literature on the 














CHAPTER 3 – METHODS 
 
3.1    Drug susceptibility testing 
 
Three Mycobacterium tuberculosis isolates were exposed to nybomycin using the 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay. The 
results thereof prompted the screening of a much larger collection of                    
M. tuberculosis isolates, as well as other commonly isolated human bacterial 
pathogens, by using Clinical and Laboratory Standards Institute (CLSI) agar 
dilution methodology with a multipoint inoculator. The susceptibility of Neisseria 
gonorrhoeae, Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, 
Pseudomonas aeruginosa, Acinetobacter baumanii, Staphylococcus aureus and 
Enterococcus faecalis isolates to nybomycin, quinine, chloroquine, mefloquine and 
primaquine were determined using the same multipoint inoculation methodology. 
Unexpected results obtained with nybomycin and M. tuberculosis were confirmed 
with a second round of testing using the MTT assay and a subset of                    
M. tuberculosis isolates. Susceptibility of M. tuberculosis to a deoxynybomycin 
derivative (DNM-2) was likewise determined using the same subset of isolates and 
MTT testing methodology. 
 
3.1.1    Isolate selection 
 
The initial screening investigation was performed using three M. tuberculosis 
isolates from the Department of Infection Prevention and Control, School of 
Laboratory Medicine and Medical Sciences, College of Health Sciences,  
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University of KwaZulu-Natal, South Africa. The susceptibility of two 
fluoroquinolone-susceptible and one fluoroquinolone-resistant isolate to 
nybomycin was investigated using the MTT assay. Results from the screening 
investigation prompted further investigation using a larger selection of                  
32 M. tuberculosis isolates. Seventeen M. tuberculosis isolates were obtained 
from the culture collection of the Division of Molecular Biology and Human 
Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, 
South Africa. A further     14 clinical isolates were included from the culture 
collection of the Department of Infection Prevention and Control, School of 
Laboratory Medicine and Medical Sciences, College of Health Sciences, University 
of KwaZulu-Natal, South Africa. Routine drug susceptibility testing using the          
1% proportion method and IS 6110 fingerprinting have been previously performed 
for all isolates. The results of these tests were taken into consideration during the 
isolate selection process, to assure that a diverse collection of M. tuberculosis 
isolates was studied. The final collection for testing using multipoint inoculation 
included 12 fluoroquinolone-susceptible and 20 fluoroquinolone-resistant              
M. tuberculosis isolates. Susceptibility of M. tuberculosis isolates to isoniazid, 
rifampicin, amikacin and ofloxacin were also determined using the same multipoint 
inoculation methodology. This was done in order to both confirm the validity of the 
method and to verify the previously determined drug resistance profiles. The 






Table 3.1    Bacterial species and antimicrobial agents investigated using the 
multipoint inoculation method. 
 
Bacterial species Number of isolates* Drugs investigated 





• N. gonorrhoeae 
• E. coli 
• K. pneumoniae 
• E. cloacae 
• P. aeruginosa 
• A. baumanii 
• S. aureus 
• E. faecalis 
• 30 (7, 8, 15) 
• 6 (2, 2, 2) 
• 4 (2, 1, 1) 
• 4 (1, 0, 3) 
• 7 (2, 0, 5) 
• 5 (1, 1, 3) 
• 4 (2, 1, 1) 









Fluoroquinolone-susceptible control strains included in the above: M. tuberculosis 
H37Rv (ATCC 27294), N. gonorrhoeae ATCC 49226 and E. coli ATCC 25922.  
 
*The total number of isolates tested is followed by a breakdown according to 
fluoroquinolone resistance: (susceptible, resistant) or (susceptible, intermediate, 
resistant). 
 
** Susceptibility of S. aureus and E. faecalis to nalidixic acid was not investigated, 
as there are currently no minimum inhibitory concentration (MIC) breakpoints 
published for nalidixic acid and these two bacterial species. 
 
Unexpected results obtained with nybomycin and M. tuberculosis were confirmed 
with a second round of testing using the MTT assay. Due to financial constraints, a 
subset of 10 fluoroquinolone-susceptible and 13 fluoroquinolone-resistant            
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M. tuberculosis isolates were selected for confirmatory testing. DNM-2 was 
acquired at this stage and bacterial susceptibility to DNM-2 was determined using 
the same subset of 23 M. tuberculosis isolates and MTT testing methodology.  
 
All N. gonorrhoeae isolates (n=30) studied were obtained from the culture 
collection of the Department of Infection Prevention and Control, School of 
Laboratory Medicine and Medical Sciences, College of Health Sciences, University 
of KwaZulu-Natal, South Africa.  E. coli (n=6), K. pneumoniae (n=4), E. cloacae 
(n=4), P. aeruginosa (n=7), A. baumanii (n=5), S. aureus (n=4) and E. faecalis 
(n=4)   isolates were obtained from the culture collection of the Medical 
Microbiology Laboratory, National Health Laboratory Services, Inkosi Albert Luthuli 
Central Hospital, Durban, South Africa. Results of routinely performed drug 
susceptibility testing were taken into consideration to ensure that both 
fluoroquinolone-susceptible and fluoroquinolone-resistant isolates were studied for 
all species. Susceptibility of isolates to ciprofloxacin and nalidixic acid were 
evaluated concurrently. The antimicrobial agents tested using the multipoint 
inoculator are presented in table 3.1. 
 
3.1.2    Retrieval of isolates from storage 
 
M. tuberculosis isolates stored at -70 °C were removed from the freezer and 
thawed at room temperature. Once thawed, 100 μl of each isolate was transferred 
into a container (Sterilin Polypropylene 30 ml Universal Container, Thermo Fisher 
Scientific, Massachusetts, USA) containing three milliliters of sterile Middlebrook 
7H9 broth (Appendix A.1). Inoculated broths were then incubated in an upright 
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position at 37 °C in a shaking incubator (New Brunswick I26 Incubator Shaker, 
Eppendorf, Germany) for up to four weeks until growth was observed. 
 
All other bacterial species were recovered from -70 °C storage by inoculating one 
bead for each isolate onto a separate chocolate agar plate (Appendix A.2). 
Inoculated plates were incubated for 24 to 48 hours at 37 oC in 5% CO2 (Shel Lab 
CO2 Incubator SC031, Sheldon Manufacturing, Cornelius, Oregon, USA) until 
growth was observed. Some of the N. gonorrhoeae isolates failed to grow with this 
approach and these were first cultured in brain heart infusion broth (Appendix A.3) 
before being subcultured onto chocolate agar plates. 
 
3.1.3   Preparation of working cultures 
 
3.1.3.1   M. tuberculosis 
 
After vortexing (Vortex Mixer VM-300, Axiom Solutions, Bürstadt, Germany) for 
two minutes, 200 µl of each broth culture was aspirated and then spread out 
evenly across a Middlebrook 7H11 agar plate (Appendix A.3), for single colony 
growth. A chocolate agar plate (Appendix A.2) was inoculated to exclude potential 
contamination. The chocolate agar plates were incubated in 5% CO2 at 37 oC for 
two days and then inspected for the presence of any growth. The inoculated 
Middlebrook 7H11 plates were heat-sealed in gas permeable bags and incubated 
in 5% CO2 at 37 oC for seven days, after which they were transferred to the hot 
room (ambient air, 37 oC) for another five weeks. After a total of six weeks’ 
incubation, a single colony from each M. tuberculosis isolate was picked off and 
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inoculated into 5 ml Middlebrook 7H9 broth with Tween-80 and sterile glass beads 
(Appendix A.1). Tween-80 has a surfactant action and its purpose was thus to help 
prevent bacterial clumps from forming135. Sterile glass beads served to help break 
down bacterial clumps during vortexing steps. Single colonies were used in order 
to avoid inadvertently using mixed or contaminated cultures in subsequent 
investigations. The inoculated broths were then incubated at 37 oC in a New 
Brunswick I26 Incubator Shaker for two to three weeks, until a turbidity of 
approximately 1.0 McFarland was reached (Appendix A.5). M. tuberculosis 
cultures with this turbidity contain approximately 2-3 x 108 colony forming units per 
milliliter (CFU/ml) and are considered to be in the log phase of growth. Throughout 
the incubation period, the screw-caps were left slightly loose to allow gas diffusion 
and thereby avoiding the formation of an anaerobic environment. Each container 
was also mixed with the vortex mixer for one minute on alternate days to help 
avoid bacterial clumping. After the desired turbidity was reached, the vortex mixer 
was used for two minutes for each culture to break down bacterial clumps after 
which each broth culture was passed four times through a 25-gauge needle using 
a syringe. Each culture was also sonicated twice (Misonix Sonicator s-4000, 
QSonica, Connecticut, USA) for ten seconds at an amplitude of 10%, reaching a 
power of 10 Watt. A ten second pause was allowed in-between the two 10 second 
sonication periods so that the container could be tilted three times to mix its 
contents. Thereafter, the cultures were left undisturbed for 20 to 30 minutes so 
that any residual clumps could sink to the bottom of the container. This 
comprehensive attempt at reducing bacterial clumping was embarked upon in 
order to minimize the chances of drug susceptibility testing results indicating false 
antibiotic resistance.  A second sterility check was performed at this stage by 
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culturing some of the supernatant on chocolate agar plates. The supernatant was 
then aspirated and transferred to a sterile 30 ml universal container where its 
turbidity was adjusted to a McFarland standard of 0.5 (Appendix A.5). This 
turbidity indicates the presence of approximately 1.5 x 108 CFU/ml. The adjusted 
supernatants i.e. working culture solutions were used for all subsequent laboratory 
investigations and small volumes thereof were also dispensed into cryovials and 
stored at -70 oC for later use.  
 
3.1.3.2   Other bacteria 
 
Single colonies were picked off and again cultured for 24 to 48 hours on chocolate 
agar plates (Appendix A.2). This was done to avoid contaminants and to make 
sure pure cultures were being used. From pure subcultures, suspensions with a 
McFarland of 0.5 were made in phosphate buffered saline (PBS) (Appendix A.6). 
Each sample was homogenized with a vortex mixer for 30 seconds and its turbidity 
adjusted to a McFarland of 0.5. The adjusted bacterial suspensions i.e. working 
cultures were used for all subsequent susceptibility testing. Colonies were also 
suspended in storage medium and stored at -70 oC for later investigations 
(Appendix A.7).  
 
3.1.4    Screening with the MTT assay 
 
The MTT assay was performed as described previously180. This established 
methodology compares well with reference susceptibility testing methods180,181. 
Testing was done in triplicate. 
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3.1.4.1    Preparation of nybomycin working solution and 96-well test plate 
 
Nybomycin powder with a purity of 99% was procured from SantaCruz 
Biotechnology, Dallas, Texas, USA. A small amount of the antibiotic powder was 
dissolved in DMSO and further diluted with sterile PBS to a final concentration of 
200 μg/ml with 4% DMSO. This was then used for two-fold serial dilutions with 
Middlebrook 7H9 broth in a sterile 96-well flat-bottom plate. Ten two-fold dilutions, 
from 200 μg/ml to 0.39063 μg/ml were prepared. Figure 3.1 illustrates how the           
96-well plate was set up. 
 
Figure 3.1    96-well test plate for pilot susceptibility testing of M. tuberculosis with 
highest and lowest final nybomycin concentrations of 100 µg/ml and 0.19531 
µg/ml respectively. 
1 2 3 4 5 6 7 8 9 10 11 12
A dH₂0 dH₂0 dH₂0 dH₂0 dH₂0 dH₂0 dH₂0 dH₂0 dH₂0 dH₂0 dH₂0 dH₂0 A
B dH₂0 100 50 25 12.5 6.25 3.125 1.5625 0.78125 0.39063 0.19531 dH₂0 B
C dH₂0 100 50 25 12.5 6.25 3.125 1.5625 0.78125 0.39063 0.19531 dH₂0 C







































control empty empty empty empty dH₂0 G
H dH₂0 dH₂0 dH₂0 dH₂0 dH₂0 dH₂0 dH₂0 dH₂0 dH₂0 dH₂0 dH₂0 dH₂0 H
1 2 3 4 5 6 7 8 9 10 11 12  
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Values displayed are the final drug concentrations (µg/ml) after 1:2 dilution with 
bacterial inoculum.  
Negative control: 200 µl sterile Middlebrook 7H9 broth. 
Positive control: 100 µl bacterial inoculum with 100 µl sterile Middlebrook 7H9 
broth. 
 
3.1.4.2    Preparation of inoculum and inoculation of test plate 
 
The turbidity of previously prepared bacterial working cultures was adjusted to 0.5 
McFarland and then further diluted 1:100 to provide a bacterial suspension with 
1.5 x 106 CFU/ml for each M. tuberculosis isolate. One hundred microliters of each 
bacterial suspension were added to each drug-containing well and the positive 
control wells. Contents were mixed by pipetting up and down three times. The final 
M. tuberculosis concentration in each well was therefore 7.5 x 105 CFU/ml.  
 
3.1.4.3    Culture, incubation and reading of results 
 
The plates were heat-sealed in gas-permeable bags and incubated at 37 oC in 
ambient air for seven days. After seven days of incubation, 15 µl of the 5 mg/ml 
MTT solution (Appendix A.8) was added to one positive control and one negative 
control well, mixed by pipetting, sealed as described before and incubated 
overnight. After overnight incubation 50 µl SDS-DMF solution (A.11) was added to 
the same two control wells. The plate was placed back in the incubator for two to 
three hours before the color reaction was read. A color change from yellow to 
purple indicated the presence of actively metabolizing cells and a yellow color 
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indicated negative growth. If no growth was observed in the positive control well, 
then the process was repeated with another positive control well, on the same day. 
Once growth has been observed in the positive control well, and the negative 
control showed no growth, then 15 µl MTT solution was added to all the other 
bacteria-containing wells and another negative control well. The MIC (µg/ml) was 
then read the next day after the addition of SDS-DMF and the incubation step, as 
described. The MIC was determined as the lowest drug concentration where a 
yellow colour was visible with the naked eye. 
 
3.1.5    Screening with the multipoint inoculator method 
 
The CLSI recommended agar dilution methodology was used for all drug-bug 
combinations182–185. Drug suppliers, purity and solvent particulars of each 
compound tested are presented in table 3.2. Antibiotic stock solutions, bacterial 











Table 3.2    Characteristics of antibiotics used for susceptibility testing with the 
multipoint inoculator. 
 
Antibiotic Supplier* Purity (%) Solvent 
Isoniazid Sigma-Aldrich ≥ 99 Distilled water 
Rifampicin Sigma-Aldrich ≥ 97 Methanol 
Ofloxacin Sigma-Aldrich 98 Acetic acid 
Amikacin Sigma-Aldrich 98 Distilled water 
Quinine sulfate Sigma-Aldrich ≥ 98 Distilled water 
Chloroquine diphosphate Sigma-Aldrich ≥ 98 Distilled water 
Mefloquine hydrochloride Sigma-Aldrich > 98 DMSO 
Primaquine biphosphate Sigma-Aldrich 98 Distilled water 
Ciprofloxacin Sigma-Aldrich ≥ 98 Distilled water 
Nalidixic Acid Sigma-Aldrich ≥ 98 Ethanol 
Nybomycin BioAustralis > 95 DMSO 
 
*Sigma-Aldrich, South Africa 
*BioAustralis, Smithfield, New South Wales, Australia 
All compounds were stored at temperatures recommended by the supplier. 
 
For M. tuberculosis, drug susceptibility testing with isoniazid, rifampicin, ofloxacin 
and amikacin served three purposes. Firstly, it confirmed the previously performed 
phenotypic classification of M. tuberculosis isolates with the 1% proportion 
method.  Secondly, it served as an internal confirmation of the accuracy of the 
multipoint inoculator method as it was used in this study. Thirdly, it provided a 
quantitative means of comparing inhibitory drug levels of ofloxacin with that of 
nybomycin in order to identify a possible reverse antibiotic effect with nybomycin. 
 
For the other bacterial species, drug susceptibility testing with ciprofloxacin and 
nalidixic acid served similar purposes. Additionally it also provided a quantitative 
means of comparing inhibitory drug levels of ciprofloxacin with that of nybomycin, 
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quinine, chloroquine, mefloquine and primaquine in order to identify a possible 
reverse antibiotic effect with nybomycin with the other quinoline-containing drugs. 
 
3.1.5.1    Determining drug concentration testing ranges and preparation of 
antibiotic stock solutions 
 
There are no MIC breakpoints (µg/ml) available for testing bacteria with 
nybomycin, quinine, chloroquine, mefloquine and primaquine. Hiramatsu et al 
reported the minimum concentration of nybomycin to inhibit wild type S. aureus to 
be ≥ 64 μg/ml, while isolates with phenotypic fluoroquinolone resistance, required 
nybomycin concentrations ranging from ≤ 0.06 to 1.0 μg/ml143,166. Three drug-
susceptible M. tuberculosis isolates investigated by Arai et al required at least 4.2, 
5.2 and 6.3 μg nybomycin per milliliter respectively for visual inhibition of 
growth165. Due to the limited data available and the high cost of nybomycin 
antibiotic powder, it was decided to test twelve two-fold dilutions of nybomycin 
from 32 to 0.0156 μg/ml for all isolates. 
 
Critical drug concentrations for the anti-tuberculosis drugs tested in this study have 
been previously published by the World Health Organization (WHO) and are 
presented in table 3.3186. For this study, these same drug concentrations were 
used as MIC resistance breakpoints (µg/ml). The full range of drug concentrations 




Table 3.3    WHO recommended critical concentrations used for determining drug 
resistance of M. tuberculosis isolates186. 
 






These critical concentrations (µg/ml) are specifically intended for use with the      
1% proportion method on Middlebrook 7H10 agar186. 
 
Table 3.4 Antimicrobial drug concentrations used for MIC (µg/ml) determination in 
M. tuberculosis isolates using the multipoint inoculator. 
 
Antibiotic Concentrations (µg/ml) 
Isoniazid - 0.0313 0.0625 0.125 0.25 0.5 1 2 4 8 16 32 64 
Rifampicin - 0.0313 0.0625 0.125 0.25 0.5 1 2 4 8 16 32 64 
Amikacin - 0.0313 0.0625 0.125 0.25 0.5 1 2 4 8 16 32 64 
Ofloxacin - 0.0313 0.0625 0.125 0.25 0.5 1 2 4 8 16 32 64 
Nybomycin 0.0156 0.0313 0.0625 0.125 0.25 0.5 1 2 4 8 16 32 - 
 
CLSI recommended susceptibility, intermediate and resistance breakpoints (µg/ml) 
were used with ciprofloxacin and nalidixic acid against the other bacterial isolates 





Table 3.5    CLSI susceptibility, intermediate and resistance breakpoints (µg/ml) 
for ciprofloxacin and nalidixic acid. 
 
Antibiotic Test organism/s 
MIC (µg/ml) breakpoints 
Susceptible Intermediate Resistant 
Ciprofloxacin 
• N. gonorrhoeae ≤ 0.06 0.12 - 0.5 ≥ 1 
• E. coli 
• K. pneumoniae 
• E. cloacae 
• P. aeruginosa 
• A. baumanii 
• E. faecalis 
• S. aureus 
≤ 1 2 ≥ 4 
Nalidixic Acid* 
• E. coli 
• K. pneumoniae 
• E. cloacae 
• P. aeruginosa 
• A. baumanii 
≤ 16 - ≥ 32 
 
*Gram-positive bacteria are intrinsically resistant to nalidixic acid. 
The full range of drug concentrations tested with N. gonorrhoeae, E. coli,              
K. pneumoniae, E. cloacae, P. aeruginosa, A. baumanii, E. faecalis and S. aureus 
are presented in table 3.6 and table 3.7. 
 
Table 3.6    Antimicrobial drug concentrations used for MIC (µg/ml) determination 
in N. gonorrhoeae using the multipoint inoculator. 
 
Antibiotic Concentrations (µg/ml) 
Ciprofloxacin - - - 0.0625 0.125 0.25 0.5 1 2 4 8 16 32 64 128 
Nalidixic acid - - - 0.0625 0.125 0.25 0.5 1 2 4 8 16 32 64 128 
Nybomycin 0.0078 0.0156 0.0313 0.0625 0.125 0.25 0.5 1 2 4 8 16 - - - 
Quinine - - - 0.0625 0.125 0.25 0.5 1 2 4 8 16 32 64 128 
Chloroquine - - - 0.0625 0.125 0.25 0.5 1 2 4 8 16 32 64 128 
Mefloquine - - 0.0313 0.0625 0.125 0.25 0.5 1 2 4 8 16 32 64 - 
Primaquine - - - 0.0625 0.125 0.25 0.5 1 2 4 8 16 32 64 128 
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Table 3.7    Antimicrobial drug concentrations used for MIC (µg/ml) determination 
in E. coli, K. pneumoniae, E. cloacae, P. aeruginosa, A. baumanii, E. faecalis and 
S. aureus isolates using the multipoint inoculator. 
 
Antibiotic Concentrations (µg/ml) 
Ciprofloxacin - - - - 0.125 0.25 0.5 1 2 4 8 16 32 - - 
Nalidixic acid - - - 0.0625 0.125 0.25 0.5 1 2 4 8 16 32 64 128 
Nybomycin 0.0078 0.0156 0.0313 0.0625 0.125 0.25 0.5 1 2 4 8 16 - - - 
Quinine - - - 0.0625 0.125 0.25 0.5 1 2 4 8 16 32 64 128 
Chloroquine - - - 0.0625 0.125 0.25 0.5 1 2 4 8 16 32 64 128 
Mefloquine - - 0.0313 0.0625 0.125 0.25 0.5 1 2 4 8 16 32 64 - 
Primaquine - - - 0.0625 0.125 0.25 0.5 1 2 4 8 16 32 64 128 
 
*Gram-positive bacteria are intrinsically resistant to Nalidixic Acid 
 
Antibiotic stock solutions were prepared by first weighing out and adding the 
required amount of antibiotic powder to sterile 30 ml universal containers. The 
equation below was used to calculate the amount of each drug required for one 
round of drug susceptibility testing, and the calculation results for all drugs are 
presented in table 3.8. 
 
Drug required (gram) = HDC x AV x DDF x CF x 100/P 
= HDC x 20 x 2 x 10-6 x 100/P 
= HDC/P x 0.004 
 
• HDC = Highest drug concentration to be tested (μg/ml) 
• AV = Agar volume in each plate 
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• DDF = Double dilution factor. This was 2 for all drugs, because a double 
amount of drug was required in the first plate from where 1:2 dilutions were 
made to the subsequent plates 
• CF = Conversion factor i.e. 10-6 to convert microgram to gram 
• P = % purity of antimicrobial powder, as indicated by the manufacturer  
 
Table 3.8 Amount (gram) of antibiotic powder required to test all required drug 
concentrations once with the multipoint inoculator. 
 
Antibiotic Highest concentration tested (µg/ml) M. tuberculosis N. gonorrhoeae 
• E. coli 
• K. pneumoniae 
• E. cloacae 
• P. aeruginosa 
• A. baumanii 
• E. faecalis 
• S. aureus 
Isoniazid 64 0.00259 g - - 
Rifampicin 64 0.00264 g - - 
Amikacin 64 0.00261 g - - 
Ofloxacin 64 0.00261 g - - 
Nybomycin 32 0.00135 g - - 
16 - 0.00067 g 0.00067 g 
Ciprofloxacin 128 - 0.00522 g - 
32 - - 0.00131 g 
Nalidixic Acid 128 - 0.00522 g 0.00522 g 
Quinine sulfate 128 - 0.00522 g 0.00522 g 
Chloroquine 
diphosphate 128 - 0.00522 g 0.00522 g 
Mefloquine 
hydrochloride 64 - 0.00261 g 0.00261 g 
Primaquine 
biphosphate 128 - 0.00522 g 0.00522 g 
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Double amounts of the calculated minimum required antibiotic presented in table 
3.8 were weighed out and used. This was necessary to account for some losses 
during the subsequent filtering of stock solutions aimed at removing bacterial 
contaminants.  
 
Each antibiotic stock solution was therefore prepared by adding 0.8 ml solvent 
(table 3.2) to the weighed out antibiotic powder. The antibiotic powder was 
carefully mixed with the solvent by pipetting up and down five to ten times. A 
vortex mixer was also used to make sure the antibiotic powder is thoroughly mixed 
and in solution. Using no more than 0.8 ml of solvent assured that the bacteria 
were not exposed to more than 1% solvent, as higher concentrations of solvents 
may adversely affect bacterial growth.  
 
Next a 1:10 dilution was made by adding 7.2 ml sterile PBS to the antibiotic 
suspension. It was then mixed using the vortex mixer and the resultant 8 ml 
antibiotic stock solution was filter sterilized through a 0.22 micron Millipore filter 
(Merck Millipore, SA). The final product was then either used immediately, or 
stored in cryovials at -70 oC until further use.  
 
The preparation of nybomycin stock solution deviated from the above-explained 
procedure. Due to the high cost of nybomycin, only small amounts could be 
procured and double volumes could not be used as for the other antibiotics. The 
weighed-out amount of antibiotic was therefore dissolved in 0.4 ml solvent and 
thereafter diluted with 3.6 ml sterile of PBS to give a final volume of 4 ml. As some 
antibiotic stock solution usually inadvertently get left behind in the 0.22 micron 
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Millipore filter during filter sterilization, this step was omitted. Great care was thus 
taken to ensure the nybomycin powder were not contaminated during the handling 
thereof. All antibiotic stock and working solutions were only frozen and thawed 
once, after which they were discarded. 
 
3.1.5.2    Preparation of antibiotic working solutions and culture media 
 
Either freshly prepared or stored antibiotic stock solution were retrieved from the   
-70 oC freezer and left to thaw at room temperature. In preparation for agar plate 
pouring, 17 sterile 30 ml universal containers were positioned in a row on a tube 
rack. Two milliliters PBS were added to all containers, except the first one. Four 
milliliters stock solution were added to the first container and two-fold serial 
dilutions performed by removing 2 ml from the first container and adding it to the 
second container. It was then thoroughly mixed by pipetting up-and-down five 
times and thereafter 2 ml were transferred to the third container. This mixing and 
transferring of 2 ml of antibiotic solution from one container to the next was 
repeated up to the twelfth tube.  Two milliliters antibiotic solution was discarded 
from the twelfth container so that only 2 ml fluid remained in it. The first               
12 containers represented the 12 antibiotic concentrations that were tested for 
each antibiotic and the last five containers were used as drug-free controls. 
 
Eighteen milliliters of freshly prepared and cooled down Middlebrook 7H10 agar 
(Appendix A.12), maintained in its liquid state in a water bath set at 45 oC, were 
next added to each 2 ml of antibiotic working solution in the 30 ml container. For 
Neisseria gonorrhoeae, GC agar (Appendix A.13) was used and for the other 
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bacterial species Mueller-Hinton agar (Appendix A.14). In the same way, media 
was added to the five containers containing 2 ml of PBS without any antibiotic. 
Immediately after 18 ml of media was added to any particular container, its screw-
cap was tightly closed and the container carefully tilted three times to mix its 
contents. The cap was then removed and the full 20 ml amount of media promptly 
poured into an empty 90 mm Petri dish before the agar had time to solidify. The 
agar plates were closed and left on the benchtop until the agar solidified, after 
which the plates were sealed in plastic bags and stored at 4-8 oC until further use. 
Plates were used within one week of preparation. 
 
3.1.5.3    Preparation of inoculum and inoculation of solid agar plates 
 
A Steers-type multipoint inoculator known as the Cathra replicator was used to 
inoculate all bacterial isolates onto the surfaces of agar plates containing various 
concentrations of the different test antibiotics182,187,188. The replicator seed tray is 
made up of 37 individual wells that each can accommodate 0.5 ml of a separate 
bacterial isolate suspension. Crystal violet was added to the first well on the seed 
tray in order to assist the correct marking and numbering of each isolate after the 
inoculation process was complete. Each floating pin of the instrument has a 
diameter of 3 mm and is designed to pick up and transfer a single drop with a 
volume of 2 μl, from the replicator seed tray to each of 37 separate spots on the 
agar surface of a single solid agar plate182,184,189,190.  
 
To ensure that approximately 104 CFU were delivered to each 2 μl spot, the 
bacterial working solution was first diluted 1:10 in sterile PBS containing              
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1% Tween-80 (Appendix A.6) to obtain a concentration of 107 CFU/ml183,184,189. 
Each well of the Cathra replicator seed tray was loaded with 0.5 ml of inoculum of 
a different isolate184. Inoculation with the Cathra multipoint inoculator proceeded in 
a systematic fashion starting with the plates containing the lowest drug 
concentration and ending with the plates containing the highest drug 
concentration. Additionally, there was a drug-free plate included before the first 
and last drug-containing plates, as well as after every third drug-containing plate. 
These measures served as (1.) antibiotic-free controls, (2.) contamination controls 
as well as (3.) to reduce the potential carry-over of antibiotic to the seed wells and 
subsequent agar plates.  
 
3.1.5.4    Culture, incubation and reading of results 
 
After inoculation, plates with M. tuberculosis were left in the biosafety cabinet for 
up to an hour for the inoculums to dry. Next the plates were heat-sealed in gas-
permeable plastic bags and incubated at 37 oC in 5% CO2. After one week 
incubation, the cultures were transferred to a hot room with a temperature of 37 oC 
and ambient air for an additional 2 to 4 weeks of incubation. Plates were read after 
3 to 4 weeks’ incubation, or later depending on when the positive controls 
indicated visible growth. For the other bacterial species, the plates were incubated 
for 24 hours at 37 oC in 5% CO2. Incubation was extended for an additional         
24 hours for the N. gonorrhoeae isolates. 
 
The multipoint plate reader was used to inspect agar plate surfaces for any signs 
of growth. The MIC (μg/ml) was determined as the lowest concentration of drug 
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where no bacterial growth could be observed.  
 
3.1.6    Further drug susceptibility testing with the MTT assay 
 
In order to confirm the susceptibility results obtained with the multipoint inoculator, 
the MTT assay was used with a subset of 23 M. tuberculosis isolates. This well-
established method compares closely with reference susceptibility testing 
methods180,181. DNM-2 was likewise evaluated against the same subset of 23      
M. tuberculosis isolates.  
 
3.1.6.1    Preparation of antimicrobial working solutions and 96-well test plate  
 
As stated before, nybomycin was procured from BioAustralis (Smithfield,          
New South Wales, Australia) and DNM-2 was donated by Paul Hergenrother179. 
 
There is currently no published data for laboratory investigations performed with 
the deoxynybomycin-derivative in M. tuberculosis and therefore also no MIC 
breakpoints (µg/ml) to adopt. Parkinson et al reported MICs with DNM-2 of 
between 0.0625 and 4 μg/ml for methicillin-resistant S. aureus and between 0.25 
and 8 μg/ml for vancomycin-resistant E. faecalis for nybomycin. With only one 
published paper on the deoxynybomycin-derivative as guidance, it was decided to 
investigate M. tuberculosis susceptibility to 12 different DNM-2 concentrations i.e. 
12 μg/ml and eleven two-fold dilutions thereof. A limited amount of the DNM-2 
powder necessitated the use of micro broth dilution methodology for susceptibility 
testing. M. tuberculosis susceptibility to nybomybcin were determined alongside 
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DNM-2 using the same micro broth dilution methodology and the same drug 
concentrations that were used with the solid agar dilution method. Nybomycin 
susceptibility testing was repeated using this methodology in order to confirm the 
results obtained with the solid agar method. The same nybomycin concentrations 
were investigated than were tested with the multipoint inoculator.  
 
Nybomycin. The supplied nybomycin antibiotic powder had a purity of >95%. 
Therefore every 1.05263 µg of the powder represented 1 µg pure nybomycin and 
this was taken into account for all the subsequent calculations. In order to ensure 
that bacteria will not be exposed to more than 1% DMSO in the final culture,  
1.052 mg nybomycin was weighed out and added to 625 µl DMSO. This was 
thoroughly mixed and dissolved by pipetting up-and-down and with the vortex 
mixer and provided an effective nybomycin stock solution with a concentration of 
1600 µg/ml. Antibiotic working solutions were prepared by diluting the stock 
solution 1:50 i.e. adding 40 µl of stock solution to 1960 µl Middlebrook 7H9 broth 
whereupon a final concentration of 32 µg/ml was reached. Two hundred 
microliters of this antibiotic working solution were added to the first well and two-
fold serial dilutions performed by transferring 100 µl from the first well to the 
second well prefilled with 100 µl Middlebrook 7H9 broth. The resultant 200 µl was 
mixed by pipetting up and down three times and thereafter 100 µl was aspirated 
and transferred to the third well. This two-fold serial dilution process was continued 
until the last well was reached, after which 100 µl was discarded so that the last 
well remained with 100 µl antibiotic solution. The remaining antibiotic stock 
solution was stored in cryovials at -70 oC for future use. Antibiotic solutions were 
only frozen and thawed once, after which they were discarded. 
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DNM-2. Stock solutions were prepared by dissolving 0.72 mg antibiotic powder in 
0.6 ml DMSO, followed by extensive mixing with the vortex mixer for 15 minutes 
until it was fully dissolved, to give a final concentration of 1200 µg/ml. The 
antibiotic stock solution was diluted 1:50 by adding it to 29.4 ml Middlebrook 7H9 
broth, in order give the highest testable antibiotic concentration of 12 µg/ml, as 
well as a maximum DMSO concentration of 1%. Higher drug concentrations could 
unfortunately not be tested due to the poor solubility of DNM-2. Antibiotic solutions 
were only frozen and thawed once, after which they were discarded. 
 
Preparation of 96-well test plate. Testing was conducted in a sterile 96-well, flat-
bottomed microtitre plate (Porvair, WhiteSci, SA). As illustrated in figure 3.2, the 
outside wells of the plate were filled with 100 µl sterile distilled water to minimize 
any effect that evaporation might have during incubation. All wells earmarked for 
the different concentrations of antibiotic as well as nine positive control wells each 
received 100 µl Middlebrook 7H9 broth, the three wells identified to receive the 
highest antibiotic concentration were left empty. Nine negative control wells were 
filled with 200 µl Middlebrook 7H9 broth. Two hundred microliters of the antibiotic 
working solution were added to each of the three wells reserved for the highest 
concentration of antibiotic. Antibiotic two-fold serial dilutions were performed by 
removing 100 µl from the highest antibiotic concentration well and transferring it to 
the second highest antibiotic concentration well that already contain 100 µl of 7H9 
broth, followed by pipetting up and down five times to ensure adequate mixing and 
homogeneity. One hundred microliters were then removed from the second well 
and transferred to the third well. This process of transferring 100 µl between wells 
together with mixing by using the pipette, was repeated until the last well 
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representing the lowest antibiotic concentration, where the final 100 µl was 
discarded and the well left with 100 µl antibiotic solution. This was completed 
immediately before the addition of microbial inoculum. 
 
Figure 3.2    96-well test plate for susceptibility testing with highest and lowest 
final nybomycin concentrations of 32 µg/ml and 0.01562 µg/ml respectively. 
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Values displayed are the final drug concentrations (µg/ml) after 1:2 dilution with 
bacterial inoculum.  
Negative control: 200 µl sterile Middlebrook 7H9 broth. 
Positive control: 100 µl bacterial inoculum with 100 µl sterile Middlebrook 7H9 
broth. 
(Test plate for DNM-2 was prepared in a similar fashion, but with a highest 
concentration of 12 µg/ml and a lowest concentration of 0.00586 µg/ml.) 
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3.1.6.2 Preparation of inoculum and inoculation of test plate  
 
Performed according to section 3.1.4.2 
 
3.1.6.3 Culture, incubation and reading of results 
 
Performed according to section 3.1.4.3 
 
3.2    DNA isolation 
 
3.2.1    Bacterial cultures 
 
M. tuberculosis working cultures were prepared as described in section 3.1.3. One 
hundred microliters of each culture was inoculated and spread out on Middlebrook 
7H11 plates. Three separate agar plates were inoculated for each isolate. The 
plates were heat-sealed in gas-permeable plastic bags and incubated at 37 oC in 
5% CO2 for one week after which they were transferred to the hot room for an 
additional 4-6 weeks until a lawn of growth was observed on each plate. 
 
3.2.2   DNA isolation with the cetyltrimethylammoniumbromide method 
 
The cetyltrimethylammoniumbromide (CTAB) method was used as previously 
described by Van Soolingen et al, with minor modifications174,191–193. Preparation of 
all reagents and solutions are described in Appendix A. Colony growth were 
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harvested from the surface of Middlebrook 7H11 agar media with a sterile plastic 
loop and suspended in a sterile, round-bottomed 2 ml Eppendorf tube prefilled with 
500 µl of sterilize distilled water. The tubes were then closed and placed for        
30 minutes in a heating-block set at 80 oC to heat-kill the live bacteria. Next the 
tubes were transferred to an Eppendorf thermomixer set at 60 oC and 70 µl 10% 
SDS and 50 µl proteinase K (10 µg/ml) were added to it. The Eppendorf 
thermomixer was set at low shaking mode i.e. 10 second periods of mixing 
alternating with 10 second periods of no mixing. The Proteinase K is used to both 
digest protein to release DNA from cells and to inactivate DNases that may 
degrade DNA. The action of Proteinase K is potentiated by SDS. After one hour 
100 µl 5M NaCl and then 100 µl 10% CTAB, both preheated to 60 oC, were added 
to each tube and thoroughly mixed by inverting the tube by hand. The tubes were 
then subjected to another 15 minutes in the Eppendorf thermomixer set at 60 oC 
together with low-shaking mode. CTAB is a surfactant that, together with NaCl 
binds to and remove polysaccharides from lysed bacterial suspensions192. To 
purify the DNA further, 700 µl of a chloroform:isoamyl alcohol (24:1) mixture was 
added to all the tubes and mixed by inverting 20 to 25 times by hand. This led to 
the formation of a homogenous white “milky” solution. The tubes were then 
centrifuged for 10 minutes at 15625.503 x g and the upper aqueous phase     
(±700 µl) transferred to sterile microcentrifuge tubes containing 700 µl cold 
isopropanol (Sigma-Aldrich, SA). It was then carefully mixed by inverting the tubes 
several times so that the precipitated DNA could be seen as a thin thread. All the 
tubes were then kept overnight at 4 oC and then centrifuged at 9245.86 x g for    
10 minutes at 4 oC. Thereafter the isopropanol was decanted and each pellet 
washed with 50 µl 80% cold ethanol (Merck, SA) followed by centrifugation for a 
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further 5 to 10 minutes at 13314.038 x g. This washing step was repeated once 
and the pellet left to dry by evaporation for 30 minutes at room temperature, by 
placing each opened tube upside-down on a clean paper towel. The heat-killed, 
isolated and cleaned DNA was then kept at 4 °C in 55 µl of 1x TE buffer until use. 
 
3.2.3    Estimation of DNA purity, concentration and quality 
 
DNA purity was estimated with the A260/A230 and A260/A280 absorbance ratios using 
the NanoDrop 2000c spectrophotometer (Thermo Fisher Scientific, 
Massachusetts, USA) and DNA quality was visualized by electrophoresing 1 µl 
extracted DNA in a 1% agarose gel (Appendix A.20)174,194. 
 
Nucleotides, DNA and RNA all absorb at a wavelength of 260 nm and most other 
expected substances in molecular samples at either higher or lower wavelengths. 
By also measuring absorbance at 230 nm and 280 nm, contaminants can be 
excluded by looking at A260/A280 and A260/A230 absorbance ratios. The A260/A280 and 
A260/A230 absorbance ratios were therefore used to evaluate the purity of DNA. 
With the A260/A280 ratio, “pure” DNA is expected to have a A260/A280 absorbance 
ratio of ±1.8 and a A260/A230 absorbance ratio of ±2.0-2.2. If the ratios are 
considerably lower than these values, then it may indicate the presence of 
substantial amounts of impurities that absorb light at either 280 nm or 230 nm. 
Two microliters of each DNA sample were therefore loaded onto the absorbance 
platform in order for the instrument to measure absorbance194. 
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Gel electrophoresis was used to assess DNA quality. First, a 1% agarose gel was 
prepared. A casting tray and 20-well plastic comb were cleaned with 70% alcohol 
followed by the proper positioning of the plastic comb inside the casting tray. The 
open ends of the tray were then secured with masking tape to prevent the gel from 
leaking out of the tray. Next 1X Tris-borate-EDTA (TBE) buffer was freshly 
prepared by adding 100 ml of 10X TBE to 900 ml distilled water (Appendix A.21). 
The final 1% agarose solution was prepared by adding 1.4 grams of agarose 
(Seakem LE Agarose, Whitehead Scientific, SA) to 140 ml of the 1X TBE buffer. 
The agarose was then dissolved in the 1X TBE buffer by heating it in a microwave 
oven and the full amount was then poured into the casting tray once it cooled 
down to approximately 40 to 45 oC. It was then left for 30 to 40 minutes to solidify 
at room temperature (25 oC) after which the comb and masking tape were 
removed. The gel was then carefully placed in an electrophoresis tank and            
1 X TBE buffer was added to the tank so that its surface was covered with 
approximately 1-2 mm of fluid. 
 
For each DNA sample, 5 µl of gel loading dye (Appendix A.22) was first dispensed 
onto a sheet of parafilm. Next the DNA was mixed inside its tube by tapping it 
lightly with a finger a couple of times and then 1 µl of the DNA was transferred 
directly into the drop of gel loading dye. The two were then mixed by pipetting up 
and down 3 to 4 times. The resultant 6 µl drop was immediately transferred to its 
appointed well in the gel, before continuing with the next sample. The last well was 
loaded with 5 µl gel loading dye together with 1 µl of a DNA molecular weight 
marker (DNA Molecular Weight Marker II, Roche, SA). The ladder served as a 
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molecular weight marker, so that the size of DNA fragments in the gel could be 
determined.  
 
The gel was then covered with a lid so that the negative (black) cathode was 
positioned closest to the DNA samples in their wells and the positive (red) anode 
positioned furthest away from the DNA samples. DNA samples then migrated 
toward the positively charged electrode. The electrical power source was set at 
100 Volts and allowed to run for one hour. The current remained between 35 and 
50% of the Volts for the duration of the experiment. Next the gel was removed 
from its tank and placed inside the Syngene G:Box gel imaging system for image 
capturing and printing with the GeneSnap software package (Syngene, Maryland, 
USA). The size and brightness of bands were compared with that of the molecular 
weight marker as a rough estimate of the quality and quantity of the DNA. 
 
3.3    Genotyping using IS 6110 restriction fragment length polymorphism 
fingerprinting 
 
The IS 6110 restriction fragment length polymorphism (RFLP) fingerprinting 
method was used to genotype M. tuberculosis isolates, as previously described by 
Van Soolingen et al. with a few modifications191,195,196. The main six steps in this 
method included (1.) restriction and (2.) gel electrophoresis on the first day 
followed by (3.) Southern blotting and (4.) hybridization on the second day; and 
(5.) washing of hybridized membrane and (6.) band detection in the darkroom on 
the third day. Preparation of all reagents and solutions are described in     
Appendix A. 
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3.3.1    Restriction 
 
PvuII restriction endonuclease (Roche, SA) was used to digest M. tuberculosis 
DNA by cleaving at IS 6110. The appropriate volumes of DNA and sterile distilled 
water used were determined by evaluating the gel electrophoresis pictures and 
NanoDrop results to make a visual estimation of the DNA concentration. The DNA 
and sterile distilled water were then mixed together with 2.5 µl of buffer (Roche 
Diagnostics, Mannheim, Germany) and 1.5 µl PvuII restriction enzyme (Roche 
Diagnostics, Mannheim, Germany) in a sterile 1.5 ml micro-centrifuge tube to 
prepare a final volume of 22 µl. Each sample required 2 to 15 µl DNA and 7 to     
20 µl sterile distilled water to give good quality IS 6110 RFLP bands. All samples 
were mixed using a pipette and then placed in a floater in a water bath and 
incubated at 37 oC for four hours. 
 
3.3.2    Gel electrophoresis 
 
Gel electrophoresis was performed to separate the DNA fragments. A 1% agarose 
gel was prepared as described earlier. After the restriction process has been 
completed the tubes were removed from the water bath, and 5 µl of RFLP loading 
dye added to each (Appendix A.23). The gel was then loaded with DNA samples, 
but the first and last lanes were reserved for the Jacks Standard molecular weight 
marker (0.7 – 15 kilo base pairs) that served as an external reference. The 
electrical power source was set at 100 Volts and switched on until all the samples 
have moved out of their wells. The voltage was subsequently reduced to 35 Volt 
and the process allowed to continue overnight for approximately 18 to 20 hours. 
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3.3.3    Southern blotting 
 
Southern blotting employs electrophoresis to transfer DNA fragments from an 
agarose gel to a membrane. For this study, we used the Hybond-N+ membrane 
(Amersham-GE Healthcare Life Sciences, UK) which is a positively charged nylon 
membrane. It was first submerged in distilled water for a few seconds before it was 
soaked in 10X SSC for five minutes. The nylon membrane was then positioned on 
the VacuGene XL vacuum blotting unit (Amersham-GE Healthcare Life Sciences, 
UK) with the gel on top of it. After ensuring that the edges have formed a good 
seal, the VacuGene XL Blotting Pump was switched on and set to deliver            
55 millibars suctioning power. The gel was then flooded with a 1:100 dilution of 
HCl for 20 minutes, followed by flooding with Soak 1 solution for 20 minutes,    
Soak 2 solution for a further 20 minutes and 10XSSC solution for a final              
90 minutes. With the 10XSCC solution, the suctioning power was increased to      
60 millibars. Care was taken to ensure that each solution completely covered the 
surface of the gel and that it was first removed with the vacuum pump aspirator 
before the next solution was added. Thereafter the gel was discarded and the 
membrane carefully lifted and removed from the vacuum blotter and placed on 
paper towel in order to air dry for five minutes. The membrane was then briefly 
irradiated under ultraviolet light in the UVP-CL1000 cross-linker (Ultra-Violet 
Products, Cambridge, UK) in order to strengthen cross-links between the DNA 




3.3.4    Hybridization 
 
The blotted nylon membrane was rolled up and placed into a hybridization 
cylinder. As a pre-hybridization step, 20 ml of hybridization buffer (Amersham-GE 
Healthcare Life Sciences, UK) was pre-warmed to 37 oC and poured into the 
cylinder. The cylinder was then incubated for 30 minutes at 41.5 oC in the rotating 
hybridization oven. While pre-hybridization was in progress, the hybridization 
probe solution was prepared.  Hybridization probe, a 245 base pair (bp) PCR 
fragment of IS 6110, was removed from the freezer and thawed on ice. Based on 
the intensity of subsequent band formation, certain components of the 
hybridization probe solution had to be optimized. The amount of hybridization 
probe varied between 5 and 7.5 µl; and the volume of distilled water varied 
between 12.5 and 15 µl. The calculated amounts of hybridization probe and 
distilled water were then mixed together in a micro-centrifuge tube followed by 
boiling for five minutes before it was returned to the ice for roughly 10 minutes to 
cool down. Next 20 µl DNA labeling reagent (Amersham-GE Healthcare Life 
Sciences, UK) and 20 µl glutaraldehyde (Amersham-GE Healthcare Life Sciences, 
UK) were added to this micro-centrifuge tube and incubated for ten minutes in a 
water bath at 37 oC. This provided a final hybridization probe solution of 60 µl. The 
pre-hybridization buffer was decanted into a sterile glass bottle and the full volume 
of hybridization probe solution was then added to it. The resultant hybridization 
buffer was added to the hybridization cylinder and the membrane was left to 
hybridize overnight in the rotating hybridization oven at 6 revolutions per minute 
and 42 oC. 
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3.3.5    Washing of membrane 
 
The hybridization buffer that was used overnight was discarded and the nylon 
membrane rinsed with 30 ml primary wash buffer, which was immediately 
discarded as well. Another 30 ml of primary wash buffer was added to the 
hybridization cylinder and incubated for 30 minutes in the rotating hybridization 
oven at 42 oC. The primary wash buffer was discarded and the nylon membrane 
rinsed twice with secondary wash buffer (2XSSC) for 5 to 10 minutes at room 
temperature on a Stuart Orbital SSL1 shaker (Cole-Parmer, Illinois, USA). The 
solution was discarded and the nylon membrane placed into a plastic bucket. 
 
3.3.6    Detection of banding patterns 
 
Exposure of the film and the development process were performed in a dark room. 
Eight milliliters of detecting reagent (Luminata Forte Western HRP Substrate, 
Merck, SA) was added to the plastic bucket containing the hybridized membrane. 
The membrane was carefully moved around in the bucket with a tweezer for two 
minutes to ensure good coverage of the whole surface. The detecting agent was 
then drained and covered in cling wrap taking care to avoid and wipe out all air 
bubbles that may enter in-between the layers. Next, the membrane was placed 
into a cassette with Amersham Hyperfilm ECL (Amersham-GE Healthcare Life 
Sciences, UK) and the film exposed to the membrane for two minutes. The film 
was removed and placed in image developer until bands could be observed. It was 
then immediately placed in fixer solution until the background appeared clear. The 
film was thoroughly rinsed before it was hanged to air-dry.  
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3.3.7    Reading and interpretation of results 
 
The BioNumerics version 6.0 software package (Applied Maths, Sint-Maartens-
Latem, Belgium) was used to visually analyze IS 6110 RFLP banding 
patterns197,198. This software was also used to construct a dendrogram that 
approximates the degree of similarity between banding patterns197,198. It 
specifically uses the unweighted pair group clustering method of averages 
(UPGMA) and the Dice coefficient to show how well patterns cluster 
together197,199. IS 6110 RFLP genotype patterns were compared to stored profiles 
at the University of KwaZulu-Natal and Stellenbosch University for IS 6110 RFLP 
family designations199,200. Isolates in a IS 6110 RFLP family usually share at least 
two-thirds of their banding patterns and a similarity index of at least 70% was 
therefore used to signify a IS 6110 RFLP family199,201. A 5% tolerance level was 
allowed for band matching within IS 6110 RFLP families. Each IS 6110 RFLP 
family was also interrogated for the presence of clusters i.e. at least two isolates 
with at least five bands and identical banding patterns; and for non-clustering 
isolates i.e. isolates that do not have at least one other isolate with an identical 
banding pattern, also called “unique” isolates199,200. 
 
3.4   gyrA investigations 
 
The same 32 M. tuberculosis isolates used for drug susceptibility investigations in 
section 3.1.1 were included in this experiment. A 762 base pair region of the gyrA 
gene, that includes the QRDR (codons 74 to 113), were investigated for mutations 
that may confer fluoroquinolone resistance. This experiment incorporated primers 
 68 
and amplification conditions previously described by Dookie et al174. DNA isolation, 
quality determination and quantity estimation have been described in section 3.2.2 
and section 3.2.3. 
 
3.4.1    Polymerase chain reaction 
 
Dookie et al previously designed the forward and reverse primers used in this 
study with Primer-3 open source software174,202,203. The designed primers were 
manufactured by metabion, Munich Germany174,204 See table 3.9 for primer 
characteristics. Polymerase chain reaction (PCR) was performed using the 
Expand High Fidelity PCR System dNTPack kit (Roche, Mannheim, Germany) that 
includes all reagents required for the PCR reaction, except DNA and primers. The 
different components of the master mix were first aliquoted together with the 
primers into PCR tubes (on ice), followed by the addition of extracted DNA. The 
final reaction mixture for each isolate was 50 µl and is presented in table 3.10. 
After the master mix preparation and the addition of DNA, the final reaction 
mixture was loaded into the GeneAmp PCR System 9700 thermal cycler (Applied 
Biosystems, San Diego, USA) and the DNA amplified according to the cycling 
conditions described in table 3.11. Gel electrophoresis was used as described 
before to evaluate whether the amplification process was successful. The 




Table 3.9    Primers used to PCR amplify a 762 base pair region of the gyrA 
gene174. 
 
Primer Nucleotide sequence Molecular weight 
Lyophilized 
concentration 
Amount of primer 
used per reaction 
Melting 
temperature 
Forward 5’-CGA TTG CAA ACG AGG AAT AG-3’ 6199 81.8 nmol 10 pmol (1 µl) 56 
oC 




Table 3.10    Master mix components for each 50 µl reaction. 
 
Master Mix component Concentration Volume (µl) 
PCR Nucleotide Mix (dNTP)  neat 1 
PCR Buffer (Expand High Fidelity Buffer) 10X 5 
MgCl2 25 mM 3.3 
Forward primer 10 pmol (stock solutions were 100 pmol) 1 
Reverse primer 10 pmol (stock solutions were 100 pmol) 1 
DNA polymerase* (Expand High Fidelity Enzyme Mix) 3.5 U/µl  0.75 
PCR grade water neat 33.95 
DNA template (added last) 1:100 to 1:1000 dilution of original concentration** 4 
 
*The DNA polymerase enzyme (Expand High Fidelity Enzyme Mix) in this kit 
consists of Taq DNA polymerase as well as a second DNA polymerase with 
proofreading activity.  
**Concentration depended on estimated DNA concentration. 
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Table 3.11    PCR cycling conditions. 
 
  Initial denaturation Denaturation Annealing Extension Final extension 
Temperature 94 oC 94 oC 53 oC 72 oC 72 oC 
Duration 2 minutes 45 seconds 45 seconds 45 seconds 7 minutes 
 
Number of PCR cycles: 40 (denaturation, annealing and extension). 
 
3.4.2    Gel electrophoresis of PCR product 
 
Gel electrophoresis and the Nanodrop instrument were used to estimate the purity, 
concentration and quality of each amplicon, as described in section 3.2.3. 
Amplicons were diluted with 10X TE buffer to an estimated 200 ng / 2 µl 
concentration. Thirty microliters of this DNA concentration were used for gyrA 
sequencing for each M. tuberculosis isolate.  
 
3.4.3   Gene sequencing, reading and interpretation of results 
 
PCR product purification and gyrA sequencing were performed in collaboration 
with Inqaba Biotec, Pretoria, South Africa. Briefly, PCR products were first cleaned 
using ExoSAP-IT (Affymetrix, Thermo Fisher Scientific, Massachusetts, USA) 
according to the package insert. One-directional sequencing was performed using 
the same primers used for gyrA PCR, with the BigDye Terminator V3.1 Cycle 
Sequencing Kit (Applied Biosystems, Thermo Fisher Scientific, Massachusetts, 
USA) according to the manufacturer’s instructions (Table 3.9). Labeled products 
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were cleaned with the ZR DNA Sequencing Clean-Up Kit (Zymo Research, 
California, USA). The cleaned products were loaded into the ABI 3500XL analyzer 
using POP-7 Polymer (Applied Biosystems, Thermo Fisher Scientific, 
Massachusetts, USA). The final DNA sequences where trimmed, aligned and 
analyzed with BioEdit version 7.1 software package (Ibis Therapeutics, California, 
USA)205,206. All sequences were compared to that of M. tuberculosis H37Rv.  
 
3.5   Computational investigations 
 
This work was performed in collaboration with the Molecular Bio-Computation and 
Drug Design Laboratory, School of Health Sciences, University of KwaZulu-
Natal, Durban, South Africa. 
 
3.5.1    Molecular docking investigations 
 
The previously published X-ray crystal structure of M. tuberculosis gyrase (PDB 
ID: 5BS8) complexed together with DNA, moxifloxacin and a magnesium ion were 
downloaded from the online Research Collaboration for Structural Bioinformatics 
Protein Data Bank (RCSB PDB)175,177,207. Structural analysis was performed using 
the Discovery Studio 4.0 software package (Accelrys, San Diego, USA)208,209. The 
complex was validated within its binding landscape to assure the effectiveness of 
the molecular docking algorithm before further evaluation of binding energies with 
other ligands. ChemBioDraw (CambridgeSoft, Massachusetts, USA) was used to 
prepare and energetically minimize nybomycin, DNM-2 and ciprofloxacin and 
ligands210. The known moxifloxacin ligand binding domain was used to correctly 
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orientate the constructed ligands between the DNA residues. The LibDock module 
of the Discovery Studio software package was used for simulating molecular 
docking208,209.  
 
3.5.2    Molecular dynamics simulations 
 
Molecular docking scores are known to be sometimes inaccurate in determining 
ligand binding affinity211,212. Further computational investigations were therefore 
embarked upon that included molecular dynamics simulations together with free 
binding energy determination213. The wild type form of the M. tuberculosis gyrase 
A subunit was changed using Chimera software (University of California, San 
Francisco, USA) to produce Ala90Val, Asp94Gly, Asp94His and Ala90Ser protein 
configurations214. This same software was also used to add missing hydrogen 
molecules and to remove water molecules and non-standard amino acid 
residues214. Molecular dynamics simulations for docking complexes of nybomycin, 
DNM-2 and ciprofloxacin with wild type and mutant M. tuberculosis gyrase were 
performed using the SANDER program within the AMBER 14.0 software package 
(University of California, San Francisco, USA)215,216. Proteins and ligands were 
parameterized with the AMBER99SB force field as well as the Generalized Amber 
Force Field (GAFF)217. Thereafter each complex was solvated with TIP3P water 
molecules and neutralized with the addition of sodium ions218. Whilst maintaining 
periodic boundary conditions, the long-range electrostatics were treated using the 
particle-mesh Ewald method219. Hereafter, partial minimization (1000 steps of 
steepest descent followed by 500 steps of conjugate gradient) was followed by full 
minimization (50 steps of steepest descent followed by 150 steps of conjugate 
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gradient). On completion of minimization, heat was added from 0 to 300o K for       
5 picoseconds using Langevin Dynamics and then equilibrated at 300o K. A 
Berendsen barostat was used to maintain a 1 bar atmospheric pressure220. The 
temperature and pressure were kept constant for a period of 500 picoseconds. 
The SHAKE algorithm was used to constrain bonds that include hydrogen 
atoms221,222. The final molecular dynamics simulation was conducted for                
2 nanoseconds at the stabilized temperature of 300o K and pressure of 1 bar, 
without any additional constraints. A time step of 2 femtoseconds was employed 
with a distance cutoff of 12.0 Å for all the non-bonded interactions. Simulation 
trajectories were saved at every 1 picosecond time-point. Post-dynamics analysis 
employed the Molecular Mechanics/Generalized Born Surface Area (MM/GBSA) 
method to calculate binding free energies for the full 2 nanosecond simulation 
period223,224. Briefly, this method is explained by the following equations: 
 
 ΔGbind = Gcomplex – Greceptor - Gligand…………………………………. (1) 
 ΔGbind  = Egas + Gsol – TΔS………………………………..………………(2) 
 Egas = Eint + Evdw + Eele………………………………………………………(3) 
 Gsol = GGB + GSA…………………………………………………………………(4) 
 GSA = ϒSASA…………………………………………………..…………………(5) 
 
ΔGbind: change of Gibbs (free) energy between ligand and protein 
 Egas: gas-phase energy 
Gsol: solvation free energy 
 Eint: internal energy  
 Evdw: van der Waals energy  
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Eele: Coulomb energy (electrostatic) 
T: temperature in Kelvin 
S: solute entropy 
 GGB: polar solvation contribution 
GSA: nonpolar solvation contribution 
ϒSASA: solvent accessible surface area 
 
Bhakat et al published a detailed explanation of each parameter225. A free energy 
decomposition analysis was conducted with the SANDER program in AMBER 14.0 
to determine the relative contribution of residue 90 and residue 94 of the gyrase 
enzyme to overall binding strength between each ligand and gyrase215,216. 
 
3.6    Selection and whole genome sequencing of M. tuberculosis mutants 
with increased nybomycin MICs 
 
3.6.1    Selection of M. tuberculosis mutants with increased nybomycin MICs 
 
M. tuberculosis V9124 is a fully drug-susceptible isolate belonging to the 
F15/LAM4/KZN IS 6110 RFLP family and has been previously obtained from a 
patient in Tugela Ferry, KwaZulu-Natal, South Africa. It forms part of the culture 
collection of the Department of Infection Prevention and Control at the University 
of KwaZulu-Natal. This clinical isolate has been well-characterized and its whole 
genome sequence was deposited in 2016 in the Sequence Read Archive (SRA) of 
the NCBI under the accession number SRP067784226,227. This fast-growing           
M. tuberculosis isolate was chosen for the mutant selection experiment.            
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The classic Luria-Delbrück fluctuation analysis method was modified for mutant 
selection in this study125,228–230. 
 
3.6.1.1    Preparation of antibiotic dilutions and culture media 
 
M. tuberculosis V9124 displayed a nybomycin MIC of 0.5 µg/ml and mutant 
selection was subsequently done by exposing the isolate to nybomycin 
concentrations of 0.125, 0.25, 0.5, 1, 2 and 4 µg/ml. 
 
The equation below was used to calculate the amount of nybomycin required to 
conduct a mutant selection experiment four times with each of the five nybomycin 
concentrations: 
 
Drug required (gram) = HDC x AV x DDF x CF x 100/P x R 
= HDC x 20 x 2 x 10-6 x 100/P x 4 
= HDC/P x 0.016 
 
• HDC = Highest drug concentration to be tested (μg/ml) 
• AV = Agar volume in each plate 
• DDF = Double dilution factor. This was 2 for all drugs, because a double 
amount of drug was required in the first plate from where 1:2 dilutions were 
made to the subsequent plates 
• CF = Conversion factor i.e. 10-6 to convert microgram to gram 
• P = % purity of antimicrobial powder, as indicated by the manufacturer  
• R = number of times experiment needs to be repeated 
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The calculated amount of nybomycin powder was dissolved with 1.6 ml DMSO in a 
sterile 30 ml universal container and further diluted with 14.4 ml sterile PBS to give 
a final volume of 16 ml.  
 
For agar plate pouring, four rows of sterile 30 ml universal containers were 
positioned on a tube rack, with six containers in each row. The first five containers 
in each row represented the five nybomycin concentrations that were used and the 
sixth container the drug-free positive-growth control. Two milliliters PBS were 
added to all the containers, except the first four containers representing the 
highest nybomycin concentration. Four milliliters antibiotic stock solution were 
added to these four containers. Two-fold serial dilutions were performed by 
removing 2 ml from the first container and adding it to the second container. It was 
then thoroughly mixed by pipetting up-and-down five times and thereafter 2 ml 
were transferred to the third container. This procedure was repeated up to the fifth 
container after which 2 ml antibiotic containing solution was discarded so that 2 ml 
fluid remained behind in all six containers of each row. 
 
Eighteen milliliters of freshly prepared Middlebrook 7H10 agar, maintained in its 
liquid state in a water bath set at 45 oC, was next added to each 2 ml of antibiotic 
working solution in the 30 ml container. Immediately after 18 ml of media was 
added to any particular container, its screw-cap was tightly closed and the 
container carefully tilted three times to mix its contents. The cap was then 
removed and the full 20 ml antibiotic-containing media promptly poured into an 
empty 90 mm Petri dish before the agar had time to solidify. The agar plates were 
closed and left on the benchtop until the agar solidified, after which the plates were 
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sealed in plastic bags and stored at 4-8 oC until use. Plates were used within one 
week of preparation. 
 
3.6.1.2    Preparation of M. tuberculosis inoculum and inoculation of agar plates 
 
One hundred microliters of M. tuberculosis V9124 stock culture was inoculated 
into 4 ml Middlebrook 7H9 broth in a 30 ml square media bottle (Nalgene, Thermo 
Fisher Scientific, Massachusetts, USA), and incubated in a shaking incubator at   
37 oC until it reached a turbidity with an optical density at 600 nm (OD600nm) of 1.0. 
This corresponds to approximately 1 x 108 CFU/ml. Next a 1:100 dilution was 
made by mixing 0.1 ml of this bacterial suspension with 9.9 ml sterile Middlebrook 
7H9 broth, followed by a further 1:200 dilution through mixing 0.05 ml of the 1:100 
dilution with 99.95 ml Middlebrook 7H9 broth. The final 1:20,000 dilution therefore 
contained approximately 1.5 x 103 CFU/ml.  
 
Four milliliters of this low-density bacterial suspension was then dispensed into 
each of 25 separate 30 ml square media bottles. Only 20 square media bottles 
were to be used for the mutant selection, the extra five were used for positive 
growth controls and for determining the OD600nm. The cultures were incubated at 
37 oC in a shaking incubator until an OD600nm of 0.9 to 1 was reached, 
representing the end of the logarithmic growth phase. The full contents of each 
bottle was then decanted directly into a separate 50 ml PPT. Each culture was 
mixed for 60 seconds with the vortex mixer and then sonicated twice (Misonix 
Sonicator s-4000, QSonica, Connecticut, USA) for ten seconds at an amplitude of 
10%, reaching a power level of 10 Watt. A ten second pause was taken between 
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the two 10 second sonication periods to tilt the PPT three times to mix its contents. 
Each culture was then centrifuged at 3434.496  x g for 10 minutes at room 
temperature and its supernatant was decanted. After resuspending the sediment 
in 200 µl PBS with 1% Tween-80, each PPT was again mixed thoroughly by 
pipetting up-and-down 5 to 10 times to break down the clumps. The entire 200 µl 
volume of each of the 20 cultures were plated and spread out onto a separate 
antibiotic-containing plate. Similarly, the entire 200 µl volume of each of the five 
positive control cultures were plated and spread out onto separate antibiotic-free 
plates. 
 
3.6.1.3    Culture, incubation and reading of results 
 
Inoculated agar plates were kept in the biosafety cabinet for up to an hour until the 
surface was dry. The plates were then heat-sealed in gas-permeable plastic bags 
and incubated at 37 oC in 5% CO2. After one week of incubation, the cultures were 
transferred to a hot room with a temperature of 37 oC and ambient air for an 
additional 2 to 4 weeks of incubation. Plates were read after 3 to 4 weeks’ 
incubation, or later depending on when the positive controls indicated growth. Any 
growth on the plates containing 2 and 4 µg/ml nybomycin was regarded as 
potential drug-resistant mutants. Potential drug-resistant mutants were picked off 
and their level of resistance to nybomycin confirmed by agar dilution MIC 
determination with the multipoint inoculator as described in section 3.1.5. 
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3.6.2    Whole genome sequencing of M. tuberculosis mutants with increased 
nybomycin MICs 
 
Whole genome sequencing (WGS) was performed in collaboration with the 
Kwazulu-Natal Research Innovation and Sequencing Platform in Durban, South 
Africa.  
 
Two copies of the wild type M. tuberculosis V9124 isolate, five mutants displaying 
a nybomycin MIC of 2 µg/ml and five mutants displaying a nybomycin MIC of        
4 µg/ml were selected for further investigation by WGS and comparative genomic 
analysis. DNA extraction was performed using the CTAB method and the quality of 
the extracted DNA confirmed with gel electrophoresis and the Nanodrop 
instrument, as described in sections 3.2.2 and 3.2.3. The Illumina MiSeq platform 
(Illumina, San Diego, USA) was employed and the following three basic steps 
were followed: (1.) library preparation, (2.) cluster generation and (3.) sequencing. 
 
3.6.2.1    Library preparation 
 
Transposomes are enzymes with open DNA ends that can insert themselves 
randomly into strands of DNA. The Nextera XT DNA Library Preparation Kit 
(Illumina, San Diego, USA) used in this study, employs a transposome designed to 
first fragment input DNA, leaving a staggered cut at the site where it inserted itself, 
and then to ligate partial adapter sequences to these single-stranded DNA 
overlays. This modified transposition reaction is called tagmentation and enables 
dual-index sequencing of pooled libraries. Three additional motifs are 
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subsequently inserted during a reduced cycle amplification process by using the 
partial adaptor sequences. This includes both sequencing primer binding sites for 
forward and reverse primers and index sequences that allows for pooling of 
libraries by enabling in silico sample identification and sorting. It further includes 
adapter regions that are either the same (i5) or complementary (i7) to the 
oligonucleotides fixed to the surface of the flow cell slide used downstream during 
cluster formation. 
 
Sample preparation. Input DNA first had to be quantified and its quality confirmed 
as the Nextera XT kit is optimized to start with 1 ng DNA. The Qubit dsDNA HS 
Assay system (Invitrogen, Thermo Fisher Scientific, Massachusetts, USA) is a 
fluorometric-based method and was used to quantify each DNA sample. Hereafter 
individual DNA samples were diluted in molecular-grade water to reach the 
appropriate starting concentration of 0.2 ng/µl. 
 
Tagmentation of gDNA. Five microliters of normalized gDNA were added and 
mixed with 10 µl Tagment DNA BufferÒ into each well of a MicroAmp 96-well PCR 
plate (Thermo Fisher Scientific, Massachusetts, USA). Next 5 µl of Amplicon 
Tagment MixÒ was added and the plate centrifuged at 280 x g and 20 oC for         
60 seconds. Thereafter the plate was placed on a preheated Veriti thermocycler 
(Applied Biosystems, Thermo Fisher Scientific, Massachusetts, USA) and its 
contents incubated at 55 oC for 5 minutes whereafter the temperature was 
decreased to at 10 oC (holding temperature). Five microliters Neutralizing Tagment 
BufferÒ was subsequently mixed into each sample and the plate again centrifuged 
at 280 x g at 20 oC for 60 seconds. Tagmentation was completed with a final 
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incubation step at room temperature for 5 minutes. The result was 25 µl 
neutralized and tagmented genomic DNA per sample. 
 
Amplification of tagmented genomic DNA libraries. Five microliters each of Index 1 
(i7) adapter and Index 2 (i5) adapter were added to each tagmented genomic DNA 
sample followed by 15 μl Nextera PCR Master Mix. The final volume in each well 
was therefore 50 μl. The MicroAmp 96-well PCR plate was centrifuged at 280 x g 
at 20 oC for 60 seconds and PCR amplification performed with a Veriti 
thermocycler under the conditions stipulated in table 3.12 
 
Table 3.12    PCR conditions for amplification of tagmented DNA. 
 
  Temperature Duration 
Initial denaturation 72 oC 3 minutes 
95 oC 30 seconds 
*Denaturation 95 oC 10 seconds 
*Annealing 55 oC 30 seconds 
*Extension 72 oC 30 seconds 
Final extension 72 oC 5 minutes 




Library cleanup with AMPure XP beads. The 96-well PCR plate was first 
centrifuged at 280 x g at 20 oC for 60 seconds where after the full contents of each 
well was transferred to a 0.8 ml well of a MicroAmp 96-well PCR plate. Next 30 μl 
AMPure XP beads (Agencourt AMPure XP, Beckman Coulter Genomics, 
Minnesota, USA) were added to each well and the reagents mixed on a plate 
shaker at 695.485 x g for 2 minutes. After incubation at room temperature for        
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5 minutes, the PCR plate was positioned on a magnetic stand to allow the liquid to 
settle and become clear (approximately 2 minutes). The supernatant was 
aspirated and discarded from each well and the remaining contents were washed 
twice by adding 200 μl 80% ethanol to each well and letting it stand for 30 seconds 
on the magnetic stand, followed by aspiration and discarding of the supernatant. 
Care was taken to remove all the residual ethanol from each well by carefully 
aspirating through a 20 μl pipette tip. The plate was then allowed to air-dry on the 
magnetic stand for 15 minutes after which 52.5 μl Resuspension Buffer was added 
to each well and the contents mixed by shaking the plate at 1800 revolutions per 
minute for 2 minutes. The midi plate was next incubated at room temperature for  
2 minutes and placed back on the magnetic stand until the liquid was clear again 
(approximately 2 minutes). Finally, 50 μl supernatant was transferred from each 
well to a new MicroAmp 96-well PCR plate. 
 
Check library size distributions. To assess the library size distributions of each 
cleaned library, 1 μl of neat library DNA was analyzed with the Labchip GX touch 
(PerkinElmer, Massachusetts, USA). Each sample was quantified using the Qubit 
instrument as described earlier. 
 
Normalization of libraries by concentration. The quantity of each of the 12 libraries 
was normalized to 4 nM in an attempt to ensure that the pooled library will have an 
equal representation. 
 
Pooling of libraries. The PCR plate was first centrifuged at 1000 x g at 20 °C for  
60 seconds after which 5 μl of each 4 nM library was transferred to a single clean 
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Eppendorf tube. The pooled libraries were then diluted to a final concentration of 
12 pM according to the loading concentration required for the Illumina MiSeq 
sequencing platform. PhiX Control v3 (Illumina, San Diego, USA) was included as 
an internal sequencing control. This adapter-ligated library was derived from the 
small, well-characterized PhiX genome. The PhiX library provides a quality control 
for cluster generation, sequencing, and alignment. To accommodate for the low 
diversity of the M. tuberculosis genome, PhiX was added to the pooled library to a 
final concentration of 10%.  
 
3.6.2.2    Cluster generation 
 
Clustering is the process whereby clonal groups of template DNA are produced 
and attached to the surface of a flow cell (Illumina, San Diego, USA)231. This on-
board process ensures that multiple copies of each DNA fragment are available for 
sequencing231. The flow cell is a glass slide with several physically separated 
lanes, each coated with two types of oligonucleotides: one type (P5) is 
complementary to the oligonucleotide sequence on one end of the DNA fragment 
(i5) and the other type (P7) is complementary to the oligonucleotide sequence on 
the other end of the DNA fragment (i7)231. 
 
The pooled single-stranded DNA library was loaded into a flow cell of the onboard 
cluster module within the MiSeq instrument. Single DNA fragments were then 
captured by the surface-bound oligonucleotides (P5) on the flow cell followed by 
the formation of complementary strands by polymerase enzyme. The resultant 
double-stranded DNA was denatured and the original template washed away. The 
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non-binding end of the DNA fragment then bent over to hybridize to the second 
type of oligonucleotide (P7) on the flow cell surface. Polymerase enzyme once 
again produced a complementary strand, thereby forming a double-stranded 
bridge. Subsequent denaturation resulted in two separate DNA molecules 
attached to the flow cell surface. This isothermal process is called “bridge” 
amplification and through repeated cycles of denaturation and extension results in 
the amplification of single DNA strands into millions of separate clonal clusters 
across the flow cell surface, each cluster containing approximately 1000 copies. 
Bridge amplification and cluster formation were completed after washing away of 
all the reverse strands, leaving only forward strands for sequencing. 
 
3.6.2.3    Gene sequencing 
 
The Illumina MiSeq sequencing platform is a next generation sequencing (NGS) 
technology that uses a method similar to capillary electrophoresis 
sequencing126,232. The major advancement with NGS is that millions of DNA 
fragments are sequenced simultaneously instead of just one fragment at a time126. 
For this study, 2 x 250 bp paired-end sequencing was performed using the MiSeq 
v2 (500 cycle) reagent kit (Illumina, San Diego, USA). This kit provides up to        
15 million reads per run and a maximum output of 8.5 giga base pairs126. 
 
DNA polymerase enzyme catalyzes the addition of four fluorescently labeled 
dNTPs into growing nucleic acid chains during cycles of DNA synthesis126. Laser 
excitation and imaging are used to identify each fluorescently labeled dNTP as 
soon as it is incorporated into the growing nucleic acid chain126. The intensity of 
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the signal thus produced is measured and used by the MiSeq software for creating 
chromatogram peaks and thereby for assigning nucleobases126. After each read, 
the nucleotide label is enzymatically cleaved to permit the next dNTP to be 
incorporated during the following cycle126. 
 
3.6.3    Bioinformatics analysis of whole genome sequencing results 
 
Bioinformatics analysis of gene sequences was performed in collaboration with the 
KwaZulu-Natal Research Innovation and Sequencing Platform in Durban, South 
Africa.  
 
Raw sequencing reads were obtained in FASTQ format from the Illumina MiSeq 
instrument. Quality filtering and trimming were performed using the Trimmomatic 
software tool (Rheinisch-Westfälische Technische Hochschule, Aachen, 
Germany)233,234. This process involved both the removal of adaptor sequences 
used for sequencing and the deletion of regions with low base call quality, as 
determined by Phred+33 scoring234. Sequences were therefore trimmed from their 
ends to the loci where low-quality base calling appears233,234. Hereafter, trimmed 
genome sequence reads from the 12 genomic DNA samples were each mapped 
against the M. tuberculosis H37Rv reference genome (Ensembl number: 
ASM19595v2) using the Burrows-Wheeler Aligner software package235–238. Single 
nucleotide polymorphism (SNP) calling was conducted for each of the samples 
using Samtools software239,240. To correct for “strand bias” characteristic to 
Illumina sequencing data, all SNPs were further filtered using BCFtools239,241. The 
resultant SNP data was analyzed with the TBProfiler tool to identify the presence 
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of known drug resistance mutations, as previously described142,242. The TBProfiler 
tool is able to identify most of the common SNPs that confer resistance to 
isoniazid, rifampicin, pyrazinamide, ethambutol, fluoroquinolones, 
aminoglycosides, capreomycin, and ethionamide142,242. SNPs were also annotated 
and analyzed with the snpEff software and Variant Effect Predictor (VEP) online 
tools to help identify and describe their basic effects243,244.  
 
All SNPs potentially resulting in amino acid changes were tabulated using Excel 
and those common to all 10 mutant sequences, as well as the 2 wild type control 
sequences, were removed. SNPs present in PE and PPE genes were also filtered 
out. PE and PPE are two large mycobacteria-specific families of genes that 
contain proline-glutamic acid (PE) or proline-proline-glutamic acid (PPE) motifs. 
Many of the PE and PPE genes appear to play a role in antigenic variation and 
immune modulation, but they are remarkably polymorphic and therefore difficult to 
study245. SNPs present in the mutant sequences, but not in the wild type 
sequences, were considered as potentially associated with M. tuberculosis 










CHAPTER 4 – RESULTS 
 
4.1    Introduction 
 
Following previous work published by Hiramatsu et al and Arai et al, the in vitro 
inhibitory effect of nybomycin was explored in three Mycobacterium tuberculosis 
clinical isolates143,165,166. The results thereof prompted the screening of 
susceptibility of a diverse collection of bacterial isolates to various quinoline 
compounds. M. tuberculosis was subsequently further investigated with IS 6110 
RFLP fingerprinting, confirmatory nybomycin susceptibility testing and the testing 
of DNM-2, a compound closely related to nybomycin. Mycobacterial DNA gyrase 
enzyme was investigated as the potential site where nybomycin binds to and exert 
its effect. This was attempted through gyrA quinolone resistance-determining 
region (QRDR) sequencing and in silico investigations. Nybomycin resistant 
mutants were also obtained and their genomes sequenced for comparison with the 
wild type organism to elucidate the possible mechanism of resistance of              
M. tuberculosis to nybomycin. 
 
4.2    In vitro inhibitory effect of quinolones on various bacterial species 
 
After encouraging in vitro susceptibility results were obtained with nybomycin and 
M. tuberculosis, the study was expanded with testing of a larger and more diverse 
collection of M. tuberculosis isolates as well as various other bacterial species. 
The goal was to determine whether (1.) nybomycin exhibits an inhibitory effect on 
any of the bacterial species and (2.) whether nybomycin acts as a reverse 
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antibiotic in these same isolates. In a similar fashion, we also included and 
investigated four quinoline containing drugs that are currently registered for human 
use: quinine, chloroquine, mefloquine and primaquine. 
 
4.2.1    M. tuberculosis 
 
Three M. tuberculosis isolates were screened for susceptibility (µg/ml) to 
nybomycin using Middlebrook 7H9 broth with 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyl tetrazolium bromide (MTT) salt as growth detecting reagent. This was 
done in triplicate and the results are displayed in table 4.1. 
 
Table 4.1    Nybomycin minimum inhibitory concentrations (µg/ml) of 
fluoroquinolone-susceptible and fluoroquinolone-resistant M. tuberculosis isolates. 
 
M. tuberculosis Isolate 
number 
Phenotypic 
classification A B C Final MIC 
TF 1538 Susceptible 6.25 6.25 3.125 6.25 
MODS 11 MDR 12.5 12.5 25 12.5 
MODS 387 XDR 1.5625 1.5625 0.78125 1.5625 
 
Nybomycin minimum inhibitory concentration (MIC) values for the fluoroquinolone-
susceptible isolates TF 1538 and MODS 11 were two to three double dilutions 
higher than that of MODS 387, the fluoroquinolone-resistant isolate. The low 
nybomycin MIC (µg/ml) seen with the XDR isolate, as well as the inverse 
relationship between fluoroquinolone susceptibility and nybomycin MIC (µg/ml) 
values, provided an impetus for further investigation of nybomycin activity against 
M. tuberculosis. 
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In order to compare the effect of nybomycin on fluoroquinolone-susceptible and 
fluoroquinolone-resistant M. tuberculosis isolates more thoroughly, and to ensure 
global appeal and applicability of the results of this study, a collection of 32 M. 
tuberculosis isolates was assembled consisting of a wide variety of IS 6110 RFLP 
genotypes and drug susceptibility profiles. The most common IS 6110 RFLP 
banding pattern was F15/LAM4/KZN (n=10) followed by Atypical Beijing F31 
(n=9), S-family F28 (n=3), non-clustering banding patterns (n=3), Beijing F29 
(n=2), LCC F150 (n=2) and one isolate each of F131 and LAM F11. The IS 6110 
RFLP banding patterns, IS 6110 RFLP family name designations and dendrogram 
















Figure 4.1  IS 6110 RFLP banding patterns, IS 6110 RFLP family name 




Drug susceptibility testing results obtained with Middlebrook 7H10 agar dilution 
and multipoint inoculation183,184,189 were used to categorize the M. tuberculosis 
isolates into DS (n=3), MDR (n=7), pre-XDR (n=6) and XDR (n=15) phenotypes, 
as displayed in table 4.2. M. tuberculosis susceptibility to nybomycin was 
investigated in the same manner and MIC (µg/ml) results are also displayed in 
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table 4.2. All MIC (µg/ml) investigations were done in triplicate with M. tuberculosis 
H37Rv as susceptible control. Raw data for MIC investigations are displayed in 
Appendix B. 
 




IS 6110 RFLP 
Genotype 
Agar dilution MIC (µg/ml) 
Drug 
Resistance 
Phenotype Isoniazid Rifampicin Amikacin Ofloxacin Nybomycin 
H37Rv H37Rv 0.125 0.25 1 0.5 1 Susceptible 
TF 1538 F131 0.0625 0.125 1 0.5 1 Susceptible 
TF 1413 Non-clustering 0.0625 0.25 1 0.5 1 Susceptible 
TF 832 LAM F11 0.125 0.25 1 0.5 1 Susceptible 
MODS 11 F15/LAM4/KZN 64 2 2 0.5 1 MDR 
TT 14 Atypical Beijing F31 16 > 64 1 0.5 1 MDR 
TT 17 Atypical Beijing F31 8 > 64 1 0.5 1 MDR 
TF 44949 S-family F28 16 > 64 1 0.5 0.25 MDR 
MODS 688 F15/LAM4/KZN > 64 64 2 0.5 1 MDR 
TF 2063 S-family F28 16 64 0.25 0.5 0.25 MDR 
MODS 682 S-family F28 16 > 64 1 0.5 1 MDR 
TT 50 Atypical Beijing F31 32 > 64 1 4 1 Pre-XDR 
TT 309 Atypical Beijing F31 32 64 >64 0.5 1 Pre-XDR 
TT 627 F15/LAM4/KZN > 64 > 64 1 4 1 Pre-XDR 
NT 1 F15/LAM4/KZN 32 2 1 16 1 Pre-XDR 
NT 66 F15/LAM4/KZN 32 > 64 1 8 1 Pre-XDR 
R 11 654 Non-clustering 32 64 1 8 0.5 Pre-XDR 
TT 169 Atypical Beijing F31 32 64 > 64 16 1 XDR  
R 2 404 Non-clustering 2 16 > 64 8 0.25 XDR 
R 4 825 Beijing F29 32 > 64 > 64 8 1 XDR 
TT 187 Atypical Beijing F31 32 64 > 64 16 1 XDR 
TT 209 Atypical Beijing F31 32 32 > 64 16 1 XDR 
R 6 609 Atypical Beijing F31 32 16 > 64 16 0.5 XDR 
R 10 741 Atypical Beijing F31 > 64 > 64 > 64 16 1 XDR 
R 10 398 F15/LAM4/KZN 32 > 64 > 64 4 1 XDR 
R 4 819 LCC F150 8 64 4 4 1 XDR 
R 10 442 LCC F150 16 > 64 > 64 2 1 XDR 
MODS 388 F15/LAM4/KZN 32 > 64 > 64 4 0.5 XDR 
MODS 387 F15/LAM4/KZN 64 > 64 > 64 4 0.5 XDR 
TF 1762 F15/LAM4/KZN 64 > 64 > 64 4 0.5 XDR 
MODS 195 F15/LAM4/KZN 32 > 64 > 64 4 0.5 XDR 
R 4 933 Beijing F29 16 > 64 > 64 8 0.5 XDR 
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The collection of 32 M. tuberculosis isolates comprised of 12 fluoroquinolone-
susceptible and 20 fluoroquinolone-resistant phenotypes. Nybomycin MIC values 
of M. tuberculosis isolates ranged between 0.25 and 1.0 µg/ml and did not show 
much variation across the different resistance phenotypes. These results differ 
markedly from the initial screening results obtained with the MTT assay. The MTT 
assay was therefore employed a second time to verify the results obtained with the 
agar dilution with multipoint inoculation by investigating 23 of the 32                     
M. tuberculosis isolates. At this time, a deoxynybomycin derivative (DNM-2) 
donated by Paul Hergenrother (Department of Chemistry, University of Illinois, 
USA)179, was also tested using the same 23 isolates and methodology. All MIC 
(µg/ml) investigations were performed in triplicate, with M. tuberculosis H37Rv as 
control. The final nybomycin and DNM-2 MIC results are shown in table 4.3 and 













Table 4.3    MIC (µg/ml) values of M. tuberculosis isolates for nybomycin and a 
















(µg/ml) DNM-2 (µg/ml) 
H37Rv H37Rv Susceptible 1 2 1.5 
TF 1538 F131 Susceptible 1 2 3 
TF 1413 Non-clustering Susceptible 1 2 3 
TF 832 LAM F11 Susceptible 1 2 3 
MODS 11 F15/LAM4/KZN MDR 1 2 3 
TT 17 Atypical Beijing F31 MDR 1 1 3 
TF 44949 S-family F28 MDR 0.25 2 3 
MODS 688 F15/LAM4/KZN MDR 1 2 3 
TF 2063 S-family F28 MDR 0.25 2 3 
TT 50 Atypical Beijing F31 Pre-XDR 1 1 3 
TT 309 Atypical Beijing F31 Pre-XDR 1 1 3 
TT 627 F15/LAM4/KZN Pre-XDR 1 1 1.5 
NT 1 F15/LAM4/KZN Pre-XDR 1 2 3 
NT 66 F15/LAM4/KZN Pre-XDR 1 1 1.5 
TT 169 Atypical Beijing F31 XDR  1 1 1.5 
R 2 404 Non-clustering XDR 0.25 2 1.5 
R 4 825 Beijing F29 XDR 1 1 1.5 
R 6 609 Atypical Beijing F31 XDR 0.25 1 1.5 
R 10 741 Atypical Beijing F31 XDR 1 1 3 
R 4 819 LCC F150 XDR 1 2 1.5 
R 10 442 LCC F150 XDR 1 2 3 
MODS 388 F15/LAM4/KZN XDR 0.5 1 1.5 
MODS 387 F15/LAM4/KZN XDR 0.5 2 1.5 
 
M. tuberculosis isolates displayed nybomycin MIC values that ranged between 
0.25 and 1.0 µg/ml with the agar dilution method and between 1.0 and 2.0 µg/ml 
with the MTT assay. For DNM-2, MIC values ranged between 1.5 and 3.0 µg/ml. 
From these results, there appears to be no direct or inverse relationship between 
MIC (µg/ml) values obtained for ofloxacin, nybomycin and DNM-2 with any of the 
tested M. tuberculosis isolates. 
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4.2.2  Neisseria gonorrhoeae, Escherichia coli, Klebsiella pneumoniae, 
Enterobacter cloacae, Pseudomonas aeruginosa, Acinetobacter baumanii, 
Enterococcus faecalis and Staphylococcus aureus 
 
A selection of Gram-positive and Gram-negative bacterial isolates exhibiting a 
wide range of susceptibility to fluoroquinolones was included for investigation. 
Drug susceptibility testing was performed in triplicate using agar dilution 
methodology with multipoint inoculation. N. gonorrhoeae ATCC 49226 and E. coli 
ATCC 25722 served as controls. MIC (µg/ml) results for the different bacterial 















Table 4.4    MIC (µg/ml) values of N. gonorrhoeae isolates for ciprofloxacin, 
nalidixic acid, nybomycin, quinine, chloroquine, mefloquine and primaquine with 
the multipoint inoculation method 
 
N. gonorrhoeae 
Isolate number Ciprofloxacin 
Nalidixic 
acid Nybomycin Quinine Chloroquine Mefloquine Primaquine 
ATCC 49226 < 0.0625 2 4 128 > 128 16 128 
526 < 0.0625 2 1 128 > 128 16 128 
840 < 0.0625 2 1 128 > 128 4 64 
924 < 0.0625 2 2 128 > 128 4 64 
556 < 0.0625 16 2 128 > 128 8 128 
373 < 0.0625 8 8 128 > 128 16 > 128 
310 < 0.0625 2 0.5 128 > 128 4 64 
360 0.25 8 4 128 > 128 16 > 128 
20 0.25 8 4 128 > 128 4 64 
172 0.25 16 2 128 > 128 4 128 
391 0.25 8 1 128 > 128 4 64 
277 0.5 8 4 128 > 128 16 128 
342 0.5 8 2 128 > 128 16 128 
524 0.5 16 2 128 > 128 16 64 
938 0.5 8 0.25 128 > 128 2 32 
336 1 8 2 128 > 128 16 128 
345 1 16 2 128 > 128 16 128 
462 1 8 0.5 > 128 > 128 4 64 
219 2 8 4 128 > 128 16 64 
74 2 8 4 > 128 > 128 16 128 
227 2 16 4 > 128 > 128 16 > 128 
108 4 16 4 > 128 > 128 16 > 128 
119 4 16 2 > 128 > 128 16 128 
236 4 8 2 128 > 128 16 > 128 
251 4 16 4 128 > 128 16 > 128 
267 4 16 4 128 > 128 16 > 128 
296 4 8 8 128 > 128 16 128 
688 4 8 4 128 > 128 16 > 128 
819 4 8 4 > 128 > 128 16 128 
766 4 8 0.5 > 128 > 128 0.5 16 
 
For N. gonorrhoeae isolates, the ciprofloxacin MIC values ranged between              
< 0.0625 and 4 µg/ml; and the nalidixic acid MIC values between 2 and 16 µg/ml. 
MIC values with nybomycin ranged between 0.25 and 8.0 µg/ml and showed no 
direct or inverse relationship with MIC values from the quinolones. One isolate had 
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a mefloquine MIC of 0.5 µg/ml and another isolate had a mefloquine MIC of           
2 µg/ml. Mefloquine MIC values for the other 28 isolates ranged between 4 and     
16 µg/ml. All N. gonorrhoeae isolates displayed quinine MIC values ≥ 128 µg/ml 
and all chloroquine MIC values were > 128 µg/ml. Twenty-eight N. gonorrhoeae 
isolates exhibited primaquine MIC values between 64 and ≥ 128 µg/ml, while one 
isolate had a primaquine MIC of 32 µg/ml and another a primaquine MIC of          
16 µg/ml. The mostly high MIC values obtained with quinine, chloroquine, 
mefloquine and primaquine provided insufficient incentive for further investigation 
of these drugs against N. gonorrhoeae.  Nybomycin MIC values are moderately 
















Table 4.5   MIC (µg/ml) values of E. coli, K. pneumoniae, E. cloacae,                   
P. aeruginosa, A. baumanii, S. aureus and E. faecalis isolates for ciprofloxacin, 
nalidixic acid, nybomycin, quinine, chloroquine, mefloquine and primaquine with 
the multipoint inoculation method. 
 
Test organism Ciprofloxacin Nalidixic acid Nybomycin Quinine Chloroquine Mefloquine Primaquine 
E. coli ATCC 25722 < 0.125 8 > 16 128 > 128 64 > 128 
E. coli no. 1 < 0.125 16 > 16 128 > 128 > 64 > 128 
E. coli no. 2 2 16 > 16 128 > 128 > 64 > 128 
E. coli no. 3 2 16 > 16 128 > 128 > 64 > 128 
E. coli no. 4 32 16 > 16 128 > 128 > 64 > 128 
E. coli no. 5 32 16 > 16 128 > 128 > 64 > 128 
K. pneumoniae no. 1 < 0.125 16 > 16 128 > 128 > 64 > 128 
K. pneumoniae no. 2 0.25 16 > 16 128 > 128 > 64 > 128 
K. pneumoniae no. 3 2 16 > 16 128 > 128 > 64 > 128 
K. pneumoniae no. 4 16 16 > 16 128 > 128 > 64 > 128 
E. cloacae no. 1 < 0.125 8 > 16 128 > 128 > 64 > 128 
E. cloacae no. 2 8 8 > 16 128 > 128 > 64 > 128 
E. cloacae no. 3 32 8 > 16 128 > 128 > 64 > 128 
E. cloacae no. 4 32 16 > 16 128 > 128 > 64 > 128 
P. aeruginosa no. 1 0.25 8 > 16 128 > 128 > 64 > 128 
P. aeruginosa no. 2 0.5 8 > 16 64 > 128 > 64 > 128 
P. aeruginosa no. 3 8 8 > 16 64 > 128 > 64 > 128 
P. aeruginosa no. 4 16 8 > 16 64 > 128 > 64 > 128 
P. aeruginosa no. 5 16 8 > 16 64 > 128 > 64 > 128 
P. aeruginosa no. 6 16 8 > 16 64 > 128 > 64 > 128 
P. aeruginosa no. 7 32 8 > 16 128 > 128 > 64 > 128 
A. baumanii no. 1 0.25 8 > 16 128 > 128 64 > 128 
A. baumanii no. 2 2 8 > 16 128 > 128 64 > 128 
A. baumanii no. 3 4 8 > 16 128 > 128 > 128 > 128 
A. baumanii no. 4 16 8 > 16 128 > 128 64 > 128 
A. baumanii no. 5 > 32 16 8 > 128 > 128 32 > 128 
S. aureus no. 1 0.5 32 4 > 128 > 128 32 > 128 
S. aureus no. 2 0.5 32 8 > 128 > 128 32 > 128 
S. aureus no. 3 2 32 4 > 128 > 128 32 > 128 
S. aureus no. 4 > 32 32 4 > 128 > 128 32 > 128 
E. faecalis no. 1 1 32 16 > 128 > 128 32 > 128 
E. faecalis no. 2 2 32 16 > 128 > 128 32 > 128 
E. faecalis no. 3 > 32 32 8 > 128 > 128 32 > 128 
E. faecalis no. 4 > 32 32 8 > 128 > 128 32 > 128 
 
Table 4.5 displays MIC (µg/ml) values obtained with five E. coli, four K. 
pneumoniae, four E. cloacae, seven P. aeruginosa, five A. baumanii four S. 
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aureus and four E. faecalis isolates. Each genus tested included fluoroquinolone-
susceptible and fluoroquinolone-resistant isolates. All Gram-negative isolates 
displayed nybomycin MIC values > 16 µg/ml, except for one A. baumanii isolate 
with a nybomycin MIC of 8 µg/ml. Nybomycin MIC values for the E. faecalis 
isolates ranged between 8 and 16 µg/ml, and for S. aureus between 4 and             
8 µg/ml. No direct or inverse relationship was observed between MIC values of 
quinolones and those of nybomycin. All Gram-negative isolates had mefloquine 
MIC values of ≥ 64 µg/ml, except for one A. baumanii isolate with a mefloquine 
MIC of 32 µg/ml. All Gram-positive isolates displayed a mefloquine MIC of              
32 µg/ml. All Gram-negative isolates had MIC values for quinine of 128 µg/ml, 
except for all seven P. aeruginosa isolates that exhibited a quinine MIC of            
64 µg/ml. All Gram-positive isolates displayed quinine MIC values of > 128 µg/ml. 
All Gram-positive and Gram-negative isolates displayed chloroquine and 
primaquine MIC values of > 128 µg/ml.  
 
4.3    In silico effect of nybomycin and DNM-2 on M. tuberculosis gyrase 
enzyme 
 
4.3.1    gyrA QRDR sequencing 
 
The most common gyrA QRDR mutations in the collection of 32 M. tuberculosis 
isolates were identified to inform the subsequent in silico investigations. This was 
done in order to ensure that insights obtained through computational methods can 
be linked to the previous in vitro susceptibility test results. DNA sequencing results 
are presented in table 4.6. 
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H37Rv H37Rv Susceptible ---- ---- ---- ---- 
TF 1538 F131 Susceptible ---- ---- ---- ---- 
TF 1413 Non-clustering Susceptible ---- ---- ---- ---- 
TF 832 LAM F11 Susceptible ---- ---- ---- ---- 
MODS 11 F15/LAM4/KZN MDR ---- ---- ---- ---- 
TT 14 Atypical Beijing F31 MDR ---- ---- ---- ---- 
TT 17 Atypical Beijing F31 MDR ---- ---- ---- ---- 
TF 44949 S-family F28 MDR ---- ---- ---- ---- 
MODS 688 F15/LAM4/KZN MDR ---- ---- ---- ---- 
TF 2063 S-family F28 MDR ---- ---- ---- ---- 
MODS 682 S-family F28 MDR ---- ---- ---- ---- 
TT 50 Atypical Beijing F31 Pre-XDR ---- ---- ---- ---- 
TT 309 Atypical Beijing F31 Pre-XDR ---- ---- ---- ---- 
TT 627 F15/LAM4/KZN Pre-XDR 91 TCG → CCG Ala → Pro A91P 
NT 1 F15/LAM4/KZN Pre-XDR 94 GAC → GGC Asp → Gly D94G 
NT 66 F15/LAM4/KZN Pre-XDR 90 GCG → GTG Ala → Val A90V 
R 11 654 Non-clustering Pre-XDR 94 GAC → TAC Asp → Tyr D94Y 
TT 169 Atypical Beijing F31 XDR  94 GAC → CAC Asp → His D94H 
R 2 404 Non-clustering XDR 94 GAC → GGC Asp → Gly D94G 
R 4 825 Beijing F29 XDR 94 GAC → GGC Asp → Gly D94G 
TT 187 Atypical Beijing F31 XDR 94 GAC → GGC Asp → Gly D94G 
TT 209 Atypical Beijing F31 XDR 94 GAC → AAC Asp → Asn D94N 
R 6 609 Atypical Beijing F31 XDR 88 GGC → TGC Gly → Cys G88C 
R 10 741 Atypical Beijing F31 XDR 94 GAC → GGC Asp → Gly D94G 
R 10 398 F15/LAM4/KZN XDR 90 GCG → GTG Ala → Val A90V 
R 4 819 LCC F150 XDR ---- ---- ---- ---- 
R 10 442 LCC F150 XDR ---- ---- ---- ---- 
MODS 388 F15/LAM4/KZN XDR 90 GCG → GTG Ala → Val A90V 
MODS 387 F15/LAM4/KZN XDR 90 GCG → GTG Ala → Val A90V 
TF 1762 F15/LAM4/KZN XDR 90 GCG → GTG Ala → Val A90V 
MODS 195 F15/LAM4/KZN XDR 90 GCG → GTG Ala → Val A90V 
R 4 933 Beijing F29 XDR 94 GAC → GGC Asp → Gly D94G 
 
As expected, only the fluoroquinolone-resistant isolates contained mutations in the 
QRDR of gyrA. However, both of the XDR isolates from the LCC F150 RFLP 
family had no mutations in the QRDR of gyrA. None of the ofloxacin resistant 
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isolates had more than one mutation. A90V and D94G were the most common 
codon changes and were present in six isolates each. There were also one each 
of D94H, D94Y, D94N, A91P and G88C codon changes. 
 
4.3.2    Molecular docking investigations 
 
The previously published X-ray crystal structure of M. tuberculosis gyrase          
(PDB ID: 5BS8) complexed together with DNA, moxifloxacin and a magnesium ion 
was reproduced and validated within its binding landscape, to assure the 
effectiveness of the molecular docking algorithm for further evaluation of binding 
energies with other ligands177,208,209. Nybomycin, DNM-2 and ciprofloxacin ligands 
were subsequently constructed with the help of the ChemBioDraw software tool 
(CambridgeSoft, Massachusetts, USA) and oriented between DNA residues, 
similar to moxifloxacin210. LibDock scores for nybomycin, DNM-2 and ciprofloxacin 
were compared to the results obtained with the validated moxifloxacin complex 
and all three ligands displayed scores higher than that obtained with moxifloxacin. 
At 152.12 kcal/mol, nybomycin displayed the highest docking score of all ligands 
evaluated in this study. The molecular docking scores are presented in table 4.7.   
 
Table 4.7    Molecular docking scores and molecular weight of nybomycin, DNM-2, 
ciprofloxacin and moxifloxacin against wild type M. tuberculosis gyrase 
 
Ligands Molecular Weight LibDock score (kcal/mol) 
Nybomycin 298.30 152.12 
DNM-2 296.33 148.69 
Ciprofloxacin 331.35 148.24 
Moxifloxacin 401.44 116.33 
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4.3.3    Molecular dynamics simulations 
 
The binding free energies (kcal/mol) of nybomycin and DNM-2 were assessed by 
comparing them with that of ciprofloxacin. Both nybomycin and DNM-2 exhibited 
strong binding affinities to both wild type gyrase and mutants, with values ranging 
between -39.21 and -45.46 kcal/mol for nybomycin and between -28.50 and -44.87 
kcal/mol for DNM-2. Binding free energies results are presented in table 4.8. The 
specific contribution of the amino acid residues coded by codons 90 and 94 of       
M. tuberculosis GyrA to overall ligand binding strength was evaluated by analyzing 
the per-residue interaction energy decomposition results, as presented in table 
4.9. Residue 90 was found to play a comparatively bigger role than residue 94 in 
the overall binding strength of gyrase to all three ligands. 
 
Table 4.8    Binding free energies of nybomycin, DNM-2 and ciprofloxacin against 
wild type and mutated M. tuberculosis gyrase. 
 
Ligands 
Binding free energies (kcal/mol) toward M. tuberculosis gyrase 
Wild type Mutants 
(Ala90  and 
Asp94) Ala90Val Asp94Gly Asp94His Ala90Ser 
Nybomycin -40.74 -45.46 -39.21 -44.02 -39.97 
DNM-2 -33.80 -44.87 -39.42 -28.50 -42.39 





Table 4.9    Per-residue interaction energy decomposition of M. tuberculosis 







M. tuberculosis GyrA 
Per-residue interaction energy decomposition (kcal/mol) towards  























































































































Finally, the residues involved in stabilizing ligands inside the binding pocket of      
M. tuberculosis gyrase containing a Ala90Val mutation were identified. Eleven 
residues were found to be key for all three of the ligands and included Arg114, 
Gly800, Val802, Ser803, Arg1259, Gly1260, Glu1278, DC1464, DA1465,         
DT3-1480 and DG5-1481. In addition to this, Gly1237 and Asp1238 were key 
residues for nybomycin and DNM-2, but not for ciprofloxacin. Lys1261 was 
determined as a key residue only with DNM-2 and ciprofloxacin. Residues 
considered to be key in only one of the ligands were DA1482 with nybomycin, 
Asp801 with DNM-2 and Glu1236 and Mg1496 with ciprofloxacin.  
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4.4    Investigation of M. tuberculosis mutants with increased nybomycin 
MICs using whole genome sequencing  
 
The Nextera XT DNA library preparation kit (Illumina, San Diego, USA) was used 
for DNA library preparation and quality indicators indicated that clustering was 
achieved with a raw density of 1017 K/mm2 and a passing filter of 92.4%.  
 
The Illumina MiSeq sequencer together with the MiSeq v2 (500 cycle) reagent kit 
were used for whole genome sequencing (WGS). A 2 x 250 paired-end 
configuration was used and yielded a total of 9233 mega base pairs i.e. 
approximately 769 mega base pairs per sample. Full genomic coverage was 
achieved for each of the isolates. The quality of the sequencing process was 
confirmed with the PhiX Control v3. 
 
Using the Burrows-Wheeler Aligner (BWA) tool, an average of 95% (and minimum 
of 94.9%) of each of the trimmed gene sequences were paired with the                        
M. tuberculosis H37Rv reference genome235–237. Cleaned and aligned sequences 
were submitted to the TB Profiler tool for identification of single nucleotide 
polymorphisms currently known to be associated with resistance to clinically used 
drug142. None of the resistance-conferring mutations in the software’s database 
were identified in any of the 12 samples. This supports the notion that nybomycin 
may have a novel mechanism of action.  
 
After gene annotation and sequence variant analysis, the results were exported to 
Microsoft Excel and the following gene variants were manually removed:             
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(1.) variants present in both the wild type and mutant sequences, (2.) variants from 
PE and PPE coding regions (3.) synonymous variants and (4.) variants located in 
intergenic regions. Gene variants unique to each of the ten mutant isolates were 
also filtered out, except where they occur in the same gene.  
The final list of 22 genes with one or more gene variants potentially linked to 
phenotypic resistance to nybomycin are presented in table 4.10, on pages 105 
through 108. Gene variants are described by highlighting the (1.) gene name, 
(2.) M. tuberculosis H37Rv locus, (3.) change type, (4.) reference nucleotide 
sequence, (5.) mutated nucleotide sequence, (6.) reference amino acid sequence 
(7.) amino acid and (6.) whether the changes were found in a mutant with a 
nybomycin MIC of 2 µg/ml or 4 µg/ml. 
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Table 4.10    Gene variants potentially responsible for phenotypic resistance to nybomycin (continued on next page) 
Gene Affected 
isolates 
















1. pstP Rv0018c 21795 D, F H, I, L missense variant G A P S 














2. Rv0338c 403406 F H missense variant A C I M 
3. mkl Rv0655 752148 D, F, 
G 
missense variant C T A V 
752297 H missense variant C G Q E 
4. Rv0823c 917610 J, L start-lost mutation and 








A M1_A12del - 
5. Rv1046c 1168716 L frameshift variant T TC A fs 
1168717 C I frameshift variant T TG E fs 
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Table 4.10    Gene variants potentially responsible for phenotypic resistance to nybomycin (continued from previous page) 
Gene Affected 
isolates 















6. Rv1435c 1612595 D missense variant C G G A 
1612606 F disruptive inframe insertion T TGGTAACGGTGCGCCCGGGATC - IPGAPLP 
1612625 E conservative inframe insertion A ATCGGGACCGGGGCGCCAGGGG - TPGAPVP 
I conservative inframe insertion A ATCGGTACCGGTGCGCCAGGGG - TPGAPVP 
1612630 F disruptive inframe insertion T TACCGGGGCGCCAGGGATCGGG - PIPGAPV 
G disruptive inframe insertion T TACCGGTGCGCCAGGGGTCGGG - PTPGAPV 
J disruptive inframe insertion T TACCGGTGCGCCCGGGGACGGG - PSPGAPV 
1612631 F conservative inframe insertion A ACCGGTGCGCCAGGGATCGGTC - GPIPGAP 
1612642 C disruptive inframe insertion A AGGGGTCGGGACCGGTGCGCCC - GAPVPTP 
I disruptive inframe insertion A AGGGATCGGTACCGGTGCGCCC - GAPVPIP 
1612646 E conservative inframe insertion A ATCGGGACCGGTGCGCCCGGGG - TPGAPVP 
H conservative inframe insertion A ATCGGGACCGGGGCGCCAGGGG - TPGAPVP 
I conservative inframe insertion A ATCGGTACCGGTGCGCCAGGGG - TPGAPVP 
L conservative inframe insertion A ATCGGGACCGGTGCGCCAGGGG - TPGAPVP 
1612647 H conservative inframe insertion T TCGGTACCGGTGCGACAGGGAG - LPVAPVP 
1612657 K disruptive inframe insertion T TGCGCCAGGGATGGGTACCGGG - PVPIPGA 
7. Rv1588c 1789650 D missense variant C T A T 
1789678 D, G I frameshift variant C CG H fs 
8. pks7 Rv1661 1879841 H, L missense variant T G V G 
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Table 4.10    Gene variants potentially responsible for phenotypic resistance to nybomycin (continued from previous page) 
Gene Affected 
isolates 















9. cut1 Rv1758 1989054 F frameshift variant TTCAGAGAG
GACTTCATC
GATGC 
T F fs 
1989055 H, J frameshift variant TCAGAGAGG
ACTTCATCG
ATGCG 
T R fs 
10. gnd1 Rv1844c 2094909 C, F conservative inframe insertion TGACAGC T A92_V93del - 
11. Rv1883c 2133467 C, E H, J conservative inframe insertion G GGTCGCATGCCGTCAC - VTACD 
2133469 C conservative inframe insertion T TCGCATGCCGTCACCG - AVTAC 
J conservative inframe insertion T TCCCATGCCGGCACCC - GVPAW 
2133471 L disruptive inframe insertion G GCATGCCGTCACCTCA - EVTAC 
12. Rv2262c 2534561 H, J frameshift variant CGG C R fs 
13. Rv2415c 2713078 G H, J, 
K, L 
conservative inframe insertion A ACCC - G 
14. Rv2492 2807873 E, F K frameshift variant A AT E fs 









A R fs 
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Table 4.10    Gene variants potentially responsible for phenotypic resistance to nybomycin (continued from previous page) 
Gene Affected 
isolates 















16. aftC Rv2673 2990584 D J frameshift variant and 
stop-lost and  








C Q fs 
17. Rv3023c 3381641 F L missense variant G T Q K 
18. Rv3645 4083347 G I missense variant A C T P 
19. dppD Rv3663c 4102108 H, J frameshift variant C CG R fs 
20. glpK Rv3696c 4138437 K missense variant G C A G 
4139181 I conservative inframe insertion A ACCC G191dup - 
4139183 C, E I, K, L disruptive inframe insertion A ACCC p.G191dup - 
4139190 C conservative inframe insertion C CCCA - LG 
21. Rv3728 4176301 K missense variant A G I V 
4176351 F missense variant A C E D 
22. sigM Rv3911 4400659 H, I frameshift variant CA C T fs 
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CHAPTER 5 – DISCUSSION AND CONCLUSION 
 
5.1    In vitro inhibitory effect of quinolines on various bacterial species  
 
5.1.1    Mycobacterium tuberculosis 
 
This is the first study to investigate the in vitro effect of nybomycin and DNM-2 on 
fluoroquinolone-resistant M. tuberculosis isolates. During the initial investigations, 
in vitro exposure of three M. tuberculosis isolates to nybomycin using the MTT 
assay suggested that nybomycin may act as a reverse antibiotic for this bacterial 
species. This prompted the testing of the susceptibility of various bacterial species 
to nybomycin and other quinoline-containing compounds. 
 
A collection of 32 M. tuberculosis isolates with diverse IS 6110 RFLP banding 
patterns and fluoroquinolone susceptibility profiles were assembled. The three      
M. tuberculosis isolates investigated during the initial susceptibility testing were 
included in this collection. Nybomycin minimum inhibitory concentrations (MIC) 
reported with the multipoint inoculator method were relatively low and ranged from 
0.25 to 1.0 µg/ml. No “reverse antibiotic effect” could be demonstrated, even when 
the original three isolates were retested. Repeat testing of a subset of 23 isolates, 
again using the MTT assay and including the three isolates investigated at the 
outset, also failed to reproduce the “reverse antibiotic effect”.  
 
These discrepant results were further investigated. The nybomycin powder used 
during the initial investigation was procured from SantaCruz Biotechnology 
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(Dallas, Texas, USA) and the nybomycin powder for all subsequent investigations 
from BioAustralis (Smithfield, New South Wales, Australia). However, it was 
established that SantaCruz, obtained their nybomycin powder from BioAustralis. 
Further inquiry into the matter prompted BioAustralis to perform HLPC analysis on 
their different stocks. This revealed that the nybomycin batch procured through 
SantaCruz consisted of approximately 4.5% deoxynybomycin, whereas no 
deoxynybomycin could be detected in all subsequent batches procured through 
BioAustralis. Slight differences between batches of culture-produced 
antimicrobials are inevitable and highlight the importance of the development of a 
chemical synthesis pathway. All further interrogation of the susceptibility testing 
methods was unsuccessful in determining any additional factor that could have 
accounted for this discrepancy. The exact origin of this discrepancy could 
therefore not be satisfactorily explained. However, MIC results obtained with the 
multipoint inoculator method and subsequent MTT assay were in agreement with 
each other and were performed using larger numbers of M. tuberculosis isolates. 
 
The relatively low nybomycin MIC results observed for all M. tuberculosis isolates 
indicate that nybomycin possess a mechanism of action unrelated to 
fluoroquinolone resistance. However, these results do not completely exclude the 
possibility of nybomycin acting as a reverse antibiotic, as it may be that this effect 
is masked due to the presence of at least one additional antibacterial mechanism. 
Such a mechanism would make it possible for susceptibility to occur in the 
presence of fluoroquinolone resistance. Computational methods were therefore 
employed in an attempt to clarify this issue. 
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To describe the cytotoxic and apoptotic potential of nybomycin, in vitro 
investigations using Vero, HeLa and A549 cell lines were prepared. Unfortunately, 
upon adding nybomycin stock solution to EMEM, the nybomycin crystalized and 
lysed all the mammalian cells within a few hours. In vivo toxicity investigations 
were therefore not further pursued. 
 
The cytotoxic potential of nybomycin and DNM-2 have been investigated in the 
past. In vivo toxicity studies showed that 250 mg/kg nybomycin was well tolerated 
by mice when the compound was suspended in peanut oil and administered 
intraperitoneally145. However, these preliminary toxicity studies were reported in 
1955 and there have since been no further reports published specifically on 
nybomycin toxicity. Egawa et al reported DNM to be non-toxic to non-cancerous 
cell lines in 2000179,246. More recently toxicity investigations were performed for 
DNM and several DNM derivatives, including DNM-2179. None of the tested 
compounds caused significant hemolysis of red blood cells; and they produced no 
appreciable intercalation of DNA with the DNA intercalation assay179. In vivo 
evaluation of DNM-2 also did not produce any observable toxicity when 50 mg/kg 
doses were administered to mice through oral lavage179. 
 
The in vitro susceptibility of 23 M. tuberculosis isolates to DNM-2 were 
investigated using the MTT assay and MIC values were in a similar range as for 
nybomycin.  Like nybomycin, DNM-2 also failed to exhibit a “reverse antibiotic 
effect”. The range of unconventional drug concentrations tested deserves further 
explanation. Paul Hergenrother (Department of Chemistry, University of Illinois, 
USA) donated 5.76 mg DNM-2 antibiotic powder for this project179. As this was a 
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very small amount of DNM-2 to work with and because DNM-2 is very poorly 
soluble in DMSO and water, it was decided to meticulously follow the donors’ 
instructions regarding antibiotic stock solution preparation. This resulted in the 
unusual final drug concentrations reported in this study whereby 1:2 dilutions were 
prepared to start from 12 µg/ml. 
 
Parkinson et al reported a peak serum DNM-2 concentration of 12.8 µg/ml in mice, 
after an oral dose of 50 mg/kg. This is 12.6 times higher than the highest 
nybomycin MIC and 4.2 times higher than the highest DNM-2 MIC observed for    
M. tuberculosis in this study179. It is therefore conceivable that DNM-2 and 
nybomycin, or related compounds, may reach sufficient levels in human blood to 
make it useful for clinical use against infection with M. tuberculosis. 
 
5.1.2    Neisseria gonorrhoeae 
 
A collection of 32 N. gonorrhoeae isolates displaying a wide range of 
susceptibilities to fluoroquinolones were assembled for in vitro investigation. This 
study was the first to investigate the in vitro susceptibility of N. gonorrhoeae 
isolates to nybomycin. Nybomycin MICs (µg/ml) obtained with the multipoint 
inoculator method ranged from 0.25 to 8.0 µg/ml, but showed no association with 
fluoroquinolone MIC results. Based on these nybomycin susceptibility results, 
infections due to both ciprofloxacin susceptible and ciprofloxacin resistant            
N. gonorrhoeae may respond to treatment with nybomycin. In view of the looming 
crises of untreatable infections due to N. gonorrhoeae, these results deserve 
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further exploration247. Nybomycin may conceivably be able to act as a microbicide 
in N. gonorrhoeae infection. 
 
The same collection of 30 N. gonorrhoeae isolates were also exposed to anti-
malarial drugs: quinine, chloroquine, primaquine, mefloquine248. MICs obtained for 
quinine, chloroquine and primaquine were high and the results are in agreement 
with the work done by Mehaffey et al who concluded that they are inactive against 
N. gonorrhoeae. This present study was the first to investigate the in vitro 
antibacterial effect of these compounds against fluoroquinolone-resistant isolates. 
Mehaffey et al also reported that mefloquine displayed marginal in vitro effectivity 
against less than 10 percent of their collection of 105 N. gonorrhoeae isolates248. 
In this present study, mefloquine MICs for N. gonorrhoeae ranged from 4 to        
16 µg/ml for 28 of the 30 isolates. The peak serum concentration of mefloquine 
after an oral dose of 250 mg drug has previously been reported as 0.656 to             
1.018 µg/ml249. Mefloquine is therefore unlikely to achieve adequate serum levels 
to be useful against infections due to N. gonorrhoeae249–251. 
 
5.1.3  Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, 
Pseudomonas aeruginosa, Acinetobacter baumanii, Staphylococcus aureus 
and Enterococcus faecalis 
 
A collection of various commonly encountered human bacterial pathogens, 
including E. coli (n=6), K. pneumoniae (n=4), E. cloacae (n=4), P. aeruginosa 
(n=7), A. baumanii (n=5), S. aureus (n=4) and E. faecalis (n=4), with different 
levels of susceptibilities to fluoroquinolones, was exposed to nybomycin as well as 
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four anti-malarial drugs. What made this study different from others is the fact that 
anti-malarial drugs were investigated against both fluoroquinolone-susceptible and 
fluoroquinolone-resistant isolates. This was done in order to identify any “reverse 
antibiotic effect” with regards to fluoroquinolone susceptibility.  
 
All Gram-negative isolates exhibited nybomycin MICs of > 16 µg/ml, except for 
one A. baumanii isolate with a nybomycin MIC of 8 µg/ml. The results agree with 
most previous studies that reported nybomycin to be inactive against Gram-
negative bacteria143,148. The only exception was Strelitz et al who reported in 1955 
that nybomycin exhibits activity against two out of the seven investigated E. coli 
isolates and against the single investigated K. pneumoniae isolate145. Their results 
were never replicated and stand in contrast to all subsequent reports143,148. 
Morimoto et al identified efflux pumps to be the cause of resistance to nybomycin 
in E. coli isolates and postulated that this may be the mechanism of resistance 
(MOR) to nybomycin in all Gram-negative bacterial species148. 
 
Nybomycin MICs for Gram-positive bacteria ranged from 4 to 8 µg/ml for S. aureus 
(n=4) and 8 to 16 µg/ml for E. faecalis (n=4). This antibacterial activity is moderate 
compared to that reported by other investigators and no “reverse antibiotic effect” 
could be observed143,145,166. This disagreement between the previously reported 
and the current results may be explained by the difference in methodology used. 
Previous reporters employed micro broth dilution assays and paper disk methods 
whereas this present study used a solid agar dilution methodology143,145. The small 
sample size in this study unfortunately prevents firm conclusions to be drawn. 
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MIC results obtained with quinine, chloroquine, mefloquine and primaquine were 
less encouraging. All Gram-positive and Gram-negative isolates displayed MICs    
> 128 µg/ml for both chloroquine and primaquine. MIC results with quinine and 
mefloquine were ≥ 64 µg/ml for all isolates, except for the Gram-positive isolates 
that exhibited mefloquine MICs of 32 µg/ml. These results are in keeping with 
published results from other investigators250–255. None of these anti-malarial drugs 
can reach adequate concentrations in human serum to be considered feasible 
treatment options of bacterial infections caused by bacterial species investigated 
in this study250,256–259.  
 
5.2    In silico effect of nybomycin and DNM-2 on M. tuberculosis gyrase 
enzyme 
 
In silico methodologies were employed in an attempt to explain the in vitro 
inhibitory effects of nybomycin and DNM-2 on M. tuberculosis isolates. Ligand-
based investigation methods such as pharmacophore modeling and quantitative 
structure-activity relationship methods are often employed for this purpose. 
However, based on the known association between nybomycin and 
fluoroquinolone-resistant S. aureus, a structure-based approach was followed as it 
was anticipated that nybomycin and DNM-2 act by inhibiting M. tuberculosis 
gyrase directly143,166,179. 
 
Molecular docking investigations were used to predict whether nybomycin and 
DNM-2 will bind to wild type M. tuberculosis gyrase with an affinity comparable to 
that seen with fluoroquinolones. The resultant LibDock scores (kcal/ml) of 
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nybomycin and DNM-2 indicate that these two compounds have at least similar, if 
not higher, affinity for wild type M. tuberculosis gyrase compared to ciprofloxacin 
and moxifloxacin. These results therefore support the notion that nybomycin and 
DNM-2 act on M. tuberculosis gyrase. The results are also in agreement with the 
in vitro results obtained with fluoroquinolone-susceptible M. tuberculosis isolates.  
 
The value of the LibDock scoring system is restricted because it is calculated by 
taking only a limited number of factors into account including molecular shape, 
electrostatic interactions, van der Waals interactions, Coulombic interactions and 
hydrogen-bond formations40,211. Molecular dynamics simulations were therefore 
employed to further refine the molecular docking investigations. Molecular 
dynamics simulations aim to mimic the natural motion of proteins by considering 
ligand position and orientation inside the binding pocket, as well as taking time, 
temperature and atmospheric pressure into consideration40,211. 
 
With the molecular dynamics studies, the investigation of the binding affinity 
between the ligands and the wild type M. tuberculosis gyrase was expanded by 
including the examination of M. tuberculosis gyrase coded by DNA containing 
common fluoroquinolone resistance-conferring mutations. Globally it has been 
reported that in the vast majority of fluoroquinolone-resistant M. tuberculosis 
isolates the resistance results from only a handful of mutations in the quinolone 
resistance-determining region (QRDR) of the gyrA gene173,176,260,261. Unlike       
other organisms such as K. pneumoniae and S. aureus, the gyrB gene is              
very seldom responsible for clinical resistance to fluoroquinolones in                                         
M. tuberculosis173,176,260,261. Most fluoroquinolone resistance-conferring mutations 
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are located in either the 90th, 91st or 94th codon of gyrA174,175,260,261. In light of the 
unexpected in vitro susceptibility results obtained with nybomycin and DNM-2 in 
the current study, it was decided prudent not to assume this to be the case with 
the selection of M. tuberculosis isolates used in this study. To this end, the QRDR 
of gyrA from all 32 M. tuberculosis isolates were sequenced an analyzed. With    
the exception of two isolates, all ofloxacin-resistant isolates harbored               
codon changes in gyrA known to confer clinical resistance to fluoroquinolones in                           
M. tuberculosis174,175,260,261. The two isolates without mutations in the investigated 
DNA segment of gyrA both belong to the LCC F150 IS 6110 RFLP family. Genetic 
analysis is warranted to identify the mutations that lead to fluoroquinolone 
resistance in these isolates, but falls outside the scope of the present study. 
 
The accuracy and therefore the interpretation of molecular dynamics simulations 
are problematic262–264. Force fields are the most widely regarded source for 
potential error262–264. Force fields consist of equations that are used to govern the 
forces interacting on all the atoms in a given experiment263,264. They are largely 
based on Newtonian physics and make poor use of quantum physics262–264. 
Several force fields have been developed to choose from but none are considered 
truly accurate263,265,266. A second concern commonly encountered with regards to 
molecular dynamics simulations is the difficulties experienced in deciding on the 
length of sampling time262,263. Both too short and too long sampling times may 
provide erroneous results and no definite guidelines exist with which to satisfactory 
address this issue262–264. Due to the inherent inaccuracies observed with molecular 
dynamics simulations, care should also be taken not to make quantitative 
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comparisons, but to rather restrict analyses to qualitative conclusions263,264,267. No 
direct comparisons of binding affinity were therefore made between the ligands.  
 
The Molecular Bio-Computation and Drug Design Laboratory (School of Health 
Sciences, University of KwaZulu-Natal, Durban, South Africa) performed the 
computational experiments and included ciprofloxacin, nybomycin and DNM-2 in 
the molecular dynamics simulations. 
 
Binding free energy results generated through molecular dynamics studies 
showed that ciprofloxacin binds stronger to gyrase with a Ala90Ser mutation than 
to wild type gyrase. This is in keeping with results from Blower and Aldred et al 
and supports the validity of this experiment175,177. As expected, ciprofloxacin also 
binds stronger to wild type gyrase than to gyrase containing either Asp94Gly or 
Asp94His mutations. However, ciprofloxacin appears to have a slightly lower 
affinity for wild type gyrase compared to gyrase containing a Ala90Val mutation. 
This unexpected finding could not be explained upon further interrogation of the 
investigation methodology and results. 
 
Nybomycin bound notably stronger to gyrase containing either Ala90Val or 
Asp94His mutations than to wild type gyrase, whereas bonds of comparable 
strength where observed when either Asp94Gly or Ala90Ser mutations were 
present. Nybomycin seems to form substantial bonds with M. tuberculosis gyrase 
regardless of whether any of the common fluoroquinolone resistance-conferring 
mutations are present in GyrA. 
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DNM-2 bound notably stronger to gyrase containing either one of Ala90Val, 
Asp94Gly or Ala90Ser mutations than to wild type gyrase, but weaker bonds 
formed when gyrase contained a Asp94His mutation. Similar to nybomycin,    
DNM-2 appears to bind strongly to M. tuberculosis gyrase regardless of whether 
any of the common fluoroquinolone resistance-conferring mutations are present in 
GyrA.  
 
Further examination of the molecular dynamics simulation results included a per-
residue interaction energy decomposition analysis of the bonds between              
M. tuberculosis gyrase and the three ligands. The specific contributions of residue 
90 and 94 to the strength of binding of the ligand-gyrase complex as a whole were 
hereby approximated. For all three ligands, residue 90 appears to have played a 
predominant role in ligand binding compared to residue 94. However, the 
contribution of residue 94 cannot be disregarded on the basis of this analysis 
alone, because it does not take into account conformational changes that may be 
the result of different amino acid variations of codon 94. Any resultant 
conformational changes in the gyrase binding pocket may lead to other gyrase 
residues playing a more significant role in ligand binding.  
 
Molecular dynamics simulations were also used to identify key residues involved in 
stabilizing the ligands inside the M. tuberculosis gyrase binding pocket harboring a 
Ala90Val mutation. The majority i.e. eleven residues were found to be key for all 
three of the ligands, illustrating potential similarity in mechanism of action between 
nybomycin, DNM-2 and ciprofloxacin with regards to M. tuberculosis gyrase.  
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In silico investigations identified a strong affinity between the two test compounds 
(nybomycin and DNM-2) and M. tuberculosis gyrase, irrespective of the presence 
of common fluoroquinolone resistance-conferring mutations in gyrA. A “reverse 
antibiotic effect” was not identified and the computational investigations therefore 
support the in vitro drug susceptibility results of this study. In silico investigations 
provided important information towards the unraveling of the mechanism of action 
of nybomycin and DNM-2 in M. tuberculosis isolates.  
 
5.3    Investigation of M. tuberculosis mutants with increased nybomycin 
MICs using whole genome sequencing 
 
Wild type M. tuberculosis V9124 was experimentally exposed to different 
concentrations of nybomycin. Mutants with increased nybomycin MICs were 
selected and WGS was used to compare the genomes of the mutants with that of 
the wild type. Analysis of the WGS results identified 22 genes that may possibly 
explain the nybomycin MIC difference between the wild type isolate and the 
mutants. Each gene is discussed separately in subsequent paragraphs.  
 
Rv0018c is the locus of pstP, a 1545 base pair (bp) gene coding for a regulatory 
protein called phospho-serine/threonine phosphatase (PstP)268,269. An identical 
missense variant was identified in this gene for five of the ten M. tuberculosis 
V9124 isolates exposed to nybomycin. It is the first gene in an operon consisting 
of five genes, all of which are considered important in the regulation of cell wall 
synthesis, cell division and cell shape270–273. The first gene downstream to pstP is 
rodA, located at Rv0017c268. This gene codes for RodA, a non-classical 
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transglycosylase involved in the synthesis of septum-peptidoglycan during cell wall 
formation268,274. RodA further assists in stabilizing the FTSZ ring, which is the 
bacterial homolog to tubulin, during cell division268. The following gene 
downstream is pbpA, located at Rv0015c268. Its product is a penicillin-binding 
protein called PbpA that is involved in the final stages of peptidoglycan synthesis 
through its transpeptidase function268,274. PbpA is further said to play a role in 
determining the shape of bacterial cells268,274. The last two genes that form part of 
this operon are pknA and pknB in positions Rv0015c and Rv0014c respectively268. 
They code for two crucial transmembrane serine/threonine protein kinases 
(STPKs) designated protein kinase A (PknA) and protein kinase B (PknB)268. Both 
are crucial in the regulation of certain morphological changes associated with cell 
division and cell differentiation268,270,273,275. Bacteria employ surface-located sensor 
proteins to transfer information from the extra-cellular to the intra-cellular area, in 
order to effectively survive in and respond to their environment276. Regulation of 
these sensor proteins is complex and involves the balancing of a reversible 
phosphorylation process mediated by kinases and phosphatases276. STPKs 
undergo auto-phosphorylation of their serine/threonine residues and then 
participate in the functioning of other transmembrane signal processes through 
transferal of its phosphate moiety270,276. PstP is the sole serine/threonine 
phosphatase in M. tuberculosis and regulates STPKs as well as other signal 
proteins by dephosphorylating their phosphorylated serine/threonine 
residues268,270,276. It was previously shown that PstP is constantly required for 
pathogen survival and mutations in pstP are therefore likely to have a detrimental 
effect on cell growth and pathogenicity270,276. PstP, PknA and PknB are 
independently indispensable for in vitro growth and the in vivo survival of              
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M. tuberculosis274. Not surprisingly, PstP has already been identified as an 
attractive target for drug discovery275. Interestingly, Arai et al previously noticed 
morphological changes in Mycobacterium smegmatis cells treated with nybomycin 
similar to that seen in M. tuberculosis with mutations in their pknA or pknB 
genes165,272. However, the authors did not find any mutations in pknA or pknB and 
did not specifically comment on whether any mutations were observed in the 
upstream pstP gene. 
 
Rv0338c is the locus of a currently unnamed 2649 bp long gene with an unclear 
function268,269. The gene product is possibly an iron-sulfur-binding reductase 
involved in intermediary metabolism and respiration268. An identical missense 
variant was identified in this gene for two of the ten M. tuberculosis V9124 isolates 
exposed to nybomycin. DeJesus et al published a groundbreaking study in 2017 
where they used fully saturated Himar1 transposon libraries to investigate and 
describe different gene regions of the M. tuberculosis genome in terms of whether 
or not it is essential for cell viability277. Rv0338c was accordingly classified as 
essential for the viability of M. tuberculosis bacilli.  
 
Rv0655 is the locus of mkl, a 1080 bp gene coding for a putative ribonucleotide-
transport ATP-binding protein named Mkl268,269. An identical missense variant was 
identified in this gene for three of the ten M. tuberculosis V9124 isolates exposed 
to nybomycin. Mkl is also called MceG because of its close relation to the 
functioning of the mce multiprotein complexes in M. tuberculosis278,279. These 
multiprotein complexes are coded by one of four mce operons (1 to 4) and function 
similarly to ABC transporter permeases and substrate-binding proteins278,279.   
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Mce-1 and Mce-4 are respectively involved with fatty acid and cholesterol uptake, 
both crucial for cell survival279. Cholesterol is important for maintaining a chronic 
infection and both Mce-1 and Mce-4 have been shown to be integral survival and 
virulence factors279,280. MceG/Mkl is coded outside these operons, but are required 
for their functioning278,279. 
 
Rv0823c is the locus of a currently unnamed 1170 bp long gene with a poorly 
defined function268,269. Predictions have this gene code for a transcriptional 
regulatory protein involved with fatty acids and other currently undefined metabolic 
processes268,269. According to the Universal Protein Knowledgebase (UniProt) 
consortium, this gene should be named dus due to its homology to proteins found 
in other organisms281. Its function is hereby more specifically predicted to be that 
of a tRNA-dihydrouridine synthase281. This transcriptional regulatory protein is said 
to catalyze the synthesis of a dihydrouridine residue located in the D-loop of most 
tRNAs281. The exact role of dihydrouridine in tRNA is not currently known. In this 
study, a start-lost mutation together with a conservative inframe deletion was 
detected in this gene for two of the ten M. tuberculosis V9124 isolates exposed to 
nybomycin. According to work done by DeJesus et al, this gene is not considered 
essential for cell viability277. 
 
Rv1046c is the locus of a currently unnamed 525 bp long gene coding for an 
uncharacterized protein268,281. It is predicted to be a functional partner of Rv1047, 
which is a potential transposase required for the transposition of IS 1081281,282. In 
the current study, a frame-shift variant was detected in this gene for three of the 
ten M. tuberculosis V9124 isolates exposed to nybomycin. However, analysis of 
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saturated Himar1 transposon libraries by DeJesus et al classifies this gene as 
non-essential for the viability of M. tuberculosis bacilli277. Interestingly, another 
gene probably involved in the transposition of IS 1081 has been identified in this 
study as potentially related to the mechanism of action of nybomycin. This gene is 
located at Rv3023 and is discussed in a later paragraph. Only one of the ten          
M. tuberculosis V9124 isolates exposed to nybomycin harbored a mutation in both 
Rv1046c and Rv3023. 
 
Rv1435c is the locus of a currently unnamed 609 bp long gene coding for a protein 
that is secreted into the extra-cellular space268,281,283. It is probably secreted via a 
classical twin-arginine translocation (Tat)-dependent pathway and is not 
considered essential for the virulence or survival of M. tuberculosis277,283. This 
study identified several conservative as well as disruptive inframe insertions in this 
gene for a number of the ten M. tuberculosis V9124 isolates exposed to 
nybomycin. Interestingly, it was previously reported that this gene contains at least 
five imperfect repeats consisting of seven amino acids each268. The bioinformatics 
analysis software may therefore have incorrectly identified and annotated such 
variations in bp positions 1612606, 1612625, 1612630, 1612631, 1612642, 
1612646 and 1612647. Nevertheless, disruptive inframe insertions were also 
found in three isolates at bp position 1612630 and in two further isolates at bp 
position 1612642. 
  
Rv1588c is the locus of a currently unnamed 669 bp long gene coding for 
REP13E12, a partial repeat protein that is part of the REP13E12 family of 
proteins268,284. The REP13E12 family consists of seven copies of a similar gene 
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sequence and is found throughout the M. tuberculosis genome284,285. This protein 
has been linked to DNA regulation and the classical RecA/LexA SOS response to 
DNA damage268,284,285. A frameshift variant was identified in this gene for three of 
the ten M. tuberculosis V9124 isolates exposed to nybomycin. The presence of 
multiple copies of this gene in M. tuberculosis possibly testifies to its importance 
for DNA-repair and bacterial survival, but makes it a poor focus for drug 
development. 
 
Rv1661 is the locus of pks7, a 6381 bp long gene coding for a probable polyketide 
synthase named Pks7268,269. Apart from a predicted but poorly defined function in 
lipid metabolism, this protein is also potentially involved in certain intermediate 
steps relating to the synthesis of polyketides which may be involved in secondary 
metabolism processess268,269. Results from the study by DeJesus et al do not 
classify this gene as essential for cell viability277. However, Rousseau et al pointed 
out that pks7 has only been observed in pathogenic mycobacterial species and 
has an apparent role during infection286. It is thus considered a virulence factor for 
M. tuberculosis and a potential drug target280,286. An identical missense variant 
was identified in this gene for two of the ten M. tuberculosis V9124 isolates 
exposed to nybomycin. 
 
Rv1758 is the locus of cut1, a 525 bp gene coding probably for a cutinase named 
Cut1268,269. The primary substrate for cutinases is cutin, the waxy outer layer of 
plants287. However, cutin is not present in the natural life cycle of M. tuberculosis, 
so cutinases probably have other functions in this organism287. Work done by 
DeJesus et al classify this gene as non-essential for cell viability277. A frameshift 
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variant was identified in this gene for three of the ten M. tuberculosis V9124 
isolates exposed to nybomycin. 
 
Rv1844 is the locus of gnd1, a 1458 bp gene coding for a possible                         
6-phosphogluconate dehydrogenase named Gnd1268,269. This enzyme is probably 
involved in the early stages of the pentose phosphate pathway (PPP) where it 
catalyzes the early oxidative decarboxylation of 6-phosphogluconate to produce 
ribulose 5-phosphate and carbon dioxide as well as reduce NADP to 
NADPH268,269. This gene was not considered essential for cell viability by DeJesus 
et al277. A conservative inframe insertion was identified in this gene for two of the 
ten M. tuberculosis V9124 isolates exposed to nybomycin. 
 
Rv1833c is the locus of a currently unnamed 462 bp long gene coding for an 
uncharacterized protein268,281. DeJesus et al do not classify this gene as essential 
for cell viability277. Conservative inframe insertions were identified in four of the ten 
M. tuberculosis V9124 isolates exposed to nybomycin. 
 
Rv2262c is the locus of a currently unnamed 1083 bp long gene coding for an 
uncharacterized protein possibly involved in lipid metabolism268,281. DeJesus et al 
classify this gene as non-essential for cell viability277. A frameshift mutation 
identified in this gene for two of the ten M. tuberculosis V9124 isolates exposed to 
nybomycin. 
 
Rv2415c is the locus of a currently unnamed 894 bp long gene coding for an 
uncharacterized protein possibly involved in DNA binding and repair268,281.    
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Results from the study by DeJesus et al do not classify this gene as essential for 
cell viability277.  A conservative inframe insertion was identified in this gene for five 
of the ten M. tuberculosis V9124 isolates exposed to nybomycin. 
 
Rv2492 is the locus of a currently unnamed 753 bp long gene coding for an 
uncharacterized protein with an undetermined function268,281. DeJesus et al placed 
this gene within a region of the M. tuberculosis genome that they identified as non-
essential for cell viability277. A frameshift variant was identified in this gene for 
three of the ten M. tuberculosis V9124 isolates exposed to nybomycin. 
 
Rv2522c is the locus of a currently unnamed 1413 bp long gene coding for an 
uncharacterized protein with an undetermined function268,281. DeJesus et al 
classifies this gene as non-essential for cell viability277. A frameshift variant was 
identified in this gene for two of the ten M. tuberculosis V9124 isolates exposed to 
nybomycin. 
 
Rv2673 is the locus of aftC, a 1302 bp gene coding for a possible arabinofuranosyl 
transferase named AftC268,269. AftC is involved in the biosynthesis of the 
mycolylarabinogalactan-peptidoglycan (mAGP) complex that forms an essential 
part of the mycobacterial cell wall268,269,288. It is considered essential for cell 
viability277,288. A frameshift variant, stop-lost and splice region variant were 




Rv3023c is the locus of a currently unnamed 1248 bp long gene coding for a 
protein that possibly functions as a transposase for IS 1081268,281. Although it is 
required for the transposition of IS 1081, it is not considered essential for cell 
viability277. An identical missense variant was identified in this gene for two of the 
ten M. tuberculosis V9124 isolates exposed to nybomycin. 
 
Rv3645 is the locus of a currently unnamed 1650 bp long gene coding for a 
protein that is predicted to be a conserved transmembrane protein with an 
unknown function268,281. DeJesus et al classified this gene as essential for cell 
viability277. An identical missense variant was identified in this gene for two of the 
ten M. tuberculosis V9124 isolates exposed to nybomycin. 
 
Rv3663c is the locus of dppD, a 1647 bp gene coding for a putative ATP-binding 
protein that forms part of an ABC transporter involved the uptake of small 
peptides268,269,289. This transmembrane protein is known as DppABCD and 
although not considered essential for cell viability, it has been identified as a 
virulence factor277,280,289. A frameshift variant was identified in this gene for two of 
the ten M. tuberculosis V9124 isolates exposed to nybomycin. 
 
Rv3696c is the locus of glpK, a 1554 bp gene coding for a probable glycerol 
kinase named GlpK268,269. GlpK is considered important for the regulation of 
glycerol uptake and metabolism268,269. It is involved in the first step of the glycerol 
kinase pathway by catalyzing the phosphorylation of glycerol to produce              
sn-glycerol 3-phosphate268,269. DeJesus et al did not classify this gene as essential 
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for cell viability277. A disruptive inframe insertion was identified in this gene for five 
of the ten M. tuberculosis V9124 isolates exposed to nybomycin. 
 
Rv3728 is the locus of a currently unnamed 3198 bp long gene coding for a 
conserved two-domain membrane protein that is probably involved in sugar or 
drug efflux268,281. Gupta et al observed that this gene is upregulated when the 
bacterium is exposed to various anti-tuberculosis drugs and is therefore possibly 
important in the development of MDR-TB290. Several efflux-pumps have been 
identified in M. tuberculosis that have been linked to resistance to various anti-
tuberculosis drugs291. DeJesus et al categorized this gene as non-essential for cell 
viability277. Two missense variants were identified in this gene for two of the ten      
M. tuberculosis V9124 isolates exposed to nybomycin.  
 
Rv3911 is the locus of sigM, a 669 bp gene coding for an initiation factor named 
SigM268,269 This protein helps the attachment of RNA polymerase to certain 
initiation sites268,269. SigM is one of 13 sigma factors coded by M. tuberculosis and 
is considered an alternative to the main sigma factor, SigA280. SigM is not 
considered essential for cell viability by DeJesus et al277. However, it controls the 
expression of four esat-6 homologs and sigma factors have been identified as 
potential drug targets277,281. A frameshift variant was identified in this gene for two 
of the ten M. tuberculosis V9124 isolates exposed to nybomycin. 
 
Arai et al previously exposed M. smegmatis with a nybomycin MIC of 1 µg/ml to 
increased concentrations of nybomycin165. M. smegmatis colonies with a 
nybomycin MIC of 10 µg/ml were selected and investigated using WGS165. 
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According to a preliminary analysis of their WGS results, the authors hypothesized 
that nybomycin targets the mycobacterial genome and not specific proteins165. 
They proceeded to test this hypothesis by investigating the binding affinity of 
nybomycin to plasmid DNA using a competitive inhibitor experiment using 
nybomycin, a nybomycin probe and a dummy probe165. The investigators 
concluded that nybomycin has general DNA binding activity and that its binding 
strength varies depending on the exact DNA sequence involved165. However, 
these results are not in agreement with earlier nybomycin research conducted by 
Hiramatsu et al with S. aureus that implicated gyrase to be the site of action143. 
Differences between S. aureus, M. smegmatis and M. tuberculosis, as well as 
between plasmid DNA and genomic DNA, may have been responsible for the 
different conclusions that were reached with the different studies. The present 
study was not designed in a way that could support or disprove the prediction of 
Arai et al that nybomycin directly binds to and inhibit various areas of the              
M. tuberculosis genome165. 
 
For this study, WGS was conducted with its primary aim to identify a potential 
mechanism whereby M. tuberculosis resists the action of nybomycin. With this 
approach, the mechanism whereby nybomycin acts on M. tuberculosis can 
potentially be deduced much easier, but only after its MOR has been confirmed.  
 
None of the ten M. tuberculosis isolates with increased MICs for nybomycin 
harbored any significant mutations in gyrA or gyrB. Also, none of the 22 genes 
identified as potentially responsible for resistance of M. tuberculosis to nybomycin 
can be confidently associated with a MOR that may involve fluoroquinolones, such 
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as efflux pumps or inactivating enzymes. The only potential exception is Rv3728 
that codes for a poorly described transmembrane pump, known to be upregulated 
in the presence of certain anti-tuberculosis drugs.  More broadly speaking, WGS 
did not identify any known drug resistance determinants responsible for resistance 
to the currently used anti-tuberculosis drugs. This indicates that M. tuberculosis 
probably employs a novel MOR against nybomycin. It further suggests that 
nybomycin may use a novel mechanism of action against M. tuberculosis. 
 
Although it is possible that any of these 22 genes may be associated with the 
mechanism whereby M. tuberculosis resist nybomycin, the establishment of such 
a link was not pursued in this study. Further investigations are required and may 
include comparing nybomycin MICs of wild type M. tuberculosis with that of          
M. tuberculosis mutants created through gene knock-out experiments, where each 
one of the 22 genes identified in this study have been knocked out to create a 
separate mutant.  
 
5.4    Conclusion 
 
This was the first study to investigate the in vitro effect of nybomycin against 
various commonly encountered drug-resistant human bacterial pathogens. In vitro 
drug susceptibility testing with DNM-2, a chemically altered compound closely 
related to nybomycin, was also conducted with the M. tuberculosis isolates. 
Fluoroquinolone-susceptible and fluoroquinolone-resistant isolates were compared 
in order to identify whether a “reverse antibiotic effect” could be elicited. With the in 
vitro investigations, no “reverse antibiotic effect” could be identified in any of the 
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bacterial species, but M. tuberculosis and N. gonorrhoeae isolates displayed 
relatively low MIC values for nybomycin. This effect was irrespective of the 
presence of fluoroquinolone resistance. Nybomycin also displayed some inhibitory 
activity against S. aureus and E. faecalis isolates, albeit to a much lesser extent 
than that seen with M. tuberculosis. Exposure of M. tuberculosis isolates to DNM-2 
produced results similar to that observed with nybomycin. 
 
Gyrase enzyme was predicted to be a target site for the binding of nybomycin and 
DNM-2 whereby they exert an inhibitory effect on M. tuberculosis. This hypothesis 
was supported by molecular docking investigations. Molecular dynamics 
simulations further confirmed the importance of residue 90 of GyrA for the binding 
affinity of the test ligands to gyrase enzyme. Residue 94 was also identified as 
important for ligand binding affinity, but this was probably an indirect effect through 
conformational changes of the gyrase binding pocket and thus implies the 
involvement of other gyrase residues.  
 
The in vitro nybomycin and DNM-2 susceptibility testing results together with the 
molecular docking and molecular dynamics simulation results suggest the 
presence of an additional mechanism of action, apart from the mechanism 
involving gyrase enzyme. This is supported by WGS results that also indicate that 
resistance to nybomycin is unlikely to be directly related to quinolone resistance, 
as no mutations were observed in the gyrA or gyrB genes. 
 
WGS results identified 22 genes that are possibly responsible for a mechanism 
whereby M. tuberculosis resist the inhibitory action of nybomycin. This should be 
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the starting point for further investigations and could include gene knock-out 
experiments as well as gene expression profiling. Further investigation of these 
potential resistance determinants, may very well lead to the discovery of a novel 
mechanism whereby nybomycin and DNM-2 act against M. tuberculosis. There 
are however, several hurdles facing in vivo investigations with nybomycin. Most 
important is the issue of poor solubility in all solvents routinely used. For in vivo 
investigations, it may be prudent to rather focus on derivatives that have been 
designed to have better solubility, such as DNM-2. Other concerns with nybomycin 
is its high cost and batch-to-batch variability that are inherent to culture-derived 
antimicrobials. DNM-2 is manufactured through chemical synthesis and therefore 
has much less batch-to-variability and may be easier to produce in larger 
quantities. Nybomycin and   DNM-2 are considered serious drug leads for the fight 
against M. tuberculosis and deserves further exploration. This is especially urgent 
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APPENDIX A – MEDIA AND REAGENTS 
 
A.1    Middlebrook 7H9 broth 
 
1. Add 4.7 gram Difco Middlebrook 7H9 Broth base (Becton Dickinson, USA), 
2 ml glycerol (Rochelle Chemicals & Lab Equipment, SA) and 0.5 ml 
Tween-80 (Merck, SA) to 900 ml distilled water in a 3 liter Erlenmeyer flask. 
For diluting drugs, the Tween-80 was omitted. 
2. Gently swirl flask to dissolve powder completely 
3. Sterilize by autoclaving at 121 oC for 15 minutes 
4. Cool down to room temperature 
5. Add 100 ml OADC enrichment (BBL Middlebrook OADC Enrichment, 
Becton Dickinson, USA) containing oxidase, albumin, dextrose and 
catalase  
6. Dispense 3 to 5 ml volumes into 30 ml universal containers (Sterilin 
Polypropylene 30 ml Universal Container, Thermo Fisher Scientific, 
Massachusetts, USA) 
7. If mixing with vortex mixer to reduce clumping is anticipated, then 
aseptically add 3 to 5 sterile glass beads (diameter of 5 mm) per container 
8. Store at 4 to 8 oC until use 
 
A.2    Chocolate agar plates 
 
1. Prepare a double strength base by adding 36 gram GC Agar Base (Oxoid, 
England) to 500 ml distilled water in a 3 liter Erlenmeyer flask 
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2. Slowly bring to boil and swirl flask and to dissolve powder completely 
3. In a separate Erlenmeyer flask, dissolve 20 gram Bacto Hemoglobin 
powder (Oxoid, England) in 500 ml distilled water 
4. Sterilize both solutions separately by autoclaving at 121 oC for 15 minutes 
5. Cool down both solutions in a water bath to 50 oC 
6. Reconstitute 10 ml of Vitox growth supplement (Oxoid, England) and add to 
the GC base medium dissolved in 500 ml 
7. Aseptically add the 500 ml hemoglobin solution to the GC base medium 
8. Mix the two solutions by gently swirling the flask 
9. Dispense 20 ml media into each petri dish with a diameter of 90 mm 
10. Leave at room temperature until have agar fully solidified 
11. Pack in plastic packets and store at 4 to 8 oC until use 
 
A.3    Brain heart infusion broth 
 
1. Add 37 gram Brain Heart Infusion base (Oxoid, England) to 1000 ml 
distilled water in a 3 liter Erlenmeyer flask 
2. Slowly bring to boil and swirl flask and to dissolve powder completely 
3. Sterilize by autoclaving at 121 oC for 15 minutes 
4. Cool down at room temperature 
5. Dispense into the required volumes  





A.4    Middlebrook 7H11 agar plates 
 
1. Add 19 gram BBL Seven H11 Agar Base (Becton Dickinson, USA) and 5 ml 
glycerol (Rochelle Chemicals & Lab Equipment, SA) to 900 ml distilled 
water in a 3 liter Erlenmeyer flask 
2. Gently swirl flask to dissolve powder completely 
3. Sterilize by autoclaving at 121 oC for 10 minutes 
4. Cool down in a water bath to 50 to 55 oC 
5. Aseptically add 100 ml OADC enrichment (BBL Middlebrook OADC 
Enrichment, Becton Dickinson, USA) containing oxidase, albumin, dextrose 
and catalase  
6. Gently swirl flask to mix contents 
7. Dispense 20 ml media into each petri dish with a diameter of 90 mm 
8. Leave at room temperature until have agar fully solidified 
9. Pack in plastic packets and store at 4 to 8 oC until use 
 
A.5    McFarland turbidity standards 0.5 and 1.0 
  
1. Add 0.5 ml of concentrated H2SO4 (Merck, SA) to 49.5 ml of sterilized 
distilled water to make a 1% H2SO4 solution 
2. Add 0.175 gram of BaCl2.2H2O (Sigma-Aldrich, SA) to 10 ml of sterilized 
distilled water to make a 1% BaCl2.2H2O solution 
• For a McFarland standard of 0.5, mix 0.05 ml of the 1% BaCl2.2H2O 
solution with 9.95 ml of the 1% H2SO4 solution  
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• For a McFarland standard of 1.0, mix 0.1 ml of the 1% BaCl2.2H2O 
solution with 9.9 ml of the 1% H2SO4 solution  
3. Cover tube with tinfoil and store away from direct sunlight  
 
A.6    Phosphate buffered saline (PBS) 
 
1. Add 10 PBS tablets (Oxoid, England) to 1000 ml distilled water in a 3 liter 
Erlenmeyer flask 
2. If it is required that bacterial clumping be minimized, add (1%) 10 ml 
Tween-80 (Merck, SA) 
3. Slowly bring to boil and swirl flask and to mix contents 
4. Sterilize by autoclaving at 121 oC for 15 minutes 
5. Cool down at room temperature 
6. Dispense into the required volumes  
7. Store at 4 to 8 oC until use 
 
A.7    Storage media for bacterial isolates (excluding M. tuberculosis) 
 
1. Add 3.7 gram Brain Heart Infusion base (Oxoid, England) and 20 ml 
glycerol (Rochelle Chemicals & Lab Equipment, SA) to 80 ml distilled water. 
This provide brain heart infusion broth with 20% glycerol medium 
2. Slowly bring to boil and swirl flask and to dissolve powder and glycerol 
3. Sterilize by autoclaving at 121 oC for 15 minutes 
4. Cool down to 4 oC and dispense 1 ml amounts together with sterilized glass 
beads into cryovials. 
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A.8    MTT Solution  
 
• Dissolve 25 mg MTT powder (Sigma-Aldrich, SA) in 5 ml PBS 
 
A.9    50% DMF solution 
 
• Mix 10 ml DMF with 10 ml sterile distilled water 
 
A.10    SDS solutions 
 
• SDS (Sigma-Aldrich, SA) is toxic and SDS particles easily disperse through 
the air, so therefore work inside a fume hood and wear an appropriate mask 
• To prepare a 10% SDS solution, dissolve 4 gram SDS in 36 ml sterile 
distilled water in a 50 ml polypropylene tube 
• To prepare a 20% SDS solution, dissolve 8 gram SDS in 40 ml sterile 
distilled water in a 50 ml polypropylene tube 
1. Place tube in a water bath at 30 to 35 °C to help dissolve the powder 
2. Leave the suspension standing overnight on the bench top to allow the 
foam to settle 
3. Filter sterilize with a 0.22 micron Millipore filter (Merck, SA) and leave the 
suspension on the benchtop again, to let the foam settle 





A.11    1:1 SDS(20%)-DMF(50%) solution 
 
1. Add 20 ml 20% SDS to 20 ml 50% DMF in a 50 ml polypropylene tube 
2. Cover polypropylene tube with tinfoil and store away from direct light  
 
A.12    Middlebrook 7H10 agar  
 
1. Add 19 gram Difco Middlebrook 7H10 Agar base (Becton Dickinson, USA) 
and 5 ml glycerol (Rochelle Chemicals & Lab Equipment, SA) to 900 ml 
distilled water in a 3 liter Erlenmeyer flask 
2. For susceptibility testing purposes, add an extra 10% of the Difco 
Middlebrook 7H10 Agar powder i.e. 1.9 gram to the flask. This is to account 
for the 10% agar loss when making 1:10 dilutions with antibiotic working 
solutions. 
3. Gently swirl flask to dissolve powder completely 
4. Sterilize by autoclaving at 121 oC for 10 minutes 
5. Cool down in water bath to 50 to 55 oC 
6. Aseptically add 100 ml OADC enrichment (BBL Middlebrook OADC 
Enrichment, Becton Dickinson, USA) containing oxidase, albumin, dextrose 
and catalase  
7. Gently swirl flask to mix contents 
8. Dispense into the required volumes 
9. Leave at room temperature until agar have fully solidified 
10. Pack in plastic packets and store at 4 to 8 oC until use 
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A.13    GC agar for N. gonorrhoeae susceptibility testing 
 
1. Add 36 gram GC Agar Base (Oxoid, England) to 1000 ml distilled water in a 
3 liter Erlenmeyer flask. Add an extra 10% of the Mueller Hinton agar base 
i.e. 3.6 gram to the flask. This is to account for the 10% agar loss when 
making 1:10 dilutions with antibiotic working solutions. 
2. Slowly bring to boil and swirl flask and to dissolve powder completely 
3. Sterilize by autoclaving at 121 oC for 15 minutes 
4. Cool down in a water bath to 50 to 55 oC 
5. Reconstitute two 10 ml amounts of Vitox growth supplement (Oxoid, 
England) and add to the GC base medium dissolved in 1000 ml 
6. Gently swirl flask to mix contents 
7. Dispense into the required volumes 
8. Leave at room temperature until agar have fully solidified 
9. Pack in plastic packets and store at 4 to 8 oC until use 
 
A.14    Mueller Hinton agar 
 
1. Add 38 gram Mueller Hinton agar base (Oxoid, England) to 1000 ml distilled 
water in a 3 liter Erlenmeyer flask 
2. For susceptibility testing purposes, add an extra 10% of the Mueller Hinton 
agar base i.e. 3.8 gram to the flask. This is to account for the 10% agar loss 
when making 1:10 dilutions with antibiotic working solutions. 
3. Slowly bring to boil and swirl flask and to dissolve powder completely 
4. Sterilize by autoclaving at 121 oC for 15 minutes 
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5. Cool down in a water bath to 50 to 55 oC 
6. Dispense into the required volumes 
7. Leave at room temperature until agar have fully solidified 
8. Pack in plastic packets and store at 4 to 8 oC until use 
 
A.15    10 mg/ml Proteinase K 
 
1. Mix 1 ml of 20 mg/ml Proteinase K stock (Qiagen, Whitehead Scientific, SA) 
with 1 ml of autoclaved distilled water 
2. Store at 4 oC until use 
 
A.16    5M NaCl solution 
 
1. Dissolve 14.6 gram NaCl (Sigma-Aldrich, SA) in 50 ml distilled water 
2. Sterilize by autoclaving at 121 oC for 15 minutes 
3. Store at 4 to 8 oC until use 
 
A.17    10% CTAB solution 
 
1. Add 10 gram CTAB (Sigma-Aldrich, SA) to 100 ml sterilized distilled water 






A.18    Chloroform:Isoamyl alcohol (24:1) 
 
• Mix 1 ml of isoamyl alcohol (Sigma-Aldrich, SA) into 24 ml chloroform 
(Sigma-Aldrich, SA) 
 
A.19    TE Buffer  
 
1. Add 1.21 gram Trizma base (Sigma-Aldrich, SA) to 80 ml distilled water 
2. Adjust pH to 8.0 using HCl (Merck, SA) 
3. Add 0.37 gram EDTA (Sigma-Aldrich, SA) 
4. Check the final pH and adjust to a final volume of 100 ml 
5. Sterilize by autoclave at 121 oC for 15 minutes 
6. This produces a 10x TE Buffer solution 
7. To prepare a 1x TE Buffer solution, add 100 ml of the 10x TE buffer to 900 
ml sterilized distilled water 
8. Store at room temperature 
 
A.20    1% Agarose gel 
 
1. Add 1.4 gram agarose powder (Seakem LE Agarose, Whitehead Scientific, 
SA) to 140 ml 1x TBE buffer 
2. Heat in microwave to dissolve the powder 
3. After cooling at room temperature to approximately 45 oC, pour gel into the 
casting gel tray  
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A.21    TBE Buffer 
 
1. Dissolve 108 gram Trizma base (Sigma-Aldrich, SA), 55 gram Boric acid 
(Sigma-Aldrich, SA) and 9.3 gram EDTA (Sigma-Aldrich, SA) in 900 ml 
sterilized distilled water 
2. Adjust the final volume to 1000 ml 
3. To prepare a 1x TBE Buffer solution, add 100 ml of the10x TE buffer to 900 
ml sterilized distilled water 
4. Store at room temperature 
 
A.22    Gel loading dye for gel electrophoresis 
 
1. Measure out and mix 50 gram glycerol (Merck, SA), 5 ml 1M Tris/HCl (pH 
7.5), 5 ml 100mM EDTA (Sigma-Aldrich, SA), 0.05 gram Bromophenol blue 
(Sigma-Aldrich, SA) and 300 μl 10 mg/ml RNase (Qiagen, Sigma-Aldrich, 
SA) 
2. Add distilled water to a final volume of 100 ml 
3. Heat in a water bath to 100 oC for 15 minutes, until reagents have 
completely dissolved 
4. Store at 4 to 8 oC for a maximum of one year 
5. Before use, dispense 980 μl into a cryovial and add 20 μl GelRed Nucleic 





A.23    Gel loading dye for IS 6110 RFLP 
 
1. First prepare a 1% Double dye stock solution by dissolving 1 gram 
Bromophenol Blue (Sigma-Aldrich, SA) and 1 gram Xylene Cyanole 
(Sigma-Aldrich, SA) in 100 ml sterilized distilled water 
2. Mix 5 ml of this 1% double dye stock solution with 5 ml 10x TBE buffer,       
25 ml glycerol (Merck, SA) and 15 ml distilled water to prepare the sample 
loading dye 
3. Store at 4 to 8 oC until use 
 
A.24    SSC solutions 
 
1. Mix 175 gram 3M NaCl (Sigma-Aldrich, SA) and 88 gram 0.3M Trisodium 
citrate dihydrate (Merck, SA) in 800 ml sterilized distilled water 
2. Use HCl (Merck, SA) and sterilized distilled water to adjust the final pH to 
7.0 and the final volume to 1000 ml 
3. This provides a 20x SSC solution 
• To prepare a 10x SCC solution, add 500 ml of 20x SCC to 500 ml 
sterilized distilled water 
• To prepare a 2x SCC solution (Secondary Wash Buffer), add 100 ml 






A.25    Soak I Solution  
 
• Dissolve 20 gram 0.5M NaOH pellets (Sigma-Aldrich, SA) and 87.66 gram 
1.5M NaCl (Sigma-Aldrich, SA) in 1000 ml sterilized distilled water 
 
A.26    Soak II Solution  
 
1. Dissolve 62.6 gram 0.5M Trizma base (Sigma-Aldrich, SA) and 87.67 gram 
1.5M NaCl (Sigma-Aldrich, SA) in 800 ml sterilized distilled water 
2. Use HCl (Merck, SA) and sterilized distilled water to adjust the final pH to 
7.2 and the final volume to 1000 ml 
 
A.27    Primary Wash Buffer 
 
1. Dissolve 360 gram 6M Urea (Sigma-Aldrich, SA), 4 gram SDS (Sigma-
Aldrich, SA) and 25 ml 20x SSC in 800 ml sterilized distilled water 
2. Use sterilized distilled water to make up a final volume of 1000 ml  
 
A.28    Hybridization buffer  
 
1. Add 30 ml 5M NaCl to 270 ml Hybridisation buffer (Amersham, UK) 
2. Use a magnetic stirrer with stirrer bar to make sure the NaCl fully dissolves 
3. While on the magnetic stirrer, heat the solution 60 °C and slowly add 15 
gram Blocking agent (Amersham, UK) to it 
4. Store at -20 oC 
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APPENDIX B – RAW DATA (MINIMUM INHIBITORY CONCENTRATIONS) 





Isoniazid Rifampicin Amikacin Ofloxacin Nybomycin 
A B C Final MIC A B C 
Final 
MIC A B C 
Final 
MIC A B C 
Final 
MIC A B C 
Final 
MIC 
H37Rv 0.125 0.125 0.125 0.125 0.25 0.25 0.0625 0.25 1 1 4 1 1 0.5 0.5 0.5 1 1 1 1 
TF 1538 0.0625 <0.03125 0.0625 0.0625 0.125 0.125 0.125 0.125 1 1 4 1 0.5 0.5 0.5 0.5 1 1 1 1 
TF 1413 0.0625 <0.03125 0.0625 0.0625 0.125 0.25 0.25 0.25 1 1 4 1 0.5 0.5 0.5 0.5 1 1 1 1 
TF 832 0.0625 0.125 0.125 0.125 0.25 0.25 0.25 0.25 1 1 4 1 0.5 0.5 0.5 0.5 1 1 1 1 
MODS 11 64 64 32 64 2 2 2 2 2 2 4 2 0.5 0,5 0.5 0.5 1 1 1 1 
TT 14 16 16 16 16 64 > 64 > 64 > 64 1 1 4 1 0.5 0.5 0.5 0.5 1 1 0.5 1 
TT 17 8 4 8 8 64 > 64 > 64 > 64 1 1 4 1 0.5 0.5 0.5 0.5 1 1 0.5 1 
TF 44949 16 16 16 16 8 > 64 > 64 > 64 0.25 0.5 2 1 0.5 0.5 0.25 0.5 0.5 0.25 0.25 0.25 
MODS 688 > 64 > 64 > 64 > 64 64 > 64 64 64 2 2 4 2 0.5 0.5 0.5 0.5 1 1 1 1 
TF 2063 16 16 64 16 8 > 64 64 64 0.25 0.25 0.5 0.25 0.5 0.5 0.5 0.5 0.5 0.25 0.125 0.25 
MODS 682 16 16 16 16 > 64 > 64 > 64 > 64 1 1 4 1 0.5 0.5 0.5 0.5 1 1 1 1 
TT 50 32 32 64 32 64 > 64 > 64 > 64 1 1 4 1 2 4 4 4 1 1 1 1 
TT 309 32 64 32 32 64 64 32 64 > 64 > 64 >64 > 64 0.5 0.5 0.5 0.5 1 1 1 1 
TT 627 > 64 > 64 > 64 > 64 64 > 64 > 64 > 64 1 1 4 1 4 4 4 4 1 1 0.5 1 
NT 1 32 64 32 32 2 4 2 2 1 1 4 1 16 16 16 16 1 1 1 1 
NT 66 32 32 32 32 64 > 64 > 64 > 64 1 1 4 1 8 8 8 8 1 1 0.5 1 
R11 654  32 32 32 32 64 > 64 64 64 1 0.5 4 1 8 4 8 8 1 0.5 0.5 0.5 
TT 169 32 32 64 32 >64 64 64 64 > 64 > 64 >64 > 64 16 16 16 16 1 1 1 1 
R2 404  16 32 32 32 16 16 16 16 > 64 > 64 >64 > 64 8 8 8 8 NG 0.125 0.25 0.25 
R4 825  8 16 16 16 > 64 > 64 > 64 > 64 > 64 > 64 >64 > 64 8 8 8 8 1 1 1 1 
TT 187 32 64 32 32 64 64 64 64 > 64 > 64 >64 > 64 16 16 16 16 1 1 1 1 
TT 209 32 64 32 32 32 64 32 32 > 64 > 64 >64 > 64 16 16 16 16 1 1 1 1 
R6 609  32 32 32 32 16 16 8 16 > 64 > 64 >64 > 64 16 16 16 16 0.5 0.5 0.5 0.5 
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R10 741  > 64 > 64 32 > 64 64 >64 > 64 > 64 > 64 > 64 >64 > 64 16 16 16 16 1 1 1 1 
R10 398  64 32 32 32 64 > 64 > 64 > 64 > 64 > 64 >64 > 64 4 4 4 4 1 0.5 1 1 
R4 819  8 8 NG 8 > 64 64 64 64 8 4 4 4 4 4 4 4 1 1 0.5 1 
R10 442  16 16 4 16 64 > 64 > 64 > 64 > 64 > 64 >64 > 64 4 2 2 2 1 0.5 1 1 
MODS 388 32 64 32 32 64 > 64 > 64 > 64 > 64 > 64 >64 > 64 8 4 4 4 0.5 0.5 0.5 0.5 
MODS 387 64 64 > 64 64 64 > 64 > 64 > 64 > 64 > 64 >64 > 64 4 4 4 4 0.5 0.5 0.5 0.5 
TF 1762 32 64 64 64 64 > 64 > 64 > 64 > 64 > 64 >64 > 64 4 4 4 4 0.5 0.5 0.5 0.5 
MODS 195 32 64 16 32 > 64 > 64 > 64 > 64 > 64 > 64 >64 > 64 4 4 4 4 0.5 0.5 0.5 0.5 
R4 933  16 16 16 16 64 > 64 > 64 > 64 > 64 > 64 >64 > 64 8 8 4 8 0.5 0.5 0.5 0.5 
 
B.2    MIC (µg/ml) results for Neisseria gonorrhoeae with multipoint inoculator 
N. gonorrhoeae 
Isolate number 
Ciprofloxacin Nalidixic Acid Nybomycin 
A B C Final MIC A B C Final MIC A B C Final MIC 
ATCC 49226 0.0625 < 0.0625 < 0.0625 < 0.0625 1 2 2 2 4 2 4 4 
526 < 0.0625 < 0.0625 < 0.0625 < 0.0625 2 2 2 2 1 2 1 1 
840 < 0.0625 < 0.0625 < 0.0625 < 0.0625 2 2 2 2 1 1 1 1 
924 < 0.0625 < 0.0625 < 0.0625 < 0.0625 2 2 2 2 2 2 2 2 
556 < 0.0625 < 0.0625 < 0.0625 < 0.0625 16 16 16 16 2 2 2 2 
373 < 0.0625 < 0.0625 < 0.0625 < 0.0625 8 8 8 8 4 8 8 8 
310 0.0625 < 0.0625 < 0.0625 < 0.0625 1 2 2 2 0.5 1 0.5 0.5 
360 0.25 0.5 0.25 0.25 8 8 8 8 4 4 4 4 
20 0.25 0.5 0.25 0.25 8 4 8 8 4 4 4 4 
172 0.25 0.25 0.25 0.25 16 16 16 16 2 2 2 2 
391 1 0.25 0.25 0.25 8 4 8 8 1 1 1 1 
277 0.5 0.5 0.5 0.5 8 8 8 8 2 4 4 4 
342 0.5 0.5 0.5 0.5 8 8 8 8 2 2 2 2 
524 0.25 0.5 0.5 0.5 8 16 16 16 2 2 4 2 
938 0.5 0.5 0.5 0.5 4 8 8 8 0.25 0.25 0.25 0.25 
336 1 1 2 1 8 8 8 8 2 2 2 2 
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345 1 1 1 1 16 8 16 16 2 2 2 2 
462 1 1 1 1 8 8 8 8 1 0.5 0.5 0.5 
219 1 2 2 2 8 8 8 8 4 4 4 4 
74 1 2 2 2 8 8 4 8 2 4 4 4 
227 2 2 2 2 16 16 16 16 4 4 4 4 
108 4 2 4 4 16 16 16 16 4 4 4 4 
119 4 4 4 4 4 16 16 16 2 2 2 2 
236 4 2 4 4 8 8 8 8 2 4 2 2 
251 4 4 4 4 16 16 16 16 4 4 4 4 
267 2 4 4 4 16 16 16 16 4 4 4 4 
296 2 4 4 4 8 8 8 8 8 8 8 8 
688 4 4 4 4 8 4 8 8 4 2 4 4 
819 4 4 4 4 8 8 8 8 4 4 4 4 







Quinine Chloroquine Mefloquine Primaquine 
A B C Final MIC A B C 
Final 
MIC A B C 
Final 
MIC A B C 
Final 
MIC 
ATCC 49226 128 128 128 128 > 128 > 128 > 128 > 128 16 16 16 16 128 128 128 128 
526 128 128 128 128 > 128 > 128 > 128 > 128 16 16 16 16 128 128 128 128 
840 128 128 128 128 > 128 > 128 > 128 > 128 4 8 4 4 64 64 64 64 
924 128 128 > 128 128 > 128 > 128 > 128 > 128 4 4 4 4 64 64 64 64 
556 128 128 > 128 128 > 128 > 128 > 128 > 128 8 8 8 8 128 128 128 128 
373 128 > 128 128 128 > 128 > 128 > 128 > 128 16 8 16 16 > 128 > 128 > 128 > 128 
310 128 128 128 128 > 128 > 128 > 128 > 128 4 4 4 4 128 64 64 64 
360 128 128 128 128 > 128 > 128 > 128 > 128 16 16 16 16 > 128 > 128 > 128 > 128 
20 128 128 128 128 > 128 > 128 > 128 > 128 4 4 4 4 64 64 64 64 
172 128 > 128 128 128 > 128 > 128 > 128 > 128 4 4 4 4 128 128 128 128 
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391 128 128 128 128 > 128 > 128 > 128 > 128 4 4 4 4 64 64 64 64 
277 128 128 128 128 > 128 > 128 > 128 > 128 8 16 16 16 128 128 128 128 
342 128 128 128 128 > 128 > 128 > 128 > 128 16 16 16 16 128 128 128 128 
524 128 128 128 128 > 128 > 128 > 128 > 128 16 16 16 16 32 64 64 64 
938 128 128 > 128 128 > 128 > 128 > 128 > 128 2 2 2 2 32 32 64 32 
336 128 128 128 128 > 128 > 128 > 128 > 128 16 16 16 16 128 128 128 128 
345 128 128 128 128 > 128 > 128 > 128 > 128 8 16 16 16 128 128 128 128 
462 > 128 > 128 > 128 > 128 > 128 > 128 > 128 > 128 4 4 2 4 64 128 64 64 
219 128 128 128 128 > 128 > 128 > 128 > 128 16 16 16 16 64 64 64 64 
74 > 128 > 128 > 128 > 128 > 128 > 128 > 128 > 128 16 16 16 16 128 128 128 128 
227 > 128 > 128 > 128 > 128 > 128 > 128 > 128 > 128 16 16 16 16 > 128 > 128 > 128 > 128 
108 > 128 > 128 > 128 > 128 > 128 > 128 > 128 > 128 16 16 16 16 > 128 128 > 128 > 128 
119 > 128 > 128 > 128 > 128 > 128 > 128 > 128 > 128 16 16 16 16 128 128 128 128 
236 128 128 128 128 > 128 > 128 > 128 > 128 16 16 16 16 > 128 > 128 > 128 > 128 
251 128 > 128 128 128 > 128 > 128 > 128 > 128 16 16 16 16 > 128 > 128 > 128 > 128 
267 128 128 128 128 > 128 > 128 > 128 > 128 16 16 16 16 128 > 128 > 128 > 128 
296 128 128 128 128 > 128 > 128 > 128 > 128 16 16 16 16 128 128 128 128 
688 128 128 128 128 > 128 > 128 > 128 > 128 16 16 16 16 > 128 > 128 128 > 128 
819 > 128 > 128 > 128 > 128 > 128 > 128 > 128 > 128 16 16 16 16 128 128 128 128 
766 > 128 > 128 > 128 > 128 > 128 > 128 > 128 > 128 1 0.5 0.5 0.5 16 16 16 16 
 
B.3    MIC (µg/ml) results for Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Pseudomonas aeruginosa, 
Acinetobacter baumanii, Enterococcus faecalis and Staphylococcus aureus with multipoint inoculator. 
Bacterial isolate 
Ciprofloxacin Nalidixic Acid Nybomycin 
A B C Final MIC A B C Final MIC A B C Final MIC 
E. coli ATCC 25722 < 0.125 < 0.125 < 0.125 < 0.125 8 8 8 8 > 16 > 16 > 16 > 16 
E. coli no. 1 < 0.125 < 0.125 < 0.125 < 0.125 16 16 16 16 > 16 > 16 > 16 > 16 
E. coli no. 2 2 2 1 2 16 16 16 16 > 16 > 16 > 16 > 16 
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E. coli no. 3 2 4 2 2 16 16 16 16 > 16 > 16 > 16 > 16 
E. coli no. 4 32 16 32 32 16 16 16 16 > 16 > 16 > 16 > 16 
E. coli no. 5 32 32 32 32 16 16 16 16 > 16 > 16 > 16 > 16 
K. pneumoniae no. 1 < 0.125 < 0.125 < 0.125 < 0.125 16 16 16 16 > 16 > 16 > 16 > 16 
K. pneumoniae no. 2 0.5 0.25 0.25 0.25 16 16 16 16 > 16 > 16 > 16 > 16 
K. pneumoniae no. 3 1 2 2 2 16 16 16 16 > 16 > 16 > 16 > 16 
K. pneumoniae no. 4 16 16 16 16 16 16 16 16 > 16 > 16 > 16 > 16 
E. cloacae no. 1 < 0.125 < 0.125 < 0.125 < 0.125 8 8 8 8 > 16 > 16 > 16 > 16 
E. cloacae no. 2 8 8 8 8 8 8 8 8 > 16 > 16 > 16 > 16 
E. cloacae no. 3 32 16 32 32 8 8 8 8 > 16 > 16 > 16 > 16 
E. cloacae no. 4 32 32 32 32 16 16 16 16 > 16 > 16 > 16 > 16 
P. aeruginosa no. 1 0.25 0.25 0.25 0.25 8 8 8 8 > 16 > 16 > 16 > 16 
P. aeruginosa no. 2 0.5 1 0.5 0.5 8 8 4 8 > 16 > 16 > 16 > 16 
P. aeruginosa no. 3 8 8 8 8 8 8 8 8 > 16 > 16 > 16 > 16 
P. aeruginosa no. 4 8 16 16 16 8 8 8 8 > 16 > 16 > 16 > 16 
P. aeruginosa no. 5 16 16 16 16 8 8 4 8 > 16 > 16 > 16 > 16 
P. aeruginosa no. 6 16 16 16 16 8 8 8 8 > 16 > 16 > 16 > 16 
P. aeruginosa no. 7 32 16 32 32 8 8 8 8 > 16 > 16 > 16 > 16 
A. baumanii no. 1 0.25 0.25 0.25 0.25 8 16 8 8 > 16 > 16 > 16 > 16 
A. baumanii no. 2 2 2 2 2 8 8 16 8 > 16 > 16 > 16 > 16 
A. baumanii no. 3 2 4 4 4 8 8 8 8 > 16 > 16 > 16 > 16 
A. baumanii no. 4 8 16 16 16 8 8 8 8 > 16 > 16 > 16 > 16 
A. baumanii no. 5 > 32 > 32 > 32 > 32 8 16 16 16 8 16 8 8 
E. faecalis no. 1 1 1 0.25 1 32 32 32 32 8 16 16 16 
E. faecalis no. 2 2 2 2 2 32 32 32 32 8 16 16 16 
E. faecalis no. 3 > 32 > 32 > 32 > 32 32 32 32 32 8 4 8 8 
E. faecalis no. 4 > 32 > 32 > 32 > 32 32 32 32 32 4 8 8 8 
S. aureus no. 1 0.5 1 0.5 0.5 32 32 32 32 4 4 4 4 
S. aureus no. 2 0.5 0.5 0.5 0.5 32 32 32 32 2 8 8 8 
S. aureus no. 3 4 2 2 2 32 32 32 32 4 8 4 4 




Quinine Chloroquine Mefloquine Primaquine 
A B C Final MIC A B C 
Final 
MIC A B C 
Final 
MIC A B C 
Final 
MIC 
E. coli ATCC 25722 128 128 128 128 > 128 > 128 > 128 > 128 64 64 64 64 > 128 > 128 > 128 > 128 
E. coli no. 1 128 128 128 128 > 128 > 128 > 128 > 128 > 64 > 64 > 64 > 64 > 128 > 128 > 128 > 128 
E. coli no. 2 128 128 128 128 > 128 > 128 > 128 > 128 > 64 > 64 > 64 > 64 > 128 > 128 > 128 > 128 
E. coli no. 3 128 128 128 128 > 128 > 128 > 128 > 128 > 64 > 64 > 64 > 64 > 128 > 128 > 128 > 128 
E. coli no. 4 128 128 128 128 > 128 > 128 > 128 > 128 > 64 > 64 > 64 > 64 > 128 > 128 > 128 > 128 
E. coli no. 5 128 128 128 128 > 128 > 128 > 128 > 128 > 64 > 64 > 64 > 64 > 128 > 128 > 128 > 128 
K. pneumoniae no. 1 128 128 128 128 > 128 > 128 > 128 > 128 > 64 > 64 > 64 > 64 > 128 > 128 > 128 > 128 
K. pneumoniae no. 2 128 128 128 128 > 128 > 128 > 128 > 128 > 64 > 64 > 64 > 64 > 128 > 128 > 128 > 128 
K. pneumoniae no. 3 128 128 128 128 > 128 > 128 > 128 > 128 > 64 > 64 > 64 > 64 > 128 > 128 > 128 > 128 
K. pneumoniae no. 4 128 128 128 128 > 128 > 128 > 128 > 128 > 64 > 64 > 64 > 64 > 128 > 128 > 128 > 128 
E. cloacae no. 1 128 128 128 128 > 128 > 128 > 128 > 128 > 64 > 64 > 64 > 64 > 128 > 128 > 128 > 128 
E. cloacae no. 2 128 128 128 128 > 128 > 128 > 128 > 128 > 64 > 64 > 64 > 64 > 128 > 128 > 128 > 128 
E. cloacae no. 3 128 128 128 128 > 128 > 128 > 128 > 128 > 64 > 64 > 64 > 64 > 128 > 128 > 128 > 128 
E. cloacae no. 4 128 128 128 128 > 128 > 128 > 128 > 128 > 64 > 64 > 64 > 64 > 128 > 128 > 128 > 128 
P. aeruginosa no. 1 128 128 128 128 > 128 > 128 > 128 > 128 > 64 > 64 > 64 > 64 > 128 > 128 > 128 > 128 
P. aeruginosa no. 2 64 64 64 64 > 128 > 128 > 128 > 128 > 64 > 64 > 64 > 64 > 128 > 128 > 128 > 128 
P. aeruginosa no. 3 64 64 64 64 > 128 > 128 > 128 > 128 > 64 > 64 > 64 > 64 > 128 > 128 > 128 > 128 
P. aeruginosa no. 4 64 64 64 64 > 128 > 128 > 128 > 128 > 64 > 64 > 64 > 64 > 128 > 128 > 128 > 128 
P. aeruginosa no. 5 128 64 64 64 > 128 > 128 > 128 > 128 > 64 > 64 > 64 > 64 > 128 > 128 > 128 > 128 
P. aeruginosa no. 6 64 128 64 64 > 128 > 128 > 128 > 128 > 64 > 64 > 64 > 64 > 128 > 128 > 128 > 128 
P. aeruginosa no. 7 128 128 128 128 > 128 > 128 > 128 > 128 > 64 > 64 > 64 > 64 > 128 > 128 > 128 > 128 
A. baumanii no. 1 128 64 128 128 > 128 > 128 > 128 > 128 64 64 64 64 > 128 > 128 > 128 > 128 
A. baumanii no. 2 128 128 128 128 > 128 > 128 > 128 > 128 64 64 64 64 > 128 > 128 > 128 > 128 
A. baumanii no. 3 128 128 128 128 > 128 > 128 > 128 > 128 > 64 > 64 > 64 > 64 > 128 > 128 > 128 > 128 
A. baumanii no. 4 128 128 128 128 > 128 > 128 > 128 > 128 64 64 64 64 > 128 > 128 > 128 > 128 
A. baumanii no. 5 > 128 > 128 > 128 > 128 > 128 > 128 > 128 > 128 32 32 64 32 > 128 > 128 > 128 > 128 
E. faecalis no. 1 > 128 > 128 > 128 > 128 > 128 > 128 > 128 > 128 16 32 32 32 > 128 > 128 > 128 > 128 
E. faecalis no. 2 > 128 > 128 > 128 > 128 > 128 > 128 > 128 > 128 16 32 32 32 > 128 > 128 > 128 > 128 
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E. faecalis no. 3 > 128 > 128 > 128 > 128 > 128 > 128 > 128 > 128 32 32 32 32 > 128 > 128 > 128 > 128 
E. faecalis no. 4 > 128 > 128 > 128 > 128 > 128 > 128 > 128 > 128 32 32 32 32 > 128 > 128 > 128 > 128 
S. aureus no. 1 > 128 > 128 > 128 > 128 > 128 > 128 > 128 > 128 32 8 32 32 > 128 > 128 > 128 > 128 
S. aureus no. 2 > 128 > 128 > 128 > 128 > 128 > 128 > 128 > 128 32 16 32 32 > 128 > 128 > 128 > 128 
S. aureus no. 3 > 128 > 128 > 128 > 128 > 128 > 128 > 128 > 128 32 32 32 32 > 128 > 128 > 128 > 128 
S. aureus no. 4 > 128 > 128 > 128 > 128 > 128 > 128 > 128 > 128 32 32 32 32 > 128 > 128 > 128 > 128 
 
B.4    MIC (µg/ml) results for Mycobacterium tuberculosis with MTT assay.  
M. tuberculosis Isolate number Nybomycin DNM-2 
A B C Final MIC A B C Final MIC 
H37Rv 2 2 2 2 1.5 1.5 1.5 1.5 
TF 1538 2 2 2 2 3 3 3 3 
TF 1413 2 2 2 2 3 3 3 3 
TF 832 2 2 2 2 3 3 3 3 
MODS 11 2 2 2 2 3 3 3 3 
TT 17 1 1 1 1 3 1.5 3 3 
TF 44949 2 1 2 2 3 3 3 3 
MODS 688 2 2 2 2 3 3 3 3 
TF 2063 2 1 2 2 3 1.5 3 3 
TT 50 0.5 1 1 1 3 3 3 3 
TT 309 1 1 1 1 1.5 3 3 3 
TT 627 1 1 1 1 1.5 1.5 1.5 1.5 
NT 1 2 1 2 2 3 3 3 3 
NT 66 1 1 1 1 1.5 1.5 1.5 1.5 
TT 169 1 1 1 1 1.5 1.5 1.5 1.5 
R2 404  2 2 2 2 1.5 1.5 1.5 1.5 
R4 825  1 1 1 1 1.5 1.5 1.5 1.5 
R6 609  1 1 2 1 1.5 1.5 1.5 1.5 
R10 741  1 1 1 1 3 1.5 3 3 
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R4 819 2 2 1 2 1.5 1.5 1.5 1.5 
R10 442 2 2 2 2 3 3 3 3 
MODS 388 1 1 1 1 3 1.5 1.5 1.5 
MODS 387 2 2 2 2 1.5 1.5 1.5 1.5 

